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1 Introduction 
1.1 Ulcerative colitis: a multifactorial induced complex disorder 
Several inflammatory diseases of the human mucosa, which have been unknown before 
industrialization (Bach, 2002), have significantly increased in the Western countries over the recent 
100 years. One example is inflammatory bowel disease (IBD) (Abraham and Cho, 2009b). A similar 
phenomenon has been observed in Asian countries, where hospitalized IBD patients were reported 
with an increasing frequency during industrialization (Wang et al., 2007). The transformation from 
an agrarian into an industrial society induced enormous alteration of life-style and environment. 
Keeping this in mind, the altered mucosa immunity and the luminal composition in the gut that is 
due to the drastic changes in sanitation, medication, and nutrition, could be a key trigger of an 
inflammatory barrier disorder (Rook, 2012), but the precise contribution to the disease pathogenesis 
of these factors are still unknown. 
In contrast to environmental factors, it is known that individual genomes differ in millions of 
variations, some of which might cause different phenotypes or even pathogenesis (Boomsma et al., 
2002; Kaminsky et al., 2009). However, complex diseases, such as IBD, might require many 
predisposing variants (Schreiber et al., 2005). Prior to the first genome-wide association studies 
(GWAS) in 2005, various genetic factors had been reported to be associated with IBD, including the 
IBD5 locus, the nucleotide-binding oligomerization domain containing 2/ caspase recruitment 
domain family, member 15 (NOD2/CARD15) gene, MHC locus (Brant and Shugart, 2004). Since the 
advent of GWAS, a large number of additional genetic loci have been found in the context of IBD. So 
far, genome-wide meta analysis confirmed 71 susceptibility loci for Crohn’s disease, and 47 risk loci 
which associated with ulcerative colitis (UC) (Franke et al., 2010; Anderson et al., 2011). 
The current GWAS on IBD were mostly based on cohorts of European descent. Studies targeting 
eastern populations are still lacking. Interestingly, some IBD studies reported that variants, which 
were identified in the Europeans, are not found in other Asian IBD patients (Ng et al., 2011). This 
could be partially explained by the fact that the European and Asian populations display substantial 
genetic and environmental differences, which is of clinical relevance, as the current understanding of 
disease pathogenesis assumes a complex interplay between environmental and genetic factors 
(Xavier and Podolsky, 2007). 
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1.1.1 Epidemiology of ulcerative colitis 
UC represents the major subphenotype (OMIM 191390) of IBD (OMIM 266600). It is characterized 
by an abnormal inflammatory reaction in the gut mucosa. Considerable variation in the 
epidemiology of UC has been observed when comparing the data worldwide, yet the current 
understanding suggests that industrialization might be an element in the etiology of UC (Benchimol 
et al., 2011; Molodecky et al., 2012). Molodecky and colleagues summarized the incidence and 
prevalence of UC in 2012, and demonstrated the increase over time and in different regions around 
the world. 
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Figure 1. Temporal trends of incidence rates. Data for studies that reported at least 10 years and with 
at least 3 time points for ulcerative colitis (UC). from Molodecky et al., 2012. 
Several complex disorders have been reported that the incidence rates could be stratified by sex. 
However, no data suggests that the UC has gender special effects. In contrast to that, the age-
stratified incidence rates attracted more attention. Some studies estimated the highest incidence 
rates are found in the range from 20 to 29 years, and that the pediatric incidence is increasing 
constantly (Benchimol et al., 2011). The results of early onset and chronicity are high treatment 
costs for the patient, the health care system, and the society. 
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UC rarely occurs in developing countries, however, the incidence of UC has increased rapidly in these 
countries in the recent half century. Interestingly, it was reported that individuals from developing 
regions emigrating to industrialized countries have a higher risk for developing UC, especially among 
the first-generation children (Barreiro-de Acosta et al., 2011). 
1.1.2 Clinical phenotype of ulcerative colitis 
Ulcerative colitis is classified as a complex phenotype. Initial symptoms mostly include diarrhea and 
abdominal pain. However, diarrhea as a lead symptom is unspecific, and stool samples show no 
pathological findings. UC can show clinical symptoms and an endoscopic picture similar to other 
infectious colitis diseases. The diagnosis of UC is mainly based on clinical, endoscopic, radiologic, and 
histological criteria (Nikolaus and Schreiber, 2007).  
Ulcerative Colitis 
Symptom 
 Abdominal pain Cramps, mainly left lower quadrant 
Diarrhea Frequent in adults; can alternate with constipation 
Hematochezia Always in active patients; intensity related to disease activity 
Abdominal mass Left lower quadrant, if sigmoid is inflamed in slim individuals 
Hyposomia Rare 
Malnutrition Occasional 
Abdominal distention Only in severe disease 
Obstructive symptoms No 
Perianal disease/fistula No 
Laboratory abnormalities 
 Acute reactant proteins (eg, CRP) In extensive or severe disease 
Anemia In severe disease 
Macrocytosis Rare 
Hypoalbuminemia In severe disease 
pANCA in UC + + (in UC with PSC + + +) 
ASCA  (+) 
Complications/extraintestinal 
manifestations 
 Abscess Rare 
Toxic megacolon Rare 
Ileus Rare 
Primary sclerosing cholangitis Occasional (5%–15%) 
Hepatitis Occasional 
Erythema nodosum Rare 
Pyoderma gangraenosum Rare 
Arthralgia/arthritis Frequent 
Epidemiology 
 Current smoker Rarely 
Former smoker Frequently 
Previous appendectomy Less than expected 
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Ulcerative Colitis 
Endoscopic appearance of disease 
 Distribution Continuous spread from the rectum 
Small bowel involvement Rare (back-wash ileitis) 
Rectal involvement Almost always 
Uniform, continuous disease Always 
Longitudinal, polycyclic ulcers (“snail track”) No 
Cobblestone appearance of ileum No 
Normal mucosa within inflamed areas No 
Strictures Rare, always suspicious for carcinoma! 
Mucosal edema Frequent 
Ulceration Often flat and extensive 
Circumferential inflammation Frequent 
Imaging 
 Increased bowel wall thickness Moderate 
Mesenteric lymph nodes Infrequent 
Mesenteric fat wrapping No 
Table 1. Diagnosis of ulcerative colitis (UC). Clinical, endoscopical, radiological, and histological 
characteristics of UC. According to Nikolaus and Schreiber, 2007. 
UC patients have a significant higher risk to develop primary sclerosing cholangitis and vice-versa 
(Cullen and Chapman, 2003) as well as colorectal cancer (Glória et al., 1996; Konishi et al., 2007; 
March et al., 2011). UC is also associated to other immune-mediated disorders such as arthritis, and 
multiple sclerosis (Satsangi et al., 1997). 
1.1.3 Epithelial barrier dysfunction and autoimmunity 
The gut epithelia builds an integrate physical and biochemical barrier and maintains a dynamic 
balance between the body and the environment. The commensal environmental components in the 
gut can induce the immune response at the interface, even across the barrier, directly activating 
immune system (Cho and Blaser, 2012). Unlike in CD patients, inflammation in UC typically occurs in 
proximity to the epithelium and does not affect the deeper intestinal tissues, therefore the barrier 
layer should be the main battlefield between the immune system and gut microbiota, and the 
integrity of the barrier layer might be implicated in the pathogenesis of UC (Kaser et al., 2008). In 
addition, autoimmunity might play a role in ulcerative colitis. The autoantibody p-ANCA (perinuclear 
Anti-neutrophil cytoplasmic antibody) has been detected in the blood test of UC patient. It is 
thought to be against the colonic epithelial antigen. For example tropomyosin 5, a structural protein, 
might be a putative target of p-ANCA (Geng et al., 1998), but evidence of classical antibody-
mediated autoimmunity in ulcerative colitis is still lacking. 
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1.1.4 Immunological aspects of UC 
Individual health depends on a beneficial host–microbe interaction (Duncan and Edberg, 1995). The 
most intimate contact with the outside world takes place at the surface of the intestine, particularly 
in the colon, which harbors a greater amount and higher diversity of microorganisms than any other 
organ (Shanahan, 2002). These potential 'pathogens' are recognized by toll-like receptors (TLRs) 
and/or caspase recruitment domain (CARDs) containing proteins on/in the epithelial and immune 
cells, therefore the innate immune response to the microbiota must be controlled correctly and 
effectively to maintain the intestinal homeostasis (Lee and Kim, 2007). Similarly to Crohn’s disease 
(CD), no specific pathogens were identified in ulcerative colitis, but abnormalities of innate immune 
such as variants of caspase recruitment domain family, member 9 (CARD9) (Bertin et al., 2000; 
Glocker et al., 2009; Strasser et al., 2012), increased expression of TLR2 and TRR4 by colonocytes, 
are involved in microbial recognition and inflammatory signaling. Interstingly, the secretion of 
proinflammatory cytokines, such as interleukin-1β, interleukin-6 and tumor necrosis factor α (TNF-α) 
is not only increased in patients with IBD, but also found in many other inflammatory diseases (Panja 
et al., 1998; Kaiser et al., 2000). 
The humoral and cellular adaptive immunity exhibits various potentially pathological alterations in 
ulcerative colitis. Immunoglobulins (Ig), such as IgM, IgA, and IgG levels are commonly elevated, but 
there is a disproportionate increase in IgG1 antibodies in ulcerative colitis (Takahashi and Das, 1985). 
The differentiation of helper T cells (Th) into Th1 and Th2 has been reported to be altered in IBD. 
This represents an atypical type 2 helper T cells (Th2) response in the gut mucosa of patients with 
ulcerative colitis. Interleukin-13 is secreted from the nonclassical natural killer T cells in the colon, 
which mediates epithelial cell cytotoxicity, apoptosis, and epithelial barrier dysfunction (Fuss et al., 
2004; Heller et al., 2005). Interleukin-5–producing Th2-polarized T cells are generally present in 
affected tissue of ulcerative colitis patients. However, the upregulation of Interleukin-4 (IL-4) levels, 
which represents a Th2 signature was not observed in UC (Kaser et al., 2010). IL17 which is secreted 
by recently discovered Th17 cell-lineages is significantly more abundant in UC when compared to 
controls (Sakuraba et al., 2009). Some studies indicated that although the Th17 response has the 
potential to be a proinflammatory response, it seemed to be playing mostly a regulatory role rather 
than an functional role in the inflammation (Waite and Skokos, 2012). 
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Figure 2. The T helper cell differentiation. The brown marked cytokines are the main signatures of Th1 
cells, Th2 cells and Th17 cells respectively. However, in the colonic epithelial layer of ulcerative colitis, 
it represented an atypical Th2 differentiation, because the upregulation of Interleukin-4 (IL-4) levels 
has not been observed. 
1.1.5 Genetic background of UC 
UC is thought to have a prominent heritable component (Duerr, 2007). Prior to the first genome-
wide association studies (GWAS) in 2005, genetic factors have been reported the be associated with 
IBD, including the IBD5 locus, the NOD2/CARD15 gene, and the MHC locus (Brant and Shugart, 2004). 
Since the advent of GWAS, a large number of genetic variants have been identified to be potentially 
disease relevant in IBD. A meta-analysis of six studies recently confirmed the presence of 47 loci 
associated with ulcerative colitis, of which 19 are specific for ulcerative colitis and 28 are shared with 
Crohn’s disease (Franke et al., 2010; Anderson et al., 2011). 
Risk loci, which have been identified in the meta-analysis (Anderson et al., 2011) and in individual 
studies suggested that several pathways are involved in susceptibility, manifestation and progression 
of UC. Variants of extracellular matrix protein 1 (ECM1 ) (Merregaert et al., 2010), hepatocyte 
nuclear factor 4, alpha (HNF4A) (Cattin et al., 2009), cadherin type 1 (CDH1) (Liu et al., 2009), and 
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laminin beta 1 (LAMB1) (Lee and Gross, 2007) might lead to a dysfunction of the epithelial barrier. 
The product of DAP (Bialik and Kimchi, 2010) plays very important role in apoptosis and autophagy; 
and altered PR domain containing 1 with ZNF domain (PRDM1) (Bikoff et al., 2009), interferon 
regulatory factor 5 (IRF5) (Barnes et al., 2001), and NK2 homeobox 3 (NKX2-3) (Yu et al., 2011) 
suggest impacts on transcriptional regulation. Interleukin-23 receptor (IL23R), Janus kinase 2 (JAK2), 
signal transducer and activator of transcription 3 (STAT3), Interleukin-12 beta (IL12B), and protein 
tyrosine phosphatase non-receptor type 2 (PTPN2) which are shared risk loci with CD are 
functionally linked to the IL-23 signaling pathway (Abraham and Cho, 2009a; Duvallet et al., 2011), 
and CARD9 might be involved in immunity to Mycobacterium tuberculosis and Candida albicans 
(Bertin et al., 2000; Bi et al., 2010; Strasser et al., 2012). particularly several risk loci linked to CD and 
other autoimmune diseases, such as IL-10, IL7R, IL23R, and Interferon-γ (IFN-γ), which participate 
helper T-cell types 1 and 17 (Th1 and Th17) differentiation (Atarashi and Honda, 2011). 
1.1.6 Environmental factors 
Host factors are thought to play a very important role in the pathogenesis of ulcerative colitis. 
Similarly, environmental factors should not be ignored. The recent worldwide trends in UC 
epidemiology indicated that the environmental factors might significantly contribute to the 
pathogenesis of UC, yet quantification of such contributions remains difficult (Bernstein et al., 2010). 
Acid, bile and phasic ‘housekeeping’ motility patterns, which are secreted into the intestinal lumen, 
can hinder microbial colonization. However, numerous bacteria still can grow in the distal small 
intestine (Mahida and Rolfe, 2004). The exact number and species cannot be determined with the 
currently available technologies, moreover, the gut flora is believed to be constantly altered due to 
substantial environmental changes which are partially fast and irreversible (Benchimol et al., 2011; 
Molodecky et al., 2012; Rook, 2012). Similar changes could be observed in diet: low-fiber, high-sugar 
and high animal-fat food composition became widespread (O’Sullivan and O’Morain, 2006). 
Normally, the mucosal immune system is required to respond to pathogens, while maintaining 
appropriate tolerance to the commensal bacteria and diet antigens. Current studies indicate that 
this balance is disrupted in UC (Shanahan, 2002; Mahida and Rolfe, 2004; Danese and Fiocchi, 2011). 
Smoking is suggested to be associated with IBD pathogenesis , but interestingly, smoking seems to 
have a protective effect in UC (Cosnes et al., 2004). A meta-analysis in 1989 revealed a pooled odds 
ratio of 0.41 (0.34-0.48), indicating that NOT smoking and ulcerative colitis are consistent with a 
causal relationship (Calkins, 1989). Mahid and colleagues reported a similar analysis result in 2006 
and concluded that current smokers have a lower risk for UC (OR 0.58; 95% CI 0.45-0.75), while 
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former smokers has a higher risk (OR 1.79; 95% CI 1.37-2.34) (Mahid et al., 2006). In a reverse 
manner, individuals who smoked in their younger years showed a dramatically increased risk for 
developing UC (Mahid et al., 2007).  
Hygiene is thought to be a potential 'pathogenic' factor for UC, given the rising incidence of UC after 
the industrialization in both, developed and developing countries. The 'IBD hygiene hypothesis' 
states that the excessively hygienic environment negatively affects immune development of children. 
Many factors could be involved in this concept, e.g. non-contaminated food, cleaner water, 
toothpaste, smaller family size, low bacterial load on indoor-surfaces. Many studies revealed that 
most of these factors are associated with the pathogenesis of UC (Kendler and Baker, 2007). This 
gradual development has been termed “losing our old friends”, such as bacteria, virus and parasites 
(Rook, 2012).  
1.2 Epigenetic regulation in UC 
Normally, multicellular organism have identical DNA sequences in each cell (disregarding somatic 
mutations), however, differences between various cellular phenotypes are maintained by different 
expressions patterns (Jaenisch and Bird, 2003). This nongenetic program, which records 
developmental and environmental cues, is the basis of epigenetics. Epigenetics are defined as a 
heritable mechanism which alters gene expression without altering the DNA sequence (Ptashne, 
2007). 
In eukaryotic cells, DNA is wrapped around histone proteins and packaged in the nucleus, where 
repeating units of nucleosomes build a so-called chromatin. Several modifications of amino termini 
of nucleosomal histones (H) are known, such as methylation and acetylation (Barski et al., 2007; 
Bartke et al., 2010; Margueron and Reinberg, 2010). Similarly, DNA nucleotides can be methylated 
on the 5’ position of the cytosine (C) pyrimidine ring (Robertson and Wolffe, 2000; Bird, 2002; Bartke 
et al., 2010). All these modifications potentially influence gene expression (Figure 3). In addition, 
interactions between the genome and other components in the nucleus, e.g. RNA and proteins, may 
regulate the gene expression (Bernstein and Allis, 2005; Henikoff, 2008; Nagano et al., 2008; Lee, 
2009; Simon and Kingston, 2009). 
In a multicellular organisms, the unique gene-expression patterns of each cell determines the 
identity of its type, its development stage (Takahashi and Yamanaka, 2006; Ieda et al., 2010; 
Cortázar et al., 2011; Iqbal et al., 2011) and its reaction to internal and external stimuli (Jaenisch and 
Bird, 2003; Bonfanti et al., 2010; Carone et al., 2010) - this cellular identity is controlled by epigenetic 
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mechanisms. The molecular basis of epigenetics is complex, and it is known that even single-cell 
organisms do not have one single epigenome, but instead have multiple epigenomes. These 
epigenetic mechanisms (Figure 3) work throughout the genome, and interact with each other, to 
organize the genome in both the one- and the three-dimensional space (Schones and Zhao, 2008). 
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Figure 3. Characteristics of epigenomes. A: DNA methylation, B: histone modification, and C: 
nucleosome positioning and other factors such as small RNAs contribute to an overall epigenome that 
regulates transcription and influences the architecture of the genome.  
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1.2.1 Epigenitic mechanisms 
In eukaryotes, nuclear DNA is wrapped around a histone-octamers which consists of two copies of 
H2A, H2B, H3 and H4. This complex forms nucleosomes which are further compacted into higher-
order chromatin structures (Albert et al., 2007; Bartke et al., 2010). Based on the current knowledge, 
each chromatin is characterized by the presence of histone variants and modifications at the amino-
terminal end of the histone proteins, such as acetylation (ac), methylation (me), phosphorylation (p) 
and ubiquitylation (ub) (Barski et al., 2007; Zeng et al., 2010). 
The epigenetic properties of nucleosomes can be differentiated by the incorporation and location of 
histone variants (Albert et al., 2007; Henikoff, 2008). The H3 is one canonical core histone protein, 
deposited throughout the chromosome. In the centromere, the H3 is substituted by the centromere-
specific histone H3 variant (CenH3), which might be involved in the initiation of chromosome 
replication (Furuyama et al., 2006). Another important variant of H3 is H3.3, which is thought to be a 
central player in maintaining epigenetic inheritance at transcriptionally active regions (Tagami et al., 
2004). Most H3.3 variants mark the boundaries of active chromatin modifications, such as di- and 
trimethylation of K4 (H3K4me2 and H3K4me3), dimethylation of K79 (H3K79me2) and acetylation of 
multiple lysines, while negative modifications, e.g. H3K9me2 are absent. Interestingly, Ahmad and 
colleagues removed the N‑terminal tail of H3.3, but could not document any significant effect on 
chromosome assembly, which indicates that terminal modifications might have no influences to the 
localization of H3.3 (Ahmad and Henikoff, 2002). 
H2A histone family, member Z (H2A.Z) represents another kind of histone variant. A genome-wide 
study with budding yeast indicated that it is enriched at tightly packed chromosomes 
(heterochromatin) (Meneghini et al., 2003). Further studies with human cells revealed that H2A.Z is 
localized at enhancers and promoters, with a positive correlation between occupancy and 
transcriptional activity at promoters (Barski et al., 2007). Current evidence indicates that H2A.Z may 
be functionally linked to transcriptional deactivation. Moreover, H2A.Z might play an important role 
in the chromosomal stability. In addition, the crystal structure of H2A.Z indicated that it could 
increase nucleosome mobility by destabilizing nucleosome structure (Suto et al., 2000). 
Histone modifications have been suggested to have functional relevance in transcription regulation 
and genome architecture (Guelen et al., 2008). Numerous genome-wide studies revealed that 
H3K4me1 and histone acetylation are mostly enriched at transcription start sites (promoter regions 
and beginning exons) and correlate positively with expression levels. In contrast to that, H3K4me3 
seems to silence transcriptions activity. Modifications, which take place at H3K9, H3K27, and H4K20, 
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might be involved in heterochromatin formation, which is associated with transcriptional repression. 
The picture is complicated by opposing effects: H3K9me3 and H4K20me3 were detected both silent 
heterochromatic regions and at active zinc finger (ZNF) genes, respectively (Barski et al., 2007). 
These modifications are normally co-localized in the same genomic regulatory regions and termed 
‘bivalent domains’. In embryonic stem cells, it has been suggested that they may provide the 
potential for both transcriptional activation and repression during differentiation (Bernstein et al., 
2006). In addition to that, a similar effect was also found for H2A ubiquitylation which can poise the 
RNA polymerase II in mouse embryo stem cells in a bidirectional manner (Stock et al., 2007). 
1.2.2 DNA methylation patterns 
Currently, DNA methylation refers to the addition of a methyl group to the 5' residues of cytosine in 
the context of cytosine followed by guanine (CpG) dinucleotides. In eukaryotes, DNA methylation 
has also been found at other bases in diverse sequence contexts (Robertson and Wolffe, 2000; 
Paulsen and Ferguson-Smith, 2001; Klose and Bird, 2006).  
It is known that the CpGs dinucleotides are distributed asymmetrically in the human genome, which 
features CpG-rich (so-called CpG Island) and CpG-poor regions. Not all CpGs are methylated (Doi et 
al., 2009; Irizarry et al., 2009). Thirty years ago, it was hypothesized that patterns of DNA 
methylation exist, and that these patterns vary in different cell types. DNA methylation (DNAm) and 
its related proteins were suggested to alter expression through interfering the binding affinities of 
transcription factors (Holliday and Pugh, 1975; Riggs, 1975). In 1980s, Yisraeli and colleagues 
methylated the promoters of beta-globin gene with purified methylases, and they found that 
transcription of beta-globin gene was strongly inhibited in mouse fibroblasts (Yisraeli et al., 1988). 
However, most genes that have CpG-rich promoters lack methylation in this CpG-rich region, yet the 
gene is silent. One example for this phenomenon are globin genes in non-erythroid cells (Bird et al., 
1987). In contrast to that, it was reported that thousands of heavily methylated CpG islands have 
been identified in oocytes and pre-implantation embryos, and these hypermethylations are 
preferentially located within the active transcriptional units (Smallwood et al., 2011). 
DNA methylation plays essential roles in many key processes, such as genomic imprinting, X-
chromosome inactivation and suppression of repetitive elements ( Robertson and Wolffe, 2000). In 
the recent years, DNA methylation was mostly studied in the context of coding regions and 
potentially regulatory elements, however, current evidence suggests that DNA methylation is 
conditionally dynamic (Ito et al., 2010; Ficz et al., 2011; Pastor et al., 2011; Wu et al., 2011a), even 
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outside such regions (Zhang et al., 2006; Alexander et al., 2010; Medvedeva et al., 2010), yet the 
details of this are still largely unknown. 
The variation of DNA methylation in complex diseases has been mainly been investigated in the 
context of tumor and autoimmune diseases. In oncological scenarios, the general hypothesis is that 
tumor development is associated with gain or loss of DNA methylation at key elements. In particular, 
the reprogramming procedure increases the mutation risk and therefore might be involved in the 
initiation of carcinogenesis (Rai et al., 2010). For non-malignant diseases, studies on discordant 
monozygotic twins indicated that variations of DNA methylation are associated to disease 
pathogenisis, such as systemic lupus erythematosus(SLE) (Javierre et al., 2010) and autism-spectrum 
disorders (Nguyen et al., 2010). 
DNA methylation was thought to be stable, however differentiated cellular states can exhibit 
radically altered epigenetic patterns (Yamanaka and Blau, 2010; Jullien et al., 2011). Recent stem 
cells studies showed that 5' methylated cytosines (5-mC) in mammalian cells can be 
hydroxymethylated (5-hydroxymethylcytosine, 5-hmC) during the differentiation (Tahiliani et al., 
2009; Ficz et al., 2011; Gu et al., 2011; Williams et al., 2011a; Wu et al., 2011a).  
5-hmC was reported originally in the 1950s (Wyatt and Cohen, 1952). It was suggested to be strongly 
association with methylation, however, detailed knowledge of the required enzymes catalyzing this 
process in mammalian cells was unknown for decades, until Tahiliani and colleagues discovered the 
enzymatic activity of the ten-eleven translocation (TET) gene family catalyzing the underling the 
conversion of 5-mC to 5-hmC. Recent studies indicate that hydroxylation plays an essential role in 
the epigenetic reprogramming of stem cells, whereas it acts indirectly to mediate active DNA 
demethylation (Tahiliani et al., 2009). 
It has been shown that 5-hmC is abundant in pluripotent embryonic stem cells (ESCs), but it has also 
been found at lower levels in well differentiated tissues (Branco et al., 2011). 5-hmC seems to 
activate a transcription which was silenced by methylation (Tahiliani et al., 2009; Ito et al., 2010) and 
is involved in several other biological processes, however, the role and functional significance of this 
modification is still largely unknown (Ficz et al., 2011; Pastor et al., 2011; Williams et al., 2011a; Wu 
et al., 2011a). 
Hydroxymethylated Cytosine can be demethylated completely through DNA repair mechanisms. 
Hydroxyl-groups can be further deaminated by the AID/APOBEC family, finally replaced via DNA 
repair. 
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Figure 4. DNA Demethylation Pathways. The absence of DNA methyltransferases (DNMTs) regulates 
passive DNA demethylation. The ten-eleven translocation (TET) family of enzymes hydroxylates 5-mC 
to form 5-hydroxymethylcytosine (5-hmC). The AID/APOBEC family members deaminates 5-mC (or 5-
hmC) to 5-methyluracil (5-mU) or 5-hydroxymethyluracil (5hmU) which are demethylated completely 
through the UDG family of base excision repair (BER) glycosylases. Diagram by Bhutani et al., 2011. 
1.2.3 Non-coding RNA and other epigenetic mechanisms 
In addition to DNA and histone modifications, non-coding RNA (ncRNA) is another important 
epigenetic element. While 2% of the genome are protein coding regions (Alexander et al., 2010), 
about 60-70% of the genome is transcribed into non-coding RNA (Washietl et al., 2005; Mattick and 
Makunin, 2006). Recently, various non-coding transcripts have been described to play crucial 
functional roles in normal physiology and in the context of disease (Mercer et al., 2009).  
Currently, most studies in the field of ncRNAs focus on micro RNAs (miRNAs), which are small 
ncRNAs of approx. 22 nucleotides that mediate post-transcriptional gene silencing by degrading 
messenger RNAs (mRNAs) (Pasquinelli, 2012). In human cancer, miRNAs can act as oncogenes or as 
tumour suppressors and therefore can have key functions in tumorigenesis. For example, the 
miR‑200 family regulates the epithelial-to-mesenchymal transition (Davalos et al., 2011). miR‑15 
and miR‑16 are dysregulated in most B cell chronic lymphocytic leukaemias and result in 
chromosome 13q14 deletion (Calin et al., 2002).  
PIWI-interacting RNAs (piRNAs) are 24–30 nucleotides long. Unlike miRNA, piRNAs are dicer-
independent, but bind the PIWI subfamily of argonaute family proteins instead. The piRNA and PIWI 
protein complex that is formed by piRNAs and PIWI proteins suppresses transposable element 
expression and mobilization. Interestingly, the piRNA might serve as a navigating element in the 
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base-pairing recognition (Gunawardane et al., 2007). The mechanisms of piRNAs and PIWI proteins 
are mostly unknown. It was suggested that they might be involved in potentially disease-relevant 
processes, such as carcinogenesis (Lee et al., 2006; Taubert et al., 2007; Liu et al., 2010; Sun et al., 
2011), stem cell self-renewal (Sharma et al., 2001) and DNA repair (Wang et al., 2011). 
lncRNAs (long non-coding RNAs) are normally longer than 200 nucleotides and are involved in many 
biological processes. Various mechanisms have been proposed by which IncRNAs regulate the 
expression at transcriptional level. At the human Homeobox (HOX) loci, various IncRNAs are 
expressed sequentially, temporally or spatially, which regulate genes expression through modulation 
of chromatin accessibility (Rinn et al., 2007). Similar to the navigational function, X-inactivation 
specific transcript (XIST) lncRNA (17 kb) recruits the polycomb complex to silence the X chromosome. 
Its anti-sense IncNRA TSIX is transcribed from the opposite strand to XIST that regulates XIST 
transcription during X-chromosome inactivation (Navarro et al., 2006). 
Another class of lncRNAs are lincRNAs (long intergenic non-coding RNAs), which are transcribed 
from intergenic regions. One well-known example of IncRNAs is HOX transcript antisense RNA 
(HOTAIR), which is expressed in the anti-sense region of HOX genes. It is involved in polycomb 
protein retargeting throughout the genome, and associated with cancer metastasis (Gupta et al., 
2010). 
Ultraconserved regions (UCRs) transcribe numerous ncRNAs. So far, 481 ncRNAs were described to 
origin from UCRs, some of which extend to coding regions. However, more than half of them do not 
translate into any protein. Transcribed ultraconserved regions (T-UCRs) are expressed in various 
tissues, while some are specific to cell lines, whereas the function of T-UCRs is still mostly unknown. 
Interestingly, it was reported that some T-UCRscan bind to miRNAs and might be involved in the 
carcinogenesis (Calin et al., 2007).  
1.2.4 Epigenetics and environment 
Epigenetic patterns do not persist throughout life, although the epigenomes, inducing DNA 
methylation and histone modification, are believed to be stable (Reik, 2007; Kota and Feil, 2010; Law 
and Jacobsen, 2010). Epigenetic alterations in the context of stem cell reprogramming during 
differentiation are well studied. However, it is thought that epigenetic changes are regulated by both 
- environmental factors and intrinsic factors (Feil and Fraga, 2011).  
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The significant impact of environmental factors on epigenetic patterns is exemplified in honeybees, 
in which differential nutrition determines whether the bee will be a worker or a queen. Evidence 
indicates that nutrition-determined phenotype in honey bees is highly associated with DNA 
methylation (Kucharski et al., 2008). A recent study with Arabidopsis thaliana revealed that different 
ambient temperatures alter the enrichment of a variant of histone H2A.Z incorporation, and 
nucleosomes containing the alternative histone H2A.Z are essential to perceiving ambient 
temperature correctly. Nucleosomes containing variants of H2A.Z- therefore result in altering the 
transcriptome in response to the ambient temperature (Kumar and Wigge, 2010). In mammals, the 
available S‑adenosylmethionine (SAM) is the methyl donor for DNA and histone methylation. The 
amount of SAM is determined by the one-carbon-metabolism pathway. Numerous nutrients can 
affect this pathway, such as folate, vitamin B6, vitamin B12, betaine, methionine and choline. It was 
reported that histone methylation might be positively correlated with the availability of methyl 
donors (Zhou et al., 2008). However, dietary components do not only provided reagents, but also 
influence the activity of enzymes linked to epigenetic mechanisms, such as butyrate, which 
potentially inhibits the histone deacetylases (HDACs) (Dashwood and Ho, 2007). Another example in 
mammals is sirtuins, a class of HDACs that target acetylated histones which simultaneously require 
nicotinamide adenine dinucleotide (NAD+) (Imai et al., 2000; Vaquero et al., 2004). It is therefore 
supposed that the enzymatic activity of sirtuins might depend on nutritional and metabolic factors 
(Kaeberlein et al., 2005; Beher et al., 2009). Moreover, a recent study showed a strong association 
between DNA methylation and histone methylation, while sirtuin 1 (SIRT1) can deacetylate DNMT1 
and alter its activity (Peng et al., 2011). 
1.2.5 Twin studies 
For multifactorial traits or complex diseases, genome-wide association studies have shown that 
genetics contribute significantly to the variation observed on population level. Various of these 
phenotypes significantly increased over the last decades along with sudden social and environmental 
changes (Willett, 2002). Twin studies provide considerable evidence that risk factors aggregate in 
siblings attributed to shared genes and shared environment (Bouchard et al., 1999; Eaves et al., 
1999; Koopmans et al., 1999; van den Bree et al., 1999). 
Naturally, twins have a higher phenotypic resemblance than unrelated individuals. Particularly, 
monozygotic (MZ) twins have always attracted the curiosity of researchers, as MZ twins derive from 
a single fertilized egg and therefore are traditionally regarded as genetically identical (Boomsma et 
al., 2002). Despite the fact that disease-discordant MZ twins have completely identical genetic 
background, age, sex, similar maternal influences, and even other environmental factors, 
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interestingly, rates of disease discordance in MZ twins are usually higher than explainable by 
heritability (Silman et al., 1996; Kendler and Prescott, 1999; MacGregor et al., 2000). This indicaties 
that mechanisms like epigenetics might be involved in the bivalent pathogenesis (Healthy<---
>Disease) of discordant MZ twins (Petronis, 2010). 
One of the earliest epigenetic studies of MZ discordant twins was performed to interrogate different 
methylation in the dopamine D2 receptor gene (DRD2) in two schizophrenic discordant twins. In this 
study, greater methylation differences were observed between discordant MZ twins than between 
unrelated individuals (Petronis et al., 2003). Further studies identified various other phenotype-
associated methylation changes in discordant MZ twins (Mill et al., 2006; Oates et al., 2006; 
Kuratomi et al., 2008). These evidences showed that MZ twin studies are a powerful approach in 
detecting disease-related epigenetic changes and probably can detect effects, which cannot be 
identified by employing traditional studies with unrelated individuals.  
1.3 Hypothesis and Aims of the study 
Current understanding assumes that both, genetic and environmental factors, are involved in the 
pathogenesis of ulcerative colitis, yet the etiology of ulcerative colitis is largely unclear. The disease 
complexity poses a major challenge when identifying mechanisms of pathological relevance. In this 
context, epigenetic modifications might represent a major interface between internal and external 
factors.  
 Hypothesis: 
The underlying hypothesis of the study is therefore, that epigenetic modification of disease 
relevant genes results in altered gene expression with pathological consequences, contributing 
to disease mechanisms. 
 Aims: 
 The main aim of the study is to present a high-resolution map of epigenetic modifications with 
potentially disease relevant effects on the transcriptome of ulcerative colitis. Integrating these 
results into the current picture of ulcerative colitis disease pathophysiology may help to close 
the gap between genetic susceptibility, missing heritability and disease manifestation. 
 Subsequently, the alteration of DNA methylome in ulcerative colitis has been observed and 
investigated. DNA demethylation may play a important role in the pathogenesis of ulcerative 
colitis, and need further investigation.  
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2 Materials and Methods 
The initial part of this project was completed as a collaborative effort between Institute of Clinical 
Molecular Biology, University of Kiel and the Sanger Institute, University of Cambridge, while the 
downstream analysis and validation was carried out exclusively at the Institute of Clinical Molecular 
Biology as part of this thesis. 
2.1 Patient group composition and sample preparation 
2.1.1 Patient Recruitment 
The twenty monozygotic twins, discordant for ulcerative colitis (screening panel; median age: 25, 
range 18-70) recruited for this study were tested for mono/dizygosity as previously published 
(Barbaro et al., 2004; von Wurmb-Schwark et al., 2005).  
The panel for real time PCR validation of transcript levels consisted of 135 unrelated individuals 
(validation panel I; n=30 ulcerative colitis, inflamed; n=30 ulcerative colitis, non-inflamed, n=30 
healthy individuals; n=15 disease controls, inflamed; n=30 disease controls, non-inflamed; median 
age: 41 ; age range 18-76), a subgroup of which was used for pyrosequencing validation of 
methylation levels (validation panel II; n=20 ulcerative colitis, inflamed; n=20 healthy individuals, 
n=10 disease controls; inflamed, median age: 41, age range 18-68). Another subgroup of which was 
used for Chromatin immunoprecipitation following quantitative real time PCR (ChIP - qRT PCR) 
examination of hydroxymethylation levels (Examination panel; n=5 disease controls, inflamed; n=5 
ulcerative colitis, inflamed and not inflamed from same patient respectively; median age: 52, age 
range 25-64). 
Healthy individuals included in the study were undergoing colonic cancer surveillance with no 
previous unspecific changes in stool habits, where endoscopic and histological examination yielded 
no significant pathological findings. Ulcerative colitis patients were selected to display an 
endoscopically active disease in the sigmoid colon at the time of sampling. More than 2000 patients 
were screened to recruit the study population. Disease-specificity controls included individuals with 
infectious diarrhea, other forms of gastrointestinal inflammation or irritable bowel syndrome. The 
study setup was approved by the Bioethical Committee of the University of Kiel, where the patients 
were recruited. All patients gave written informed consent before data and biomaterials were 
collected. Patient characteristics are summarized in table. 
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Panel type Application Relationship of 
Individuals 
Gender Age: 
median, 
range 
Disease 
representation 
Screening 
panel 
Genome-wide 
screening of the 
transcriptome and 
methylome 
discordant twins (UC, 
HN) 
10 f 
10 m 
25, 18-70 10 UC 
10 NC 
Validation 
panel I 
validation of the 
findings in the 
transcriptome 
unrelated individuals 69 f 
66 m 
41, 18-76 30 UCi; 30 
UCni 
15 DCi; 30 
DCni 
30 NC 
Validation 
panel II 
validation of the 
findings in the 
methylome 
unrelated individuals 25 f 
25 m 
  
41, 18-68 20 UC 
10 DC 
20 NC 
 (Є panel I) 
Examination 
panel III 
Examination of the 
predictings in the 
hydroxymethylome 
unrelated individuals 5 f 
5 m 
52, 25-64 5 UCi; 5 Ucni 
5 DC 
Table 2. Study panels I, used for genome-wide assessment of differential expression and DNA 
methylation as well as for validation and examination of initial findings. f = female, m = male, UC = 
ulcerative colitis, NC = normal controls, DC = disease specificity controls, suffix: i= inflamed, ni= not 
inflamed. 
2.1.2 Samples storage and preparation 
All reagents, glassware and laboratory utensils were specially treated in order to minimize RNA and 
DNA degradation: Solutions were prepared with 0.1% Diethylpyrocarbonate (DEPC)-treated distilled 
water and sterilized by autoclaving. All glassware, ceramic mortar and pestles, Teflon pestles and 
metal spatulas were cleaned with common laboratory washing detergent, rinsed thoroughly in 
distilled water and air-dried before wrapping in aluminum foil and baking at 180 Grad Celsius (°C) for 
12-16 hours (h) before use, in order to inactivate any contaminating nucleases. All plastic ware were 
purchased as ultraviolet (UV) -sterilized consumables or nuclease-free consumables. 
All biopsies used in this study are primary tissue from the intestinal mucosa. Biopsies were taken 
under endoscopy from a defined area of the sigmoid colon, and immediately snap-frozen in liquid 
nitrogen. To minimize premature thawing of the biopsies during RNA and DNA isolation, 
homogenization equipments (mortar, pestle, polyethylene tubes) were cooled with liquid nitrogen 
prior to the begin of the isolation.  
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2.1.3 RNA extraction from biopsy 
A commercial RNA isolation kit was used to extract total RNA from biopsies (RNeasy mini-kit, 
Qiagen), according to the manufacturer’s protocol. Briefly, prior to the isolation, DNAse stock 
solution was prepared by reconstituting lyophilized DNAse enzyme (Qiagen) by the addition of 550 
microliter (µL) of RNAse-free water. This DNAse stock solution (10 µL, 2.7 Kunitz units/µL) was 
further diluted in 70 µL RDD buffer (as provided in RNAse-free DNase Kit). One mucosal biopsy was 
homogenized into a fine powder using a cooled Teflon mortar in a 1.5 milliliter (mL) microfuge tube. 
The powder was then mixed with 650 µL of RLT lysis solution, incubated at room temperature for 10 
minutes (min) and vortexed for 30 seconds (s). The lysate was then further centrifuged through a 
QIA shredder column for 2 min at 14000 rpm in a microfuge. The eluate was centrifuged for 3 min at 
14000 rounds per minute (rpm) and the cleared lysate was transferred into a new microfuge tube. 
One volume of 70% ethanol was then added to the lysate, mixed well by vortexing and loaded onto 
an RNA binding column fitted in a 2 mL collection tube. The solution was centrifuged through the 
binding column for 15 s at 10000 rpm. The mini-column was washed once with 350 µL of RW1 buffer 
on to the column, incubated for 10 min at room temperature and then centrifuged 15 s at 10000 
rpm. DNAse treatment of the RNA was carried out while the RNA was still bound on the column. The 
diluted DNAse (80 µL) was pipetted directly on to the spin column membrane and allowed to 
incubate at room temperature for 15 min. Upon completion of the digestion step, the mini-column 
was washed once with 350 µL buffer RW1 and twice with 500 µL buffer RPE. Each wash step was 
completed by centrifuging the tube 15 s at 10000 rpm. To completely rid the column of wash 
solution, the column was then centrifuged 1 min at 14000 rpm. Total RNA was eluted from the mini-
column into an RNAse-free microfuge tube by pipetting 50 µL of RNAse-free water directly onto the 
membrane, allowing to completely soak through the membrane at room temperature for 5 min and 
then centrifuging 1 min at 10000 rpm. 
2.1.4 DNA extraction from biopsies 
A commercial kit was used to isolate total DNA from biopsy material (QIAamp Tissue DNA 
preparation kit, Qiagen), according to the manufacturer’s protocol. Briefly, one mucosal biopsy was 
homogenized into a fine powder using a cooled Teflon mortar in a 1.5 mL microfuge tube. 100 µL 
Buffer ATL was added, and homogenized with rotor-stator homogenizer. 20 μl proteinase K was 
added, and mixed by vortexing, then incubated on a rocking platform at 56°C until the tissue is 
completely lysed. The 1.5 ml microcentrifuge tube then centrifuged briefly in order to remove drops 
from the inside of the lid. As RNA free genomic DNA samples are required for this project, for the 
RNAse-treatment, 4 μl RNase A (100 mg/ml) was added at first, then mixed by pulse-vortexing for 15 
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s, and incubated for 2 min at room temperature. The tube was centrifuged to remove drops from 
inside the lid before adding 200 μl Buffer AL to the sample. The sample mixed again by pulse-
vortexing for 15 s, and incubated at 70°C for 10 min. 200 μl ethanol (96–100%) was added to the 
sample, and mixed by pulse-vortexing for 15 s, the tube was then centrifuged to remove drops from 
inside the lid. The mixture was carefully applied to the QIAamp Mini spin column (in a 2 ml collection 
tube) without wetting the rim. Closing the cap, and centrifuged at 8000 rpm for 1 min. The QIAamp 
Mini spin column then placed in a new 2 ml collection tube, and the tube containing the filtrate was 
discarded. The QIAamp Mini spin column was washed with 500 μl Buffer AW1 ithout wetting the rim 
and centrifuged at 8000 rpm for 1 min, then placed in a new 2 ml collection tube, and the collection 
tube containing the filtrate was discarded. Similarly, the QIAamp Mini spin column was washed with 
AW2 at 14,000 rpm for 3 min. The QIAamp Mini spin column was placed in a new 2 ml collection 
tube and the old collection tube with the filtrate was discarded. After centrifuging at full speed for 1 
min, the QIAamp Mini spin column was placed in a clean 1.5 ml microcentrifuge tube, 50 μl distilled 
water was added and Incubated at room temperature for 1 min, then centrifuged at 8000 rpm for 1 
min. 
2.1.4.1 RNA and DNA quantity and quality control 
There are several ways to quantitate pure solutions of RNA or DNA samples, however, the most 
commonly used technique is the determination of absorbency in a UV spectrometer at 260/280 nm 
or at 260 nanometer (nm) respectively. Briefly, the distilled H2O was used as a solvent to suspend 
the nucleic acids, and place each sample in a quartz cuvette. The spectrophotometer must be 
blanked with a sample of solvent before use. For more accurate readings of the nucleic acid sample, 
it could be diluted to give readings between 0.1 and 1.0. 
As all of the downstream applications in this project were performed with fragmented genomic DNA, 
the integrity of DNA samples was not examined specially. However, the isolation of intact RNA is 
essential for the ongoing analysis. The quality control of RNA samples was performed with a 
microcapliallry electrophoresis system (Agilent 2100 Bioanalyzer). Briefly, the gel was prepared at 
first. 550 μl of RNA 6000 Nano gel matrix was pipetted into a spin filter, and centrifuged at 14,000 
rpm for 10 minutes at room temperature, then 65 μl filtered gel pipetted into 0.5 ml RNase-free 
microfuge tubes. Second, the gel-dye mix was prepared. The RNA 6000 Nano dye concentrate was 
equilibrated to room temperature for 30 min, then RNA 6000 Nano dye concentrate was vortexed 
for 10 seconds and spun down. 1 μl of dye was added into a 65 μl aliquot of filtered gel and 
vortexed, centrifuged at 12,000 rpm for 10 min at room temperature. Third, the Gel-Dye Mix was 
loaded on the RNA chip. A new RNA 6000 Nano chip was fixed on the chip priming station. 9.0 μl of 
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gel-dye mix was pipetted in the corresponding well, then the chip priming station was closed and the 
plunger was pressed until it was held by the clip. The clip was released after exactly 30 seconds, then 
the plunger was slowly pulled back to 1ml position. The chip priming station was then opened and 
9.0 μl of gel-dye mix pipetted in the corresponding wells. The remaining gel-dye mix was discarded. 
Forth, the Agilent RNA 6000 Nano Marker was loaded. 5 μl of RNA 6000 Nano was pipetted in all 
wells, except Gel-Dye Mix wells. At the end, the ladder and samples were loaded on the chip. 1 μl 
ladder was pipetted in the ladder well, and 1 μl of sample was pipetted in each of the 12 sample 
wells. The chip was horizontally placed in the adapter of the IKA vortexer and vortexed for 1 min at 
2400 rpm. Finally, the Agilent 2100 bioanalyzer was started to run the analysis, resulting in one 
electropherogram per sample.  
2.2 Genome-wide scanning of the transcriptional and methylational profiling 
All of the genome-wide scanning were performed using the samples from ten pairs monozygotic 
discordant twins, see table 3 for detail. 
Panel type Application Relationship of 
Individuals 
Gender Age: 
median, 
range 
Disease 
representation 
  
Screening 
panel 
Genome-wide 
screening of the 
transcriptome 
and methylome 
discordant twins 
(UC, HN) 
10 f 
10 m 
25, 18-70 10 UC 
10 NC 
Table 3. Study panels II, used for genome-wide assessment of differential expression and DNA 
methylation. f = female, m = male, UC = ulcerative colitis, NC = normal controls, suffix: i= inflamed, ni= 
not inflamed. 
2.2.1 Genome-wide Transcriptome Profiling (Layer I) 
Total RNA was prepared and hybridized to an Affymetrix UG 133 Plus 2.0 (Affymetrix, Santa Clara, 
California, US) according to the manufacturer’s protocol. Experimental and analytical part of the 
microarray analysis was performed following the MIAME standards.  
2.2.1.1 RNA samples labeling and target hybridization 
GeneChip® reagent kits was used to prepare biotinylated target from purified RNA samples, which is 
suitable for hybridization to GeneChip expression probe arrays. Briefly, double-stranded cDNA was 
synthesized from total RNA isolated from tissue according to the protocol provided in the kit. An in 
vitro transcription (IVT) reaction was then performed to produce biotin-labeled cRNA from the 
cDNA. The cRNA was fragmented before hybridization according to the manufacturer’s instructions. 
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A hybridization cocktail was prepared, including 15 micrograms (µg) fragmented and labeled cRNA, 
5µL control oligonucleotide B2 (3 nM), 150µL 2X hybridization Mix, 30µL DMSO, and nuclease-free 
Water to final volume of 300 μL. Probe array was equilibrated to room temperature immediately 
before use. Then, the hybridization cocktail was heated to 99°C for 5 minutes in a heat block, and at 
the same time, the array was wet with an 300µL of Pre- Hybridization Mix by filling it through one of 
the septa. The probe array filled with pre-hybridization mix was incubated at 45°C for 10 minutes 
with rotation. The hybridization cocktail was transferred that has been heated at 99°C, to a 45°C 
heat block for 5 minutes. The hybridization cocktail was centrifuged at maximum speed in a 
microcentrifuge for 5 minutes to collect any insoluble material from the hybridization mixture. The 
array was vented with a clean pipette tip and the Pre-Hybridization Mix was extracted from the array 
with a micropipettor. Then the array was refilled with the appropriate volume of the clarified 
hybridization cocktail. Probe array was then placed into the hybridization oven rotated at 60 rpm 
and incubated at 45°C for 16 hours. 
2.2.1.2 Bioinformatic analyses 
Data was normalized using GCRMA (R, Bioconductor) and signals that were not present in at least 
80% of the samples (cutoff: detection p-value ≤ 0.05) were excluded from further analysis. 
Experimental and analytical part of the microarray analysis was performed following the MIAME 
standards. Differentially expressed genes were determined using the Mann-Whitney U-test, multiple 
testing correction was performed using the Benjamini-Hochberg method (Benjamini and Hochberg 
1995) and a false discovery rate (FDR) for the signed fold changes (which were based on the ratios of 
the medians of each group compared) was estimated based on a Westfall and Young permutation, 
using K=5000 permutations (Westfall and Young 1993). Criteria for transcripts to be categorized as 
differentially expressed were set to: i) corrected p-value ≤ 0.05 and ii) FDR ≤ 5%. 
2.2.2 Genome-wide Quantification of Differentially Methylated Regions (Layer II) 
DNA was prepared and hybridized to a custom tiling array (Nimblegen, custom 385k array) as 
previously described (Rakyan et al., 2008). The array was designed to cover known 
autoimmune/inflammatory linked Loci as well as specific genes with immune-regulatory function 
and encompassed all known promoters and CpG islands (both promoter- and non-promoter-CpG 
islands). Data was normalized applying the interquantile normalization using Spotfire for functional 
genomics (TIBCO, Palo Alto, CA, USA). Differences between ulcerative colitis patients, diseased 
controls and healthy individuals were determined using the Mann-Whitney U-test, while p-values 
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were corrected according to Benjamini and Hochberg (Benjamini and Hochberg 1995). DMRs with a 
corrected p-value ≤ 0.05 were considered significantly differentially methylated. 
2.2.2.1 Immunoprecipitation of methylated DNA 
DNA concentration in the cell is relatively low. A ligation-mediated PCR (LM-PCR) step was induced 
to amplify the samples. Comparison of array hybridization performance before and after LM-PCR 
indicated that the LM-PCR did not introduce significant amplification bias (Down et al., 2008). Briefly, 
2.5 µg of genomic DNA was fragmented to a size range of from 300 to 800 bp, then blunt-ended by 
incubation for 20 min at 12°C in a 120-μL reaction tube containing the DNA sample, 1× Buffer 2 
(NEB), 10× BSA (NEB), 100 μM dNTP mix, and T4 DNA polymerase (NEB). The reaction products was 
purified with a Zymo-5 kit (Genetix) according to the manufacturer’s instructions, while the final 
elution was carried out in 30 µL of TE buffer (pH 8.5). Ligation of the adaptors was performed by 
incubating overnight at 16°C in a final volume of 100 µL containing the DNA sample, 40 μL adaptors, 
T4 DNA ligase 10× buffer, 5 μL of T4 DNA ligase (NEB). The reactions were purified with the Zymo-5 
kit as described above. In order to fill in the DNA-overhangs, the sample DNA was incubated at 72°C 
for 10 min in a reaction containing the DNA, 100 micromol (μM) dNTPs, 1× AmpliTaq Gold PCR buffer 
(Applied Biosystems), 1.5 millimol (mM) MgCl2, 5 U AmpliTaq Polymerase. The DNA was purified 
with the Zymo-5 kit as described above. A total of 50 ng of the ligated sample was set aside as the 
input fraction; 1.2 μg of the ligated DNA sample was subjected to a methyl-DNA 
immunoprecipitation (MeDIP) assay (Nimblegen) that uses antibodies specific for 5-methyl–cytosine 
residues according to the manufacturer’s instructions. The immunoprecipitated (IP) sample was also 
purified with Zymo-5 kit (using 700 µL of binding buffer) according to the manufacturer’s 
instructions. 10ng of each IP and input fraction for each sample were amplified with PCR (20 cycles) 
using the Advantage-GC genomic PCR kit (Clontech). After the LM-PCR, the duplicate reactions were 
combined, purified with a Qiagen PCR-clean up kit (Qiagen), and eluted in 50 µL H2O. The MeDIP and 
input fractions were sent to Nimblegen for hybridization. 
2.2.2.2 Array design 
The microarray consists of 382,178 50-bp anti-sense oligonucleotides. Although the aim was to 
target all annotated TSSs and nonpromoter CpG islands (CGIs), it is impossible to design enough 
suitable unique probes for 18% of the Transcriptions Start Sites (TSSs) and 28% of nonpromoter CGIs 
at that time, largely due to the presence of repeat elements. However, the array contained 50-bp 
probes tiled at ∼100 bp density throughout the entire human Major Histocompatibility Complex, 
and promoters and nonpromoter CGIs on the X and Y chromosomes. In addition, the array was 
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originally designed with NCBI build 35 version of the human genome assembly, but then mapped to 
NCBI build 36 using Exonerate (Slater and Birney, 2005). To be mapped, probes were normally 
required to align full-length and without gaps or mismatches so that the probes which aligned more 
than once to the NCBI36 sequence were removed for further analysis. Tiled regions were defined by 
clustering uniquely mapped probes within 200 bp of one another. Singleton probes were discarded. 
The tiled regions were then divided into 500-bp ROIs.  
2.2.2.3 Bioinformatic analysis 
Data was normalized applying the interquantile normalization with Spotfire (TIBCO, Palo Alto, CA, 
USA). Different methylation between ulcerative colitis patients, diseased controls and healthy 
individuals were determined using the Mann-Whitney U-test, and p-values were further corrected 
according to Benjamini and Hochberg (Benjamini and Hochberg 1995). DMRs with a corrected p-
value ≤ 0.05 were considered significantly differentially methylated. 
2.2.3 Genome-wide Quantification of individual Methylation Variable Positions (Layer III) 
DNA Methylation analysis was performed using the Illumina Infinium Human Methylation27 
BeadChip (iScan system, Illumina). while the dataset was subject to intra-array and inter-array 
normalization as published earlier (Teschendorff et al., 2010). Differences between ulcerative colitis 
patients, diseased controls and healthy individuals were determined using the Mann-Whitney U-
test, while p-values were corrected according to Benjamini and Hochberg (Benjamini and Hochberg 
1995). MVPs with a corrected p-value ≤ 0.05 were considered significantly differentially methylated. 
2.2.3.1 Bisulfite conversion 
Genomic DNA samples were treated with bisulfite (so called bisulfite conversion) using the EZ DNA 
methylation Kit (Zymo Research, D5002) according to the manufacturer's protocol with 
modifications for the Illumina Infinium Methylation Assay. Briefly, 1mg genomic DNA was mixed and 
incubated with 5 µL M-Dilution at 37°C for 15 minutes, then mixed with 100 µL of CT conversion 
reagent prepared as mentioned in the protocol and incubated in a thermocycler for 16 cycles at 95°C 
for 30 seconds and 50°C for 60 minutes. Bisulfite-converted DNA samples were then loaded onto 96-
column plates which has provided in the kit for desulphonation and purification according to the 
protocol. Concentration of eluted DNA was determined with a Nanodrop-1000.  
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2.2.3.2 Illumina Infinium Human Methylation27 BeadChip 
Bisulfite-converted DNA samples were loaded on Illumina's Infinium Human Methylation27 Beadchip 
Kit. 27,578 CpG loci were designed on the baeadchip which located within the proximal promoter 
regions of transcription start sites covering more than 14,000 human reference sequences (RefSeq) 
genes at single-nucleotide resolution. Chip processing and data generation were performed 
according to the manufacturer's manual. Briefly, 4 µL of bisulfite-converted genomic DNA samples 
were denatured in 0.014N sodium hydroxide, neutralized and amplified with kit-provided reagents 
and buffer for 20–24 hours at 37°C. Genomic DNA samples were fragmented. 12 µL of each sample 
was loaded onto a 12-sample chip, then placed into a hybridization chamber according to the 
manual. Chips were incubated at 48°C for 16–20 hours, then washed with wash buffers provided in 
the kit and assembled into a fluid flow-through station for primer-extension reaction and staining 
according to the protocol provided in the kit. A single base extension was then performed using 
labeled DNP- and biotin labeled dNTPs. Polymer-coated chips were image-processed in Illumina's 
iScan scanner. Data were generated using BeadStudio v3.0 software. Here, each interrogated locus is 
represented by specific oligomers linked to two bead types: one representing the sequence for 
methylated DNA (M) and the other for unmethylated DNA (U). The methylation status of a specifc 
CpG site is then calculated from the intensity values of the M and U alleles, as the ratio of 
fluorescent signals (β-value). This value is based on following definition and calculation: 
ß-value=Max (M,0)/[Max (M,0)+Max (U,0)+100]. 
Human HCT116 methylated DNA (Cat# D5014-2, Zymo Research) was used as a positive control for 
methylation analysis and Human HCT116 DKO DNA (DNA methyltransferase double knock-out cells 
(DNMT1 and DNMT3b) was used as a negative control for methylation analysis, prepared by Core 
Facility). Replicate samples (N = 3) were included to assess inter-array reproducibility. 
2.2.3.3 Bioinformatic analyses of differential methylation 
ß-values were normalized applying quantile normalization, the dataset quality was examined based 
on the detection p-values. Datapoints containing more than two defect (detection p-value >0.05) 
measurements were eliminated. Differences between ulcerative colitis patients, diseased controls 
and healthy individuals were determined using the Mann-Whitney U-test, while p-values were 
corrected according to Benjamini and Hochberg (Benjamini and Hochberg 1995). MVPs with a 
corrected p-value ≤ 0.05 were considered significantly differentially methylated. 
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2.3 Merging of the transcriptional and methylational data (from Layer I,II & III) 
To identify disease associated transcripts under potential epigenetic control, differentially expressed 
transcripts from layer I were selected (corrected p ≤ 0.05, FDR ≤ 5%, regulated between healthy and 
diseased individuals). The genomic transcript locations were used to generate interaction windows 
of 50 kb up and downstream of the transcription start site (TSS). These windows were examined 
whether they contain either a DMR (layer II, corrected p ≤ 0.05, between healthy and diseased 
individuals) or a MVP (layer III, corrected p ≤ 0.05, between healthy and diseased individuals). 
Transcripts, significantly regulated between healthy and diseased individuals with a significantly 
regulated DMR or MVP within the 50kb window of the TSS were considered candidates for disease 
associated transcripts under potential epigenetic control. 
 
Figure 5. Flow diagram of genome-wide analysis. 
2.4 Validation of the transcriptional and methylational candidates  
The validation steps were performed using current gold-standard methods, such as quantitative real 
time PCR for the expression candidates and the bisulfite pyrosequencing for the methylation ones. 
The individuals in the validation group were selected randomly from the group of unrelated 
individuals, and all candidates genes with potential epigenetic influence on disease associated 
mRNA-expression in cis were subjected to validation. 
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Panel type Application Relationship of 
Individuals 
Gender Age: 
median, 
range 
Disease 
representatio
n   
Validation 
panel I 
validation of 
the findings in 
the 
transcriptome 
unrelated individuals 69 f 
66 m 
41, 18-76 30 UCi; 30 
UCni 
15 DCi; 30 
DCni; 
30 NC 
Validation 
panel II 
validation of 
the findings in 
the 
methylome 
unrelated individuals 25 f 
25 m 
  
41, 18-68 20 UC 
10 DC 
20 NC 
(Є panel I) 
Table 4. Study panels III, used for validation of initial findings. f = female, m = male, UC = ulcerative 
colitis, NC = normal controls, DC = disease specificity controls, suffix: i= inflamed, ni= not inflamed. 
2.4.1 Validation of differential mRNA expression via Real-Time PCR 
Real time PCR (TaqMan) was performed according to the manufacturers guidelines (Applied 
Biosystems, Foster City, California, USA) using a 7900HT Real-Time PCR System (Applied Biosystems, 
Foster City, California, USA). Expression levels were calculated relative to beta-actin using the 
standard-curve method (Livak and Schmittgen 2001). Differences between ulcerative colitis patients, 
diseased controls and healthy individuals were determined using the Mann-Whitney U-test, while p-
values were corrected according to Benjamini and Hochberg (Benjamini and Hochberg 1995). 
2.4.1.1 Prepare the cDNA sample 
Before running the TaqMan Gene Expression Assays, total RNA from 135 unrelated individuals was 
isolated as a template for the synthesis of single-stranded cDNA, as described in section 2.1.3. The 
reverse transcription was performed using High Capacity RNA-to-cDNA Kit (PN 4387406). The 
quantity of the cDNA was measured using the UV absorbency (A260/A280) method. 
2.4.1.2 Prepare the reaction mix and load the plate 
TaqMan Gene Expression Assays (20X) and cDNA samples were thawed on ice, completely 
resuspended by gently vortexing, then briefly centrifuged to bring the liquid to the bottom of the 
tube. The master mix reagent was mixed by gently swirling the bottle. Each assay run was performed 
in technical duplicates for each sample, supplemented by endogenous control assays (ACTB) and non 
template controls (NTCs, containing H2O). 
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Symbol Gene name TaqMan ID 
FLNA filamin A, alpha (actin binding 
protein 280) 
Hs00155065_m1 
MT1H metallothionein 1H Hs00823168_g1 
SPINK4 serine protease inhibitor, Kazal 
type 4 
Hs00205508_m1 
THY1 Thy-1 cell surface antigen Hs00174816_m1 
CFI complement factor I Hs00173409_m1 
IGH@ immunoglobulin heavy constant 
gamma 1 (G1m 
marker);immunoglobulin heavy 
constant gamma 4 (G4m 
marker);immunoglobulin heavy 
locus;immunoglobulin heavy 
constant gamma 3 (G3m 
marker);immunoglobulin heavy 
variable 4-31;immunoglobulin 
heavy constant mu 
Hs00378230_g1 
HKDC1 hexokinase domain containing 1 Hs00228405_m1 
VIPR1 vasoactive intestinal peptide 
receptor 1 
Hs00270351_m1 
PTN pleiotrophin Hs01085691_m1 
IRS2 insulin receptor substrate 2 Hs00275843_s1 
TK1 thymidine kinase 1, soluble Hs00177406_m1 
SLC7A7 solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 7 
Hs00374418_m1 
ACTB actin, beta Hs99999903_m1 
Table 5. TaqMan assays for validation of findings from genome-wide data. 
 
PCR reaction mix component Volume per 20-μL reaction (μL) 
20X TaqMan® Gene Expression Assay 1 
2X TaqMan® Gene Expression Master Mix 10 
cDNA template (1 to 100 ng) 4 
RNase-free water 5 
Table 6. Component of the PCR reaction mix. 
The mixture was loaded on the 384-well reaction plate, and then the plate was sealed with the 
appropriate cover and centrifuged briefly. The plate was finally loaded into the 7900HT Fast system 
(Applied Biosystems) using the following thermocycling profile: 50°C for 2 min; 95°C for 10 min; and 
40 cycles of: 95°C for 15 s; 60°C for 1 min. 
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2.4.1.3 Bioinformatic analyses 
Upon completion of the run, the data was generated by the Sequence Detection System (SDS) 2.0 
software. Differences between ulcerative colitis patients, diseased controls and healthy individuals 
were determined using the Mann-Whitney U-test, while p-values were corrected according to 
Benjamini and Hochberg (Benjamini and Hochberg 1995). 
2.4.2 Validation of differential DNAm via Pyrosequencing 
Validation of initial findings was performed via bisulfite conversion followed by pyrosequencing 
(Roche, 454) as previously described (Bollati et al., 2007). Differences between ulcerative colitis 
patients, diseased controls and healthy individuals were determined using the Mann-Whitney U-
test, while p-values were corrected according to Benjamini and Hochberg (Benjamini and Hochberg 
1995). 
 
Gene Symbol Forward 
primer 
Reverse 
primer 
Seqence 
primer 
Target sequence 
THY1 agtttaggggttga
agaa 
cctatccctcccta
at 
taggggttgaagaa
g 
AYGTAATGTTTAGAGTAAAAAGY
GTTTGTAGTTTTTTGAAGGGTTGG
GTGTTTTGGAATAGATGAGGGGG
YGAAATGGGGTTGGGGATTAGG
GAYGGA 
IGH@ gtttgataaagtaa
gggtatt 
cttcctaaacact
caatctatat 
agataaaggatgtt
ttg 
YGTGGGGAAATGTGGTGATA 
SPINK4 ggatttgggttatttt
tgt 
ctaccaaatatttt
ttccttaact 
gattagtgatttaaa
tagaaa 
AAGTAYGGTTTTGATGGAGTATA
AATTTAATGGGGTAGAGGAAAAG
GGGAAAGGTAATAAATAAGATG
GTTATAATGTATGTTAAAYGGT 
SLC7A7 gggttttatagtgtt
agttaggat 
cacctaccttttca
ttcttaac 
taaagtgttgggatt
at 
AGGYGTGAGTTATYGYGTTTGGTT
TGATTTTTTTATATTTTTTAGGAAA
GTGGAGTTAATTTATATTTGAGG
AAGGYG 
CFI ggttgtgatttattgt
aattgtag 
tacttattatttcc
cctttctat 
ttttttgtgtgtaagg
t 
ATAGTGTTAYGAAGATAGTGAGA
TTGATTTTTTTTTTTAATAGTTTTT
TAGTAYG 
HKDC1 agggggttatagag
ttatgtta 
accaccaaatctc
attacta 
tggaaatttgtaga
gtag 
TTTTATYGGTTGAAAGTTGGTTTT
GTTTAGTGTTTAATTTYGTAGAAG
ATTTTTTTYGGTTGAGTGGGTTTG
GTAGAGTTTYGGT 
HKDC1 agagggagggatt
aaag 
acattttccccaa
att 
aggttggaggtattt
a 
GTTYGTAATATTTYGTTTTTTAGG
AGGTTTGTTAGTTTGGATTGGAA
GYGTGTAATATTTTAGAGTYG 
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Gene Symbol Forward 
primer 
Reverse 
primer 
Seqence 
primer 
Target sequence 
FLNA ggggatagggatta
gaa 
cccctctaccaac
ctataa 
gtgtttttgtaggtgt
t 
TTTYGTGAGGTTATTATTGAGTTT
AGTGTGGAYGTTYGGGTTTTGAT
ATAGATYGGAGGGTYGTAYGTTA
AGGTTYG 
FLNA ggggatagggatta
gaa 
cccctctaccaac
ctataa 
tggttaattttttagg
taa 
TTTGAYGGAGATTTAYGTTTAGGA
TYGTGGYGATGGTATGTATAAAG
TGGAGTATAYGTTTTAYGAGGAG
GGTGYG 
PTN ttgggtgaatttgta
taa 
aaaaccctctcta
aacac 
tgtattgaatgaaat
gat 
AATTTTAGAGAYGTAAAGTTTAGT
TTTTAAGTTTTATAAATTTTAGAG
TTTGAGTTATTTTGAYG 
PTN ttgggtgaatttgta
taa 
aaaaccctctcta
aacac 
ggtaagtagtattta
attgg 
GAATTTTGAGAYG 
TK1 gtgtttaagtattgg
ggattt 
cccaaacaaaat
tcctta 
agtattggggatttg GTAYGTATTAGGYGTTTTGTATGT
TTATAGGAGTGTTTTAGAYGGTTT
TTAAGTTTTTTTTTTGGAATTTTAA
TTTAATAAATGAGTTAATTTYG 
MT1H tgtggggagtaggt
ta 
acaactccttttct
aatca 
tggggagtaggtta
g 
GATTTYGGGGTAYGYGGAAYGTT
AAAGGGYGGGAGTAGTAGGTAA
TTTTAGGGAATTGGGTAGGTTYG
G 
MT1H tgtggggagtaggt
ta 
acaactccttttct
aatca 
ggtagggtgaaata
ag 
TAGTTTATTYGGGTGTATAGTTTT
TTTYGYGGGAGTYGTTGYGAAAG
GGTYGTTTTYGYGGTGTGTATYGA
TTTGYG 
MT1H tgtggggagtaggt
ta 
acaactccttttct
aatca 
ttgagtttagggtat
tttg 
YGTTYGATTYGTTTGTTGYGTATA
GTTTAGTTTAGGATYGYGGGYGG
TTYGGATTTAGTGGGTYG 
Table 7. The methylation candidates from both DMR data set and MVP data set, were validated using 
pyrosequencing. 
2.4.2.1 Bisulfite Treatment 
1µg DNA was denatured in 50 μL NaOH (2 mol/L) for 20 min at 37°C. Then, the denatured DNA 
sample was mixed with 30 μL freshly prepared hydroquinone (10 mmol/L) and 520 μL sodium 
bisulfate (3 mol/L) (Sigma-Aldrich, St. Louis, MO) at pH 5.0. The mixture was then incubated at 50°C 
for 16 hours. The bisulfite-converted DNA was purified using the Wizard DNA Clean-Up System 
(Promega, Madison, WI). The DNA was eluted in 50 μL of warm water, and 5.5 µL NaOH (3 mol/L) 
were added for 5 min. The DNA was ethanol precipitated with glycogen as a carrier and resuspended 
in 20 μL water. Bisulfite-treated DNA was stored at −20°C until further processing. 
2.4.2.2 PCR and Pyrosequencing 
DNA methylation was quantified using bisulfite pyrosequencing. Briefly, the samples were bisulfite 
converted and PCR amplified using biotin-labeled primer and the final PCR product was purified 
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using Sepharose beads. The PCR product was then bound to Streptavidin Sepharose High 
Performance (Amersham Biosciences, Uppsala, Sweden), and the immobilized PCR product binding 
the Sepharose beads was purified, washed, denatured using NaOH solution (0.2 mol/L), and washed 
again using the Pyrosequencing Vacuum Prep Tool (Pyrosequencing, Inc., Westborough, MA) 
according to the manufacturer's recommendations. Pyrosequencing primer (0.3 μmol/L) was then 
annealed to the purified single-stranded PCR product and pyrosequencing was performed using PSQ 
HS96 Pyrosequencing System (Pyrosequencing). DNA methylation was expressed for each DNA locus 
as percentage (methylated cytosines / methylated cytosines + unmethylated cytosines). The non-
CpG DNA fragments were used as built-in controls to verify bisulfite conversion. Each marker was 
tested in three replicates and their average was used in the further statistical analysis. 
2.4.2.3 Statistical analysis 
Differences between ulcerative colitis patients, diseased controls and healthy individuals were 
determined using the Mann-Whitney U-test, while p-values were corrected according to Benjamini 
and Hochberg (Benjamini and Hochberg 1995). 
2.5 Gene Ontology analysis 
Gene Ontology analysis was performed as previously published (Tavazoie et al., 1999). Biological 
processes associated to the transcripts and candidate genes were retrieved from the Gene Ontology 
Consortium (www.geneontology.org). 
2.6 Chromatin- immunoprecipitation following quantitative real-time PCR 
The validated data indicated that the inflammatory response in ulcerative colitis and acute colitis 
might be mediated on the similar regulatory pattern and through distinct DNA modifications. The 
following techniques were performed as a pilot project to examine the differences of DNA 
hydroxylation between ulcerative colitis and acute colitis. 
2.6.1 Preparation of samples and control DNA 
The genomic DNA samples were fragmented according to the mechanical fragmentation protocol. 
briefly, 20µg genomic DNA was pipetted into a 1,5 ml microcentrifuge and the final volume was 
adjust to 300µl by addition of 10mM Tris-HCl pH 8,5. Then, using a tip probe sonicator, the mixture 
was sonicated with 15 pulses of 20 seconds, with a20 second pause on ice between each pulse. The 
sheared DNA was quantified by ethidium staining after electrophoresis on a 3% agarose gel. Finally, 
the fragmented DNA was purified using Chromatin IP DNA Purification Kit (Active Motif, Nr. 58002) 
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Two kinds of control DNA fragments were amplified using PCR for the further experiments to verify 
the immunoprecipitation efficiency. Two DNA fragments of house keeping gens were amplified with 
normal primers (GAPDH forward primer: TTGACGCTGGGGCTGGCATT, reverse primer: 
CTCCCTAGGCCCCTCCCCTCTT; ACTB forward primer: CAAGAGATGGCCACGGCTGCT, reverse primer: 
GGATGCTCGCTCCAACCGACT.), respectively, and in the amplification of GAPDH, special 
hydroxymethylated cytosine (Zymo Research Corporation) was used and fully hydroxymethylated 
fragment was generated. 
2.6.2 Immunoprecipitation of 5-hydroxymethylcytidine enriched DNA fragments 
Immunoprecipitation was performed using a hMeDIP Kit (Active Motif, Nr.55010). The hMeDIP 
contains a highly specific purified 5-hydroxymethylcytidine antibody and the necessary buffers. 
Briefly, 200 µl PCR tube was set up for each immunoprecipitation reaction. 500ng DNA sample and 
controls DNA were added in the tube and mixed with 10 µl buffer C, and 1µl PIC provided in the Kit, 
and sterile water to a final volume of 96 µl respectively. Then 4 µl 5-hydroxymethylcytidine antibody 
was added, then incubated overnight with end to end rotation at 4°C. The next day, the PCR tube 
was centrifuged quickly to collect the contents at the bottom, and the Protein G magnetic beads 
were resuspended. 25 µl Protein G beads were added to each tube, and incubated for 2 hours at 4°C 
with end to end rotation. At this stage, the target DNA was captured on the beads. The tubes were 
then placed on a magnetic stand to pellet beads to the side of the tube. The supernatant was 
discarded, and the beads were washed three time with buffer C and D provided in the Kit, according 
to the protocol. The beads were then resuspended with 50 µl elution buffer AM2 by pipetting three 
times, and incubated for 15 minutes at room temperature with end to end rotation to keep the 
beads in suspension. The tubes were centrifuged to collect liquid from the cap, then, 50 µl 
neutralization buffer was added and mixed with pipetting up and down. The tubes were placed on 
the magnetic stand again, in order to transfer the supernatant, which contains the target DNA, to 
the fresh tubes. 
2.6.3 Examination of 5-hydroxymethylcytidine enrichment via qRT PCR 
In order to determine the enrichment of the candidates sequences, the following quantitative real 
time PCR was performed, which the TaqMan assays were designed using primer express 3.0 (Applied 
Biosystem). Similarly, this quantitative real time PCR was performed according to the manufacturers 
guidelines (Applied Biosystems) using a 7900HT Real-Time PCR System, but without cDNA synthesis. 
Enrichment levels were calculated relative to control DNA samples using the standard-curve method 
(Livak and Schmittgen 2001). Differences between inflamed mucosa of ulcerative colitis patients and 
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not inflamed ones, and the inflamed mucosa of diseased controls were determined using the Mann-
Whitney U-test, while p-values were corrected according to Benjamini and Hochberg (Benjamini and 
Hochberg 1995). 
Panel type Application Relationship of 
Individuals 
Gender Age: 
median, 
range 
Disease 
representation 
  
Examination 
panel III 
Examination of the 
prediction in the 
hydroxymethylome 
unrelated individuals 5 f 
5 m 
52, 25-64 5 UCi; 5 Ucni 
5 DC 
Table 8. Study panels IV, used for examination of initial findings. f = female, m = male, UC = ulcerative 
colitis, DC = disease specificity controls, suffix: i= inflamed, ni= not inflamed. 
 
Design_ID Forward Primer Reverse Primer Probe 
HKDC1_Promoter GGTGGCACCCAATTCTCAA
G 
CTGGATGGTAGCTGAGGT
TTAGTG 
AACCCATCAATACCCTGCT
TCCCCC 
MT1H_Promoter ACTAGAAAAGGAGCTGCC
AACTGT 
TTCCCAAGCGAGAAGAGA
AGAG 
CTCCACCACGCCCTCCAC
GTGT 
PTN_Promoter CTTAGCGTCTTTCCTGTATT
GAATGA 
ATTCGTCAAAGTAGCTCA
AACTCTGA 
AGACGCAAAGCCCAGCCT
CCAAGTT 
SPINK4_Promoter GGGCCATCCCTGCAATCT GCTTTTTCTGTTTGGGTCA
CTAATC 
TACCATGTCAGGCACTGT
TCTGAGCCC 
THY1_Promoter AAGACGTAATGCCCAGAG
CAA 
CCATTTCGCCCCCTCATC CCTGCAGCCCCCTGAAGG
GC 
TK1_Promoter CCACCTACCTCTGCAGACA
TCTT 
GTAGACGCCATGATGGAT
GTGT 
AAGGAACCTTGCTTGGGA
AACCCACA 
Table 9. Designed TaqMan assays. 
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3 Results 
3.1 Genome-wide profiling of transcription and DNA methylation in ulcerative 
colitis  
A 3-layer genome-wide scanning of the transcriptome, differentially methylated regions and 
differentially methylated variable positions in twins, discordant for ulcerative colitis. 
3.1.1 Genome-wide transcriptome profiling (Layer I) 
The genome-wide transcriptome analysis (layer #1) of the mucosa of monozygotic twins, discordant 
for ulcerative colitis, identified 18097 out of 54675 transcripts analyzed as present. Within the 
present transcripts, 361 are differentially expressed in UC significantly (Benjamini-Hochberg-
corrected p-value ≤ 0.05; FDR (false discovery rate) ≤ 5%), 247 transcripts are downregulated and 
114 are upregulated respectively. Most significant candidates associate with inflammation, such as 
immune response, macrophage activation, complement activation, cell adhesion, cytokines signaling 
and metabolism (Figure 11). All the significant candidates are listed in table S 1.  
3.1.2 Genome-wide methylome profiling (Layer II and layer III) 
It is still unknown, whether the single CpG or the regional DNA methylation has the potential 
regulatory function on transcription. The analysis of differentially methylated regions (DMRs, layer II) 
examined 392750 regions, of which 389359 were detecteabled as present in the mucosal tissue 
samples. 345 DMRs showed differential methylation between healthy and diseased individuals 
significantly (Benjamini-Hochberg-corrected p-value ≤ 0.05). With in the significant candidates, 240 
candidates are hypomethylated and 105 are hypermethylated in UC respectively. Most of them are 
detected in the promoter, gene body, strongly indicating the potentially regulatory function for the 
associated transcription in cis. The significant candidates from layer II are listed in table S 2. 
3.1.3  Genome-wide quantification of individual methylated variable positions (Layer III) 
As mentioned above, the regional methylation and single CpGs were interrogated separately. The 
analysis of individual methylated variable positions (MVPs, layer III) examined 27578 positions were 
analyzed, of which 23085 were detected as present in the mucosal tissue samples. 703 MVPs 
showed differential methylation between healthy and diseased individuals significantly (Benjamini-
Hochberg-corrected p-value ≤ 0.05). Surprisingly we found that about 95% (666/703) of the 
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significant candidates reflect hypomethylation in UC. The significant candidates from layer III are 
listed in table S 3. 
The genome-wide 3-layer screen identified 61 disease-associated transcripts that were also 
associated with at least one disease-associated MVP or DMR when applying a cis-interaction window 
of 50 kb from the transcription start site in silico. By definition, those 61 transcirpt-methylation pairs 
where called risk loci. Disease-associated transcripts were defined by their significantly differential 
expression when comparing healthy individuals to UC patients (Benjamini-Hochberg-corrected p-
value ≤ 0.05; false discovery rate ≤ 5%), and disease-associated MVPs and DMRs were defined by 
their significantly differential methylation when comparing healthy individuals to UC patients 
(Benjamini-Hochberg-corrected p-value ≤ 0.05; false discovery rate ≤ 5%). In addition, the 61 
candidates do not represented 61 gene-expressions and -methylations (which take place on the 
gene-body or the regulatory region). While, 1) the 50 kb window is really long, some methyltion 
candidates locate far away from the transcription stop-codon; 2) Some candidates represent the 
same gene. From the 61 disease- and MVP/DMR-associated transcripts, 12 candidates with the 
closest proximity between MVP/DMRs and transcript location were subjected to further validation 
and replication in a larger collection of primary tissue from the intestinal mucosa. Two of those 12 
represent controls: altered mRNA expression with no altered methylation (IGHG1) and altered 
methylation with no altered mRNA expression (SLC7A7). 
3.1.4 Merging of the transcriptional and methylational data (from Layer I,II & III) 
The combination of the three layers illustrates, that epigenetic differences as well as their potential 
transcriptional consequences can be monitored in complex primary tissue on a genome-wide scale 
(genome-wide overview: figure 6). 
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Figure 6. A: Genome-wide profiles of DNAm and gene expression. The x-axis represents the genomic 
location with chromosomes represented as rows. The significance of the differences between UC 
patients and healthy individuals is displayed as –log (p) for the mRNA and as log (p) for the epigenetic 
modifications. Effect size (induction/fold change) is encoded by colors (methylation: upregulated = 
black, not regulated = blue, downregulated = purple; mRNA-expression: upregulated = red, no 
regulation = yellow, downregulated = green); B: selected candidate HKDC1 (the dotted line indicates 
the significance threshold). 
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3.1.5 Intra-class correlations of the three-layer dataset 
Similar degrees of heritability have been observed on all 3 levels, as documented by the intra-class 
correlations (figure 7) 
A
B
C
10
10 100 1000
0.01 0.1 1
0.1
1
1000
10000
1000 10000
A: mRNA levels (n=14000)
B: MVP signals (n=27000)
C: DMR signals (n=400000) 
100
1000
X-axis: UCtwin
Y-axis: HNtwin
max ICC
min ICC
 
Figure 7. Intra Class Correlation for all three levels of the genome-wide functional epigenetic map. A: 
mRNA levels (n=1400 transcripts); B: MVPs (n=27.000 signals); C: DMRs (n= 400.000 signals). Red 
areas indicate where differentially regulated items are found. Intra class correlation coefficient was 
calculated based on the variance within twins compared to the variance between unrelated 
individuals. 
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3.1.6 Overview: genomic location of the different methylation in ulcerative colitis 
Hypomethylation is a prominent finding in promoter regions (figure 8A), while hypermethylation is 
frequent in gene-introns (figure 8B) 
Promoter
Exon
Intron
Other
A: methylation downregulated
B: methylation upregulated
 
Figure 8. Distribution of significant MVPs/DMRs in different genomic regions (promoters, exons, 
introns and others). A: Distribution of significantly hypomethylated CpGs when comparing ulcerative 
colitis patients to healthy controls, B: Distribution of significantly hypermethlated CpGs when 
comparing ulcerative colitis patients to healthy controls. 
3.1.7 Principle component analysis of the significant candidates 
The principle component analysis displayed that the disease is the strongest component (PC1), yet 
mRNA and DNAm do not contribute equally to the separation between healthy and diseased 
individuals (plots for significant expression changes and significant epigenetic modifications: 
supplemental figure 10). 
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Figure 9. Principal component analysis of differential transcription and DNAm in UC. A: the two 
strongest components separating the samples based on all significantly differentially expressed mRNA 
transcripts (n=361) are displayed. B: the two strongest components separating the samples based on 
all significantly differentially methylated CpGs (n=731) are displayed. Arrows indicate the connection 
from the healthy twin to its diseased sibling. Grey areas represent the healthy group, while one 
outlier (pair 12) was not located within the healthy group in either of the two approaches. 
3.1.8 Correlation between the expressional and methylational data (in cis) 
Correlation analysis of quantitative expression values and MVP or DMR data revealed a correlation 
in selected candidate transcripts (median spearman-rho r=0.58), correlation in identified candidate 
loci (r=0.49), no correlation in the group of disease-associated transcripts (r=0.15) and no correlation 
when analyzing all transcripts (r=0.16). The correlation within the selected candidates was 
significantly different from all other gene-sets. 
Results 
 
43 
0.0
0.2
0.4
0.6
0.8
1.0
co
rr
el
at
io
n
[s
p
ea
rm
an
 r
h
o
 r
-v
al
u
e]
va
lid
at
ed
 
ca
n
d
id
at
e 
lo
ci
n
=1
0
d
is
ea
se
-
as
so
ci
at
ed
 lo
ci
n
=3
6
1
al
l l
o
ci
an
al
yz
ed
n
=1
8
9
0
7
1.10 x 10-6
1.01 x 10-6
3.91x 10-4
se
le
ct
ed
ca
n
d
id
at
e 
lo
ci
n
=6
1
 
Figure 10. Correlation analysis of mRNA expression and epigenetic modification. Each box-plot 
represents an individual loci/transcript correlation set based on a Spearman-Rho correlation, 
displaying the 25th, 50th and 75th percentile. Whiskers correspond to the 5th and 95th percentile 
while outliers are plotted separately. P-values describe the differences between the individual sets of 
r-values, calculated by a Mann-Whitney U-test. For better readability r-values were transformed to 
absolute values. 
3.1.9 Gene ontology (GO) analysis of the disease relevant processes 
A large number of differentially regulated transcripts (independent of MVPs and DMRs) were 
associated with inflammation, immune response and other disease relevant processes when 
performing a Gene Ontology (GO) analysis. Similarly, regulated transcripts in close proximity to 
MVPs and/or DMRs were also found to be associated to inflammation and immune response (figure 
11). 
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Figure 11. Biological processes affected by differential DNAm or gene expression in UC patients. The 30 
most significantly enriched biological processes are displayed for three different categories: i) all 
MVPs and DMRs, ii) all mRNA transcripts and iii) all mRNA transcripts associated with at least one 
MVP and/or DMR. Significance is displayed as –log10 (p). 
3.2 Validation of selected candidate transcripts under potential epigenetic control 
Of the 61 disease- and MVP/DMR-associated transcripts, 10 candidates with the closest proximity 
between MVP/DMRs and transcript location were subjected to further validation and replication in a 
larger collection of primary tissue from the intestinal mucosa (validation panel I and II, table 3). This 
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was performed by pyrosequencing (bisulfite modified DNA, n=50 individuals) for methylation data 
and TaqMan based real-time PCR (n=135 individuals) for differential mRNA expression. Significance 
criteria were defined in concordance to the initial screening step (Benjamini-Hochberg-corrected p-
value ≤ 0.05). Distinct patterns of differential DNAm/expression pairs as paradigms for different 
scenarios of epigenetic modulation were selected while focusing on the commonly accepted pattern 
of hypermethylation with transcriptional repression and hypomethylation with increased mRNA 
expression:. i) Pairs with negative correlation of DNAm and mRNA expression, represented by 40 
MVPs and 5 transcripts: increased DNAm accompanied by decreased mRNA expression (MT1H) and, 
ii) decreased DNAm and with increased mRNA expression (CFI, HKDC1, SPINK4, THY1), iii) pairs with 
positive correlation of DNAm and mRNA expression, represented by 21 MVPs and 3 transcripts: 
increased DNAm accompanied by increased mRNA expression (TK1), and iv) decreased DNAm and 
with decreased mRNA expression (FLNA, PTN). Control transcripts loci were chosen to replicate 
MVPs/DMRs without a cis-modulation of mRNA expression (SLC7A7, 4 MVPs) or differential mRNA 
expression without the presence of any MVP or DMR (IGHG1, 1 MVP). The MVPs and DMRs which 
potentially associated with alterations in expression levels occurred both at the start of the CpG 
island (HKDC1, TK1) as well as at the end of a CpG island (all other candidates), generally referred to 
as CpG island shores (Doi et al., 2009; Irizarry et al., 2009). Results for one selected example, 
representing a validated disease associated transcript, are shown in figure 12 (HKDC1). 
Gene symbol; 
name 
prominent gene ontology 
terms (selected) 
Cyto- 
Genetic 
band 
CpG-
position 
relative 
to 
transcript 
CpG methylation 
p-value 
(observations per 
gene) 
mRNA 
regulation 
fold-
change; 
p-value 
CFI; complement 
factor I 
complement activation; 
innate immune response 
4q25 post TSS, 
SGB 
↓ 1.51*10
-05
  (2) ↑ 5.71; 
4.45*10
-09
 
FLNA; Filamin A, 
alpha 
positive regulation of I-
kappaB kinase/NF-kappaB 
cascade 
Xq28 post TSS, 
SGB 
↓ 1.63*10
-02
  (2) ↓ -2.85; 
7.72*10
-06
 
HKDC1; 
hexokinase 
domain 
containing 1 
Glycolysis 10q22.1 pre and 
post TSS 
↓ 7.94*10
-06
  (6) ↑ 2.01; 
5.16*10
-06
 
IGHG1
1)
; 
immunoglobulin 
heavy constant 
gamma 1 (G1m 
marker) 
immune response; 
antigen binding 
14q32.33 post TSS, 
SGB 
 (-) 1.56*10
-
01
 
 (0) ↑ 8.25; 
8.90*10
-09
 
MT1H; 
metallothionein 
1H 
metal ion binding; protein 
binding 
16q13 post TSS ↑ 1.50*10
-02
  (2) ↓ -1.66; 
3.04*10
-05
 
PTN; Pleiotrophin positive regulation of cell 
proliferation 
7q33 post TSS ↓ 2.42*10
-02
  (1) ↓ -4.16; 
2.76*10
-08
 
SLC7A7
2)
;solute blood coagoulation, 14q11.2 postTSS ↓ 5.21*10
-06
  (4)  (-) 1.16; 
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Gene symbol; 
name 
prominent gene ontology 
terms (selected) 
Cyto- 
Genetic 
band 
CpG-
position 
relative 
to 
transcript 
CpG methylation 
p-value 
(observations per 
gene) 
mRNA 
regulation 
fold-
change; 
p-value 
carrier family 7 
(cationic amino 
acid transporter, 
y+ system), 
member 7 
leukocyte migration 6.73*10
-01
 
SPINK4; serine 
peptidase 
inhibitor, Kazal 
type 4 
Serine-type 
endopeptidase inhibitor 
activity 
9p13.3 post TSS, 
SGB 
↓ 3.03*10
-06
  (2) ↑ 13.05; 
4.45*10
-09
 
THY1; Thy-1 cell 
surface antigen 
positive regulation of t 
cell activation 
11q23.3 post TSS ↓ 2.28*10
-03
  (2) ↑ 2.99; 
4.75*10
-07
 
TK1; thymidine 
kinase 1, soluble 
DNA replication 17q23.2- pre TSS ↑3.08*10
-03
  (2) ↑ 1.32; 
2.30*10
-02
 q25.3 
Table 10. Validation of differential DNAm linked to disease-associated transcripts by TaqMan real-time 
PCR (mRNA expression in n=135 individuals, validation panel I) and pyrosequencing (CpG methylation 
in n=50 individuals, validation panel II). 1) Negative control candidate for differential expression 
without epigenetic modification; 2) Negative control candidate for epigenetic modification without 
differential mRNA expression.TSS = Transcription start site; SGB = spanning to gene body; in case of 
multiple CpGs, all relative positions are described. Upregulation is indicated by arrow up (↑); 
downregulation is indicated by arrow down (↓); no regulation is indicated by a dash (-) as measured 
in the validation panel. P-values presented were corrected for multiple testing using the Benjamini-
Hochberg correction. In case of multiple observations, the lowest p-values were presented. 
 
Figure 12. Validation of candidate transcripts, example: HKDC1. A: Relative position of CpGs (arrows up, 
continiously numbered 1-8) and real-time PCR probe (dark grey); B: quantitative results of the 
validation: i) methylation (via pyrosequencing, CpGs continuously numbered 1-8 in concordance to 
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Fig13A) in n=50 individuals (validation panel II), the order of assays displayed corresponds to the 
order in Fig 13A, ii) mRNA (via real-time PCR, right) in n= 135 individuals (validation panel I). 
Significant differences between UC patients and normal controls are indicated by a star (* p ≤ 5*10-3; 
** p ≤ 5* 10-4; *** p ≤ 5*10-6). 
The regulatory patterns observed in the validation panel displayed a high robustness as documented 
by the frequencies of their occurences: A random individual from the validation panel has a median 
chance of over 80% to exhibit the regulatory pattern described for the 10 candidate loci (Figure 13). 
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Figure 13. Frequencies of validated effects. Frequencies are presented as percentages at which a 
significant effect (either epigenetic modification or mRNA regulation at p ≤ 0.05) is observed in 
concordance with the initial finding (screening cohort). IGHG1 and TH1 represent control transcripts 
(marked with a *), where transcript changes were not cis-linked to epigenetic modifications. The 75
th
 
percentile is highlighted to emphasize the high frequencies. 
A substratification analysis performed on validation panel I and II revealed no influence of the 
potential confounding factors age, gender, biopsy location and medication on the main findings 
(mRNA: figure 14 and DNAm: figure 15). 
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Figure 14. Impact of potential confounding factors on the differential mRNA expression. Each originally 
selected candidate transcript is represented in a separate panel (A-J). Each panel shows 7 color coded 
sets of analysis from validation panel I, split into healthy individuals (HN) and ulcerative colitis 
patients (UC): no substratification (all samples included)2); substratified by age (all individuals 
younger than 30 years were excluded); substratified by gender (females only); substratified by gender 
(males only); substratified by biopsy position (all non-sigmoidal biopsies excluded); substratified by 
medication (all individuals with immunosuppressant therapy removed) and substratified by 
medication (all individuals with steroid therapy removed). Box plots represent the 20th, 50th and 
75th percentile, while whispers illustrate the 5th and 95th percentile: 1) negative control candidate 
for differential expression without epigenetic modification; 2) negative control candidate for 
epigenetic modification without differential mRNA expression. 
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Figure 15. Impact of potential confounding factors on the differential DNA methylation. Each originally 
selected candidate loci is represented in a separate panel (A-J). Each panel shows 7 color coded sets 
of analysis from validation panel II, split into healthy individuals (HN) and ulcerative colitis patients 
(UC): no substratification (all samples included)2); substratified by age (all individuals younger than 30 
years were excluded); substratified by gender (females only); substratified by gender (males only); 
substratified by biopsy position (all non-sigmoidal biopsies excluded); substratified by medication (all 
individuals with immunosuppressant therapy removed) and substratified by medication (all 
individuals with steroid therapy removed). Box plots represent the 20th, 50th and 75th percentile, 
while whispers illustrate the 5th and 95th percentile. 1) negative control candidate for differential 
expression without epigenetic modification; 2) negative control candidate for epigenetic modification 
without differential mRNA expression. 
Combining the the three screening layers and the validation shows 148-fold more differentially 
methylated MVPs in proximity to the 10 validated loci than expected by chance, corresponding to a 
p-value of p=9.11x10-44 (Fischer’s exact test). 
3.3 Potential new finding of the DNA hydroxymethylation in the acute inflammation 
The altered DNA methylationin ulcerative colitis and disease control individuals (acute interstinal 
inflammation) indicated that the RNA expression pattern might be associated to with different types 
of DNA modification (see figure 3). 10 of TaqMan assays (Primer Express 3.0, Applied Biosystems) 
were designed to examine the DNA hydroxymethylation status of similar regulatory elements (500 
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bp around TSS) of the 10 candidates in a smaller collection of primary tissue from the intestinal 
mucosa (validation panel III, table 3). 4 assays did not lead to quantifiable results, the remaining 6 
results are shown in figure 16 and 17. It appears that in disease control individuals, DNA 
hydroxymethylation is highger than in ulcerative colitis when analyzing identical genomic regions, 
however, the observed trends did not show significance in the individual candidate loci. In contrast 
to that, a combined analysis taking all loci into account shows a significantly increased 
hydroxymethylation in disease control individuals when comparing them to ulcerative colitis 
patients. 
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Figure 16. Hydroxymethylation levels in promoters of candidate loci: HKDC1, MT1H, PTN, SPINK4, THY 
and TK1. The detected hydroxymethylation levels of each promoter is displayed as relative 
methylation (%). 
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Figure 17. Hydroxymethylation detection of the candidate promoters: HKDC1, MT1H, PTN, SPINK4, THY 
and TK1. The detected hydroxymethylational level of all promoters in disease controls (5 individuals, 
biopsy from inflamed region) is significantly higher than in biopsies from ulcerative colitis patients (5 
individuals, each provided two biopsies, one from an inflamed region (UC_b), the other from not 
inflamed region(UC_nb)). 
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4 Discussion 
This study aims to create a functional epigenetic map by combining genome-wide data of 
differentially methylated regions (DMRs), methylation variable positions (MVPs) and transcriptome 
data, reflecting potential effects of the epigenetic variations. A group of 20 monozygotic twins, 
discordant for ulcerative colitis (UC) were selected as an entry level to perform this three-layer 
genome-wide scan to target mechanisms that show significant differences between healthy and 
diseased individuals. From this genome-wide map, selected candidate loci were subjected to further 
validation. Finally, initial results on the role of DNA demethylation inflammatory disorders, 
representing a key element in the dynamics of epigenetics, were collected as a starting point for 
follow-up studies. Genetics and epigenetics in the pathogenesis of ulcerative colitis. 
4.1 Genetics and epigenetics in the pathogenesis of ulcerative colitis 
Recently, substantial advances have been made in the understanding of the molecular pathogenesis 
of ulcerative colitis, a large number of genetic and environmental factors were suggested to be 
associated with the susceptibility, manifestation and progression of UC (Jaenisch and Bird, 2003; Feil 
and Fraga, 2011). 
In the last few years, genome-wide studies and meta-analysis focusing on UC susceptibility loci have 
been highly successful in identifying candidates that contribute to disease susceptibility: Up-to-date, 
47 risk loci have been identified (Anderson et al., 2011). The genetic variants are thought to be 
strongly associated with innate and adaptive immune response, autophagy, apoptosis, cellular 
metabolism and phagocytosis (Anderson et al., 2011). This is in concordance with these observations 
on the transcriptome side, where the identified candidates are either directly involved in 
inflammatory processes, or modulate them. However, while genetic variation represents a rather 
static element, the transcriptome displays many dynamic features. Generally, genetic variants have 
at least two possibilities to participate the initiation and manifestation of disease:, either by 
changing the structure of the mRNA transcript, or by altering the transcriptional status. For example 
rs11209026, which located in the transcribed region and encodes the stop condon, results in a 
dysfunctional stop-codon, leading to altered amino-acid sequences. In addition, other variants which 
are localized within regulatory elements, such as rs6983267, has been mapped to conserved 
sequences within a 500-kilobases region upstream of the MYC oncogene, which may affect cancer 
development through altered regulation of MYC expression (Sur et al., 2012). Recently, Cowper-
Sal·Lari and colleagues reported that the disease risk–associated Single-nucleotide polymorphism 
(SNP) can modulate the affinity of chromatin for transcription factor and alter gene expression 
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(Cowper-Sal Lari et al., 2012). Based on the current knowledge, none of the observed disease-
associated alterations on transcriptional level are associated with the 47 previously published UC risk 
loci. Consequently, the 61 risk loci identified in this study are novel. Interestingly, interleukin-1 
receptor type II (IL1R2) was detected to be significantly downregulated in this genome-wide 
transcriptome analysis. This gene is a confirmed risk loci (rs2310173) for UC and therefore a genes of 
interest, yet the question whether rs2310173 is associated with altered IL1R2 mRNA expression 
remains unanswered. In fact, the variant is localized downstream of the IL1R2 coding region in the 
transcriptional direction, and it is well known that IL1R2 belongs to the family of interleukin-1 
receptor-like genes (Dale and Nicklin, 1999). In this gene family, the type I IL-1 receptor (IL1R1) is the 
high-affinity component of the receptor for IL-1. The type II IL-1 receptor (IL1R2) has a three-Ig-
domain extracellular portion, like IL1R1, and binds IL-1, but lacks a Toll-like cytoplasmic domain and 
gives no detectable cytoplasmic signal. IL1R1 and IL1R2 are mapped to the pericentromeric region of 
chromosome 2q, and are both transcribed in the same direction. It was thought that both genes are 
in the same transcriptional cluster (Dale and Nicklin, 1999), and surprisingly, the risk loci rs2310173 
localized between them, and near to IL1R2. The genome-wide data showed that IL1R2 was 
downregulated in UC significantly, but IL1R1 not. This may indicate indirectly that the risk loci could 
play a role in the transcription, and contribute to the initiation or manifestation of UC. 
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dbSNP Chr MVP in 
proximity 
MVP 
distance 
[bp] 
MVP 
p-value 
MVP 
fold 
change 
DMR in 
proximity 
DMR 
distance 
[bp] 
DMR 
p-value 
DMR 
fold 
change 
Associated genes/transcripts (p-value / fold change) 
rs254560 5 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs267939 5 cg21046940 8544 0.789 1.24 4_750 3442 0.974 1.08 DAP (0.517 / 1.08) 
rs678170 11 cg27227156 1670 
1)
 
1)
 97_557 1049 0.955 1.08 
2)
 
rs734999 1 cg05610148 4210 0.525 1.23 388_658 4183 1.031 -1.08 TNFRSF14 (0.971 / -1.0
2)
; MMEL1 (0.390 / -1.1
3)
; PLCH2
3)
 
rs798502 7 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 GNA12 (0.199 / 1.05) 
rs907611 11 cg26158194 249 0.496 -1.16 584_700 13 1.031 1.02 LSP1 (0.937 / 1.16) 
rs941823 13 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs943072 6 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs1297265 21 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs1801274 1 cg27470554 4504 0.315 -1.12 358_172 3917 0.974 -1.01 FCGR2B (0.679 / 1.15) 
rs2155219 11 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs2297441 20 cg18611245 10654 0.853 -1.26 159_97 433 0.955 1.07 SLC2A4RG
3)
; STMN3
3)
; ZBTB46
3)
; ZGPAT (0.945 / -1.00); RTEL1
3)
 
rs2310173 2 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 IL1R2 (0.065 / -2.31) 
rs2836878 21 
1)
 
1)
 
1)
 
1)
 741_343 33734 0.955 -1.01 
2)
 
rs2838519 21 
1)
 
1)
 
1)
 
1)
 517_389 20907 0.974 -1.06 ICOSLG
3)
 
rs2872507 17 cg14914852 15965 0.525 1.08 600_252 15642 0.955 -1.06 IKZF3
3)
; ORMDL3 (0.937 / -1.0
3)
; IKZF3
3)
; PNMT
3)
; ZPBP2
3)
 
rs3024505 1 cg17067005 5443 0.315 -1.08 143_227 22 0.974 -1.09 IL10
3)
; IL19
3)
 
rs3194051 5 cg04312209 19143 
1)
 
1)
 105_1001 18996 0.974 1.27 IL7R
3)
 
rs4246905 9 cg11809085 14508 
1)
 
1)
 643_137 14915 1.031 1.03 TNFSF8
3)
; TNFSF15
3)
 
rs4510766 7 cg01025762 38575 
1)
 
1)
 207_929 38617 0.955 1.19 
2)
 
rs4676406 2 cg07432969 9550 0.525 -1.02 218_140 11648 0.955 -1.07 GPR35 (0.846 / 1.0
2)
 
rs4728142 7 cg26616347 3786 0.912 1.25 168_892 3779 1.031 -1.02 IRF5
3)
; TNPO3 (0.954 / -1.00) 
rs5771069 22 
1)
 
1)
 
1)
 
1)
 195_653 2214 1.031 -1 PIM3 (0.837 / 1.70); IL17REL
3)
 
rs6017342 20 cg00431114 39000 
1)
 
1)
 645_453 28952 1.031 -1.02 SERINC3 (0.199 / -1.16) 
rs6426833 1 cg09195271 29362 0.525 1.08 53_167 29661 0.955 1.14 
2)
 
rs6451493 5 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 PTGER4 (0.670 / -1.05) 
rs6499188 16 cg19034028 2577 
1)
 
1)
 693_223 3875 0.974 -1.11 ZFP90 (0.945 / -1.00) 
rs6584283 10 
1)
 
1)
 
1)
 
1)
 39_119 326 1.031 -1.08 
2)
 
rs6871626 5 
1)
 
1)
 
1)
 
1)
 18_750 46859 0.974 -1.01 IL12B
3)
 
rs6911490 6 cg19464016 11932 0.789 1.38 736_824 11920 1 1.03 PRDM1
3)
 
rs6920220 6 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
3)
 
rs7134599 12 
1)
 
1)
 
1)
 
1)
 521_873 43646 1.031 1.15 IFNG
3)
; IL26
3)
 
rs7524102 1 
1)
 
1)
 
1)
 
1)
 440_344 47983 1.031 -1.06 
2)
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dbSNP Chr MVP in 
proximity 
MVP 
distance 
[bp] 
MVP 
p-value 
MVP 
fold 
change 
DMR in 
proximity 
DMR 
distance 
[bp] 
DMR 
p-value 
DMR 
fold 
change 
Associated genes/transcripts (p-value / fold change) 
rs7554511 1 cg15250507 17196 0.525 1.14 248_116 3033 0.955 -1.17 C1orf106 (0.945 / -1.0
2)
 
rs7608910 2 cg09469394 39133 0.853 1.17 200_246 39766 1.031 1.03 PUS10
3)
 
rs9268853 6 cg19248557 21804 0.912 1.09 328_1008 450 0.955 1.04 HLA-DRB5
3)
; HLA-DQA1 (0.856 / 1.0
2)
; HLA-DRB1 (0.517 / 1.61); HLA-DRA 
(0.517 / 1.68) 
rs9822268 3 cg21958034 6112 0.315 -1.07 374_156 3416 0.955 1.19 UBA7
3)
; MST1
3)
; APEH (0.665 / -1.30); AMIGO3
3)
; GMPPB (0.937 / 1.19) 
rs10758669 9 cg20394284 2605 0.853 1.02 20_920 2943 1.031 -1.05 JAK2 (0.517 / 1.06) 
rs10781499 9 cg02516189 1688 0.525 -1.11 480_724 672 1.031 -1.02 CARD9
3)
; INPP5E (0.962 / -1.00); SDCCAG3 (0.665 / -1.1
2)
; SEC16A
3)
 
rs11209026 1 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 IL23R
3)
 
rs11676348 2 cg14150666 18835 0.496 -1.07 188_388 19018 1.031 1.04 IL8RA
3)
; SLC11A1
3)
; IL8RB
3)
; AAMP (0.856 / -1.07) 
rs11739663 5 cg19108785 17929 0.853 1.42 467_749 8145 0.974 -1.08 EXOC3 (0.040 / -1.36) 
rs12261843 10 cg23218877 18043 0.912 1.02 
1)
 
1)
 
1)
 
1)
 CCNY
3)
 
rs16940202 16 
1)
 
1)
 
1)
 
1)
 700_466 23 0.955 -1.16 
2)
 
rs17085007 13 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
1)
 
2)
 
rs17388568 4 cg17850932 48539 0.789 -1.08 3_485 28543 1.031 -1.04 IL21
3)
 
rs35675666 1 cg25007680 151 0.496 1.16 509_517 40 0.955 -1.08 TNFRSF9
3)
; ERFFI1
3)
; UTS2
3)
 
Table 11. dbSNP: previously published loci, associated to ulcerative colitis  (Anderson et al., 2011); MVP: methylation variable positions (listed with its ID); DMR: 
differentially methylated region; distance describes the distance between the SNP and MVP/DMR position in bp; associated genes/transcripts are listed with their 
gene symbol, p-value and fold change; 1) the SNP is not in proximity of a detectable MVP/DMR; 2) the SNP is not in proximity of a detectable gene/transcript; 3) 
the associated gene/transcript was categorized as not expressed in the tissue. 
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Interestingly, some risk alleles are cytosine or represent a CG element, but alteration of DNA 
methylation between UC and healthy individuals could not be detected in the genome-wide data, 
since the monozygotic twins have theoretically the same genotype: Consequently, the presented 
genome-wide study setup employing monozygotic twins does not favor detecting such effects, yet 
they may play a disease relevant role.  
4.2 Environment and epigenetics in the pathogenesis of ulcerative colitis 
Environmental factors have been considered to play a role in the pathogenesis of numerous complex 
disorders, such as UC (Jaenisch and Bird, 2003; Feil and Fraga, 2011). Epidemiological studies 
investigating risk factors are based on tangible evidence, for example, food, air pollution, as well as 
many other elements of the biological and psychological environment, all of which may contribute to 
disease susceptibility. This is documented  by studies employing adopted individuals, families and 
monozygotic twins, which are carried out with the implicit assumption that any variation that is not 
attributable to genetic factors must origin from the environment (Hemminki et al., 2006). This 
assumption, however, could not be validated in this study. Genetic and non-genetic factors such as 
environment are not always easily distinguishable, as the microbiota, which is often considered an 
environmental factor, is also strongly dependent on the host genotype: In an experimental colitis 
model in mice Nod2 deficient mice could transmit their disease risk to wildtype animals via their 
microbiota (Couturier et al., JCI 2012). 
Epidemiological studies targeting environmental influence on complex diseases are vulnerable to 
variantions due to the large variety of multidirectional environmental influences which oftentimes 
cannot be estimated objectively (Taubes, 1995). These difficulties indicate that data from 
epidemiological studies require to be supported other experiments or data. 
Another uncertainty is introduced by the observation that environmental risk factors seem to have 
'heritable' partners which are embedded in the human genome (Kendler and Baker, 2007). For 
example, a Swedish twin study demonstrated that the tendency to smoke has a heritable 
component, indicating that Genetic factors play an important etiologic role in regular tobacco use 
(Kendler et al., 2000). Based on studies targeting depression, Kendler and colleagues suggested that 
genetic and environmental risk factors both contribute to the aetiology of complex disorders, 
partially explained by the finding that individuals with a defined genetic risk have the tendency to 
select high-risk environments (Kendler and Karkowski-Shuman, 1997). 
Discussion 
 
57 
This study setup is based on ten pairs monozygotic discordant twins, following the concept of a 'non-
shared environment' as suggested earlier (Lyons, 1996; Hebebrand et al., 2001). Briefly, this concept 
suggested that such setups have the possibility to find variations that cannot be attributed to 
heritable factors and that environmental influences which result in similarities in family members 
are not considered. In this context, a meta-analysis revealed that the proportion of the variation of 
individual traits that is attributable to non-shared environment among individuals is 45–60%, 
whereas the variation attributable to shared environment is nearly zero (Bouchard and McGue, 
2003). Consequently, non-shared environment could make an important contribution to the risk of 
developing complex diseases, such as UC. 
Taken together, investigating of the role of environmental factors in complex diseases generally 
needs to be broken down into specific questions. Currently, it is not possible to design a study that 
could monitor all environmental influences. For this reason, monozygotic discordant twins were 
selected to generate an in-depth picture of the UC epigenome aiming to minimize genetic and 
environmental influences.  
4.3 Ulcerative colitis: a complex epigenetic disorder 
In total, 361 differently expressed transcripts and 1048 differentially methylated DNA elements were 
identified when comparing UC patients to healthy individuals. A subset of 10 cis linked expression-
methylation pairs and 2 negative controls were further verified in a larger patient group. It is unclear 
to which extend epigenetic modifications might contribute to disease susceptibility, manifestation 
and progression, however, epigenetic mechanism are currently being discussed to be involved in 
establishing specific transcription patterns (Feil and Fraga, 2011). DNA methylation represents only 
one of many epigenetic modifications. As described in the introduction, certain forms of histone 
modification cause local formation of heterochromatin, which is readily reversible, whereas DNA 
methylation leads to a more stable long-term repression. Interestingly, recent studies reported that 
DNA methylation and histone modification do not act in an isolated manner, but can be dependent 
on one another, which was demonstrated in the context of tumorigenesis (Cameron et al., 1999). It 
is important to note that DNA methylation and histone modification are carried out by different 
chemical reactions and require different sets of enzymes. The relationship between DNA 
methylation and histone modification might be partially mediated through methylcytosine-binding 
proteins, such as methyl-CpG binding domain protein 2 (MeCP2 or MBD2), which are capable of 
recruiting histone deacetylases to the methylated region (Cedar and Bergman, 2009). However, the 
exact nature of the relationship between these epigenetic mechanisms is still not clear. DNA 
hypermethylation is not in all cases the cause of transcriptional silencing. Early experiments by Lock 
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and colleagues showed that the hypoxanthine phosphoribosyltransferase (Hprt) gene on the inactive 
X chromosome is methylated only after inactivation of the whole chromosome (Lock et al., 1987). 
Other genome-wide studies in cancer cells showed that genes with CpG island promoters that are 
already silenced by Polycomb complexes are being methylated earlier than other genes in cancer 
scenarios (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007; Gal-Yam et al., 
2008). In addition to epigenetic modifications, transcriptional patterns sometimes depend on 
specific transcription factors. In 2010, Chi and colleagues reported that ets variant 1 (ETV1) is 
universally highly expressed in gastrointestinal stromal tumor (GIST) cell lines and transcriptome 
profiling and analysis of ETV1-binding sites indicated that ETV1 is a master regulator of an ICC-GIST-
specific transcription network (Chi et al., 2010). Similarly it was recently reported that loss of 
epigenetic modification driven by the foxp3 transcription factor leads to regulatory T cell 
insufficiency (Bettini et al., 2012). 
The majority of identified loci in the presented study are associated to biological processes which are 
either directly or indirectly linked to immune processes, which is consistent with previous findings on 
functional genomics of UC (Dieckgraefe et al., 2000; Lawrance et al., 2001; Costello et al., 2005) as 
well as with findings on UC genetics (Anderson et al., 2011). Interestingly, a substantially smaller 
proportion of biological processes identified are distinct from bona fide immune processes: 
Structural, developmental and metabolic processes are prominent findings. This suggests additional 
levels of transcriptional control and strongly indicates that altered immune functions in cells of the 
intestinal mucosal might be involved in the aetiology of UC. In this context, it is widely accepted that 
the final target of the inflammatory processes appears to be the colonic epithelium. Numerous 
proinflammatory cytokines, such as IL-1, IL-6 and TNF-α, have been reported to be increased in 
serum (Gross et al., 1991) and in primary tissues (Isaacs et al., 1992; Stevens et al., 1992; Breese et 
al., 1993) of UC patients. On the other hand, most cytokine receptors are not only detected on the 
antigen presenting cells (APCs), but also constitutively expressed on intestinal epithelial cells (IECs) 
(Panja et al., 1998). There is increasing evidence that IECs may serve as targets for these locally 
produced cytokines. For example, IL-1β up-regulates IL-6 synthesis (a proinflammatory cytokine) in 
epithelial cells (Panja et al., 1995). Increasing evidence exists indicating that epithelial cell growth 
and differentiation ensures maintenance of homeostasis and plays an indispensable role in the 
pathogenesis of inflammatory disorders.  
Previous studies have addressed the epigenetic modulation in the context of IBD mostly on a 
candidate gene approach, focused on IBD-associated colorectal cancer (Moriyama et al., 2007; Dhir 
et al., 2008; Edwards et al., 2009; Gonsky et al., 2011). Together with the high tissue specificity 
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(Rakyan et al., 2008) and the fundamental differences in detection, these studies are only of limited 
use for comparison to the systematic genome-wide approach. However, The results support one 
recent report stating that epigenetic dysregulation of the IRF5 promoter is not associated with IBD 
(Balasa et al., 2010). In contrast to that, many of these findings on the mRNA level are in 
concordance with previously published studies (Dieckgraefe et al., 2000; Lawrance et al., 2001; 
Anderson et al., 2011), potentially attributed to the lower technical and/or biological variance in 
inflammation associated mRNA patterns. Among the replicated findings, several genes have been 
directly associated with chronic intestinal inflammation: pleiotrophin (PTN) has been shown to be 
functionally linked to inflammation and cancer (Kadomatsu, 2005), while Thy-1 cell surface antigen 
(THY1) mediates cell adhesion during inflammation (Jurisic et al., 2010). In the same context, the 
serine protease inhibitor 4 (SPINK4) has been shown to be differentially expressed in chronic 
autoimmune intestinal inflammation (celiac disease), likely derived from altered goblet cell activity, 
while no causative genetic variant was identified (Wapenaar et al., 2007). Although these candidate 
approaches shed light on individual genes, the disease relevance for UC and other crhonic or 
autoimmune disease was not demonstrated. In fact, all the those results are linked to non-chronic 
inflammation, leading to the fundamental question which mechanisms leads a stimulation of these 
inflammatory transcripts persistently or reiteratively in the intestinal mucosa of UC. 
4.4 Genome-wide patterns of hypomethylation are a prominent motive in UC 
The presented study reported cis-linked DNA methylation transcription partners in UC. Interestingly, 
most significant methylation candidates are hypomethlyated when comparing UC patients to 
healthy individuals (Table S 1. &2.). 
Loss of 5-mC is a broadly discussed topic in the field of epigenetic research, numerous studies 
indicate that DNA demethylation plays significant roles in various malignant events (Ehrlich, 2009; 
Rai et al., 2010; Watanabe and Maekawa, 2010; Wild and Flanagan, 2010). Thus, the degree of 
demethylation may serve as a putative molecular biomarker with predictive and prognostic value. 
This study provides insight into the genome-wide 5-mC demethylation in primary human tissue from 
the intestinal mucosa of UC patients and healthy individuals while controlling for genetic 
interference. It is tempting to speculate that the high prevalence of tumorigenesis in UC patients 
might be partially attributed to epigenetic modifications like the observed decreased genome-wide 
demethylation (Figure 18). In relevant cell culture models, an decrease in 5-mC levels via alteration 
of DNMT1 activity was shown to silence tumor suppressor genes (Peng et al., 2011). Taken together, 
this study provides multiple layers of support that genome-wide loss of 5-mC is a epigenetic motive 
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in ulcerative colitis, with potential diagnostic and prognostic advantages for the future when 
compared to global DNA hypomethylation, a recognized epigenetic motive of carcinogenesis. 
The potential clinical application of 5-mC could be supported by the possibility to detect 5-mC 
immunohistochemically. DNA demethylation has been extensively observed in numerous 
malignancies such as breast, ovarian, and colorectal carcinomas, the latter being closely associated 
to UC (Ehrlich, 2009; Watanabe and Maekawa, 2010; Wild and Flanagan, 2010). As the anti-5-mC 
antibody for immunohistochemical staining is commercially available, this approach has been well 
established in several diagnostic laboratories. In this context, These findings could be one of the very 
first steps, leading to the development of a new, simple, sensitive and practical adjuvant diagnostic 
assay, following the example of Lian and colleagues (Lian et al., 2012).  
DNA demethylation in stem cells and tumor cells raises the intriguing question about the nature of 
the biological role of 5-mC in cell differentiation, self-renewal and malignant transformation. Studies 
of genomic reprogramming indicate that DNA demethylation is involved in the regulation of cell 
differentiation and carcinogenesis (Cameron et al., 1999; Ito et al., 2010; Rai et al., 2010; Ficz et al., 
2011; Williams et al., 2011b; Wu et al., 2011b; Doege et al., 2012; Lian et al., 2012). Until now, 
tissue-specific 5-mC distribution and genome-wide mapping of 5-mC in a non-malignant disease 
have not been well studied. The findings presented here on genome-wide hypomethylation in the 
intestinal mucosa of UC patients provide new insights on the supporting role of DNA demethylation 
in pathways that are fundamental to cellular differentiation and dedifferentiation.  
4.5 DNA demethylation in chronic and acute colitis 
In general, the term DNA methylation refers to the enzymatic modification at the 5-position of 
cytosine in a CpG dinucleotide (Wigler et al., 1981; Robertson and Wolffe, 2000; Zhang et al., 2006; 
Heyn and Esteller, 2012; Jones, 2012) sequence context. This DNA modification was thought 
inheritable and 'stable' without primary DNA base sequence changes resulting in possible epigenetic 
regulation of phenotype and gene expression (Robertson and Wolffe, 2000; Weaver et al., 2004; Ma 
et al., 2009; Urdinguio et al., 2009; Wu et al., 2010). In the presented study, a genome-wide 
demethylation was found in the colonic mucosa. Following this pattern, the activation of various 
inflammatory genes associated a downregulation of DNA methylation in their regulatory regions, 
such as promoter regions or the gene body was observed. Especially, the correlation analysis of 
quantitative expression and methylation data revealed a significant negative correlation in all 
verified candidate transcripts (median spearman-rho r= -0.58). This finding is in concordance with 
the former hypothesis, that the DNA methylation regulates transcription negatively (Holliday and 
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Pugh, 1975; Wigler et al., 1981; Clark et al., 1997). The presented observations indicate that DNA 
demethylation might play a very important role in the pathogenesis of UC. On the other hand, it 
could be demonstrated that DNA demethylation in UC might be entirely different from DNA 
demethylation found in acute colitis. As showed in the example (figure 13), the upregulated 
transcription of HKDC1 accompanied by a significant downregulated DNA methylation of its 
regulatory region in UC, but not in disease controls. In the pilot study, I found that the 
hydroxymethylation levels of selected transcripts in biopsies from disease controls are significant 
higher than in biopsies from ulcerative colitis patients. 
5hmU
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TDG/SMUG1
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Figure 18. Potential DNA demethylation pathways. Passive DNA demethylation might be due to a 
reduction in activity or absence of DNA methyl transferases (DNMTs) (grey). Three enzyme families 
have been identified currently in active DNA demethylation. First, 5-methylcytosine (5-mC) can be 
hydroxylated by the ten-eleven translocation (TET) family of enzymes (green), to form 5-
hydroxymethylcytosine (5-hmC). The 5-hmC could be further oxidized to 5-formylcytosine (5-fC) and 
5-carboxylcytosine (5-caC). Second, 5-mC and 5-hmC could be further deaminated by the APOBEC 
family members (orange) to form 5-methyluracil (5mU/Thymine) and 5-hydroxymethyluracil (5hmU) 
respectively. Third, 5mU, 5hmU and 5-caC could be replaced with unmodified cytosine by DNA repair 
of base excision repair (BER) glycosylases (violet), such as uracil-DNA glycosylase/ single-strand-
selective monofunctional uracil-DNA glycosylase 1 (UDG/SMUG1) and thymine-DNA glycosylase 
(TDG)/SMUG1 in the somatic cells and stem cells respectively, culminating in DNA demethylation. 
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4.5.1 Passive mechanisms of DNA demethylation are potentially absent in UC 
DNA methyl transferases (DNMTs) are responsible for the establishment and maintenance of DNA 
methylation in mammalian cells. It has been thought that downregulation of the DNMT activity leads 
a loss of DNA methylation, such as in early mammalian development (Monk et al., 1991; Rougier et 
al., 1998). More recent studies have reported that de novo methylation in early development is 
established by DNA methyltransferases 3A (DNMT3A) and 3B (DNMT3B) (Aoki et al., 2001; Zhao et 
al., 2009; Wu et al., 2010), and the methylation patterns are inheritably maintained through cell 
divisions by DNMT1 (Klein et al., 2011; Shock et al., 2011; Song et al., 2012). The genome-wide data 
presented in this study reflected no significant transcriptional alteration of DNMT family members 
between UC patients und healthy twins, and it could not been shown that the activity of DNMTs is 
downregulated in UC, suggesting that the passive DNA demethylation might be not responsible for 
the demethylation in UC. Consequently, the loss of methylation in mucosal tissue of UC patients 
could be mediated by an active mechanism. Previous studies suggested that DNA demethylation 
could be catalyzed by a rapid and active mechanism, independent of cell division (Paroush et al., 
1990; Hsieh et al., 2009; Wu and Zhang, 2010). Until now, an enzyme which can directly 'cut off' the 
methyl group was not found, suggesting that such a biochemical reaction might not be as simple as 
originally proposed (Bird, 2002). The presented data indicates that genome-wide hypomethylation in 
the colonic epithelial tissue might be reprogrammed enzymatically (so-called active DNA 
demethylation), thus DNA demethylation could play an essential role in the initiation and 
manifestation of UC. 
4.5.2 Demethylation in mammalian cells: a multi-step process 
In contrast to histone modifications, epigenetic variations which take place directly on the DNA 
molecular are not too much. For example, the recently rediscovered 5-hmC, which has been 
reported half century ago (Wyatt and Cohen, 1952), but its biological significance was ignored until 
the identification of the ten-eleven translocation (TETs) enzyme family, which hydroxylated 5-mC to 
5-hmC. A series of studies (Ficz et al., 2011; Gu et al., 2011; He et al., 2011; Williams et al., 2011b; 
Wu et al., 2011b; Doege et al., 2012) has identified key players in this process, for example, the 5-
hmC may serve as the intermediates in the DNA demethylation. Initially, the TET family members in 
mammalian cells were characterized as fusion partners of the MLL protein in acute myeloid leukemia 
and named leukemia-associated proteins (LCX)(Ono et al., 2002a)(Ono et al., 2002b). However, 
recently, Tahiliani and colleagues reported that TETs could potentially modify the 5-mC, and convert 
5-mC to 5-hmC  (Tahiliani et al., 2009). This finding rekindled the interest on 5-hmC, as the 
hydroxymethylated cytosine can be deaminated by activation-induced cytidine deaminase/ 
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apolipoprotein B mRNA editing enzyme, catalytic polypeptide (AID/APOBEC) family members, 
leading to the possibility of complete demethylation through DNA repair. Current studies targeting 
5-hmC were mostly focused on the epigenetic reprogramming of embryoic stem cells. It is important 
to note, that 5-hmC is abundant in proliferative tissues such as pluripotent embryonic stem cells 
(ESCs), but it is also present at lower levels in somatic tissues and organs, such as blood, lung, kidney, 
and muscle (Tahiliani et al., 2009; Globisch et al., 2010; Khare et al., 2012). This is in concordance 
with the presented study, where hydroxymethlyation was altered in the colonic mucosa, suggesting 
an active mechanism. 
Based on the current knowledge, three enzymatic families might be involved in the active DNA 
demethylation in mammalian cells (Gehring et al., 2009; Tahiliani et al., 2009; Wu and Zhang, 2010; 
Cortellino et al., 2011): The ten-eleven translocation (TET) family, which can further modify 5-mC 
and hydroxylate it; the AID/APOBEC family, which can deaminate the modified cytosine and the 
family of base excision repair (BER) glycosylases, which can replace the Anomalous base with an 
unmodified cytosine, and finalize the demethylation (Figure 18). The genome-wide transcriptional 
data presented here revealed that APOBEC1, one member of the AID/APOBEC family, is significantly 
upregulated in UC than in healthy Co-twins (P vlaue 0.04994; Foldchange 8.1304), indicating an 
enhanced enzymatic activity of deamination in the inflamed tissue of UC patients, suggesting a 
potentially causal role of this enzyme in maintaining the hypomethylated state in tissue of UC 
patients. 
4.5.3 The APOBEC Family: Mediators of 5-mC or 5-hmC Deamination 
APOBEC1, which was shown to be functionally associated to UC, belongs to a family of enzymes, 
which were originally identified as RNA editors, so called “apolipoprotein B mRNA-editing catalytic 
polypeptides,” or APOBECs (Conticello et al., 2007). Recent studies indicated that members of the 
APOBEC family could also mediate deamination of cytosine residues to uracil, followed by the 
deamination of the “mismatched cytosine” which then is repaired by base excision repair (BER) 
proteins (Nabel et al., 2012; Roberts et al., 2012). Like most DNA repair mechanism, BER is error 
prone, leading to mutations in mammals (Liu and Schatz, 2009; Maul and Gearhart, 2010). The 
upregulated APOBEC1 could potentially stimulate the genomic demethylation thought deaminating 
methylated cytosines, while the deamination would also provide the probability of introducing 
mutations(Berger et al., 2011; Burns et al., 2013; Greenman et al., 2007; Jones et al., 2010; Parsons 
et al., 2011; Sjöblom et al., 2006; Stransky et al., 2011) due to the subsequently downregulated DNA 
repair mechanisms. This might partially explain why UC patients have a significantly higher risk to 
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develop colorectal cancer than CDs patients, as the differentially expression of APOBEC1 was 
observed only in UC (P value, 0.00005), but not in CD. 
The presented study suggested that APOBEC1 might be a key player in active DNA demethylation in 
UC. This is in concordance with previous studies targeting nuclear reprogramming which provided 
support for the concept that AID (another APOBEC family member) plays an essential role in active 
DNA demethylation in mammalian cells (Conticello et al., 2007; Nabel et al., 2012). In a fusion-cell 
study, rapid demethylation at the promoters of human pluripotency genes (OCT4 and NANOG) was 
detected in human somatic cells (fibroblasts) while a fusion of an excess of mouse ESCs was 
observed (Tat et al., 2011). The knock-down of AID with RNA interference blocked pluripotency gene 
promoter demethylation and gene expression. Unlike TET, which has a DNA-binding motif(Ono et al., 
2002b), AID and other APOBEC family members do not possess such motives Cairns and colleagues 
showed the role of APOBECs in genome-wide demethylation in zebrafish embryos for the first time 
in 2008 (Rai et al., 2008): Upon overexpression of AID or zebrafish APOBEC deaminases and the 
glycosylase MBD4, active DNA demethylation was observed in zebrafish embryos injected with a 
methylated linearized nonreplicating DNA. Popp and colleagues reported a similar effect of AID in 
global DNA demethylation at a later stage of embryogenesis in mice (Popp et al., 2010). AID knock-
out mice (AID−/−) is viable and fertile, although with somewhat smaller litter sizes. This mouse 
however, exhibited a genome-wide hypermethylation in its primordial germ cells (PGCs) when 
compared to wild type animals, suggesting that AID is involved in DNA demethylation (Muramatsu et 
al., 2000). In this study, I found a higher expression of APOBEC family member (APOBEC1), and a 
global hypomethylation in the colonic biopsies of UC patients. All these findings raise the possibility 
that the APOBEC family members may play important roles in compensating high DNA 
demethylation levels. 
4.5.4 Reduced BER activity may lead to carcinogenesis of UC 
DNA methylation was otentimes suggested to be associated with tumorigenesis. Three main 
molecular mechanisms have been proposed: (1) a global decrease in DNA methylation, (2) increased 
uracil misincorporation during DNA replication, and (3) increased cytosine deamination at sites of 
DNA methylation (Rai et al., 2010; Loenarz and Schofield, 2011; Moréra et al., 2012). In the 
presented study, a genome-wide hypomethylation in the intestinal tissue of UC patients could be 
shown, and it is well known that UC has a relative higher risk of carcinogenesis. As discussed above, 
DNMTs were transcribed normally, and no evidence showed a reduced activity in UC, suggesting that 
a high frequency of demethylation and remethylation might contribute to the increased risk of 
carcinogenesis in UC patients. 
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Transitions of cytosine to thymine or uracil are the most common mutation in human cells and it are 
also found very frequently in human tumors(Berger et al., 2011; Burns et al., 2013; Greenman et al., 
2007; Jones et al., 2010; Parsons et al., 2011; Sjöblom et al., 2006; Stransky et al., 2011). These 
transitions take place usually in a CpG context, and are strongly associated to deamination of 5-
methylcytosine (5-mC) to thymine, or cytosine to uracil (Waters and Swann, 2000). Mismatches 
caused by deamination (T to G or U to G) are generally repaired by the base excision repair (BER) 
pathway. Recently, deamination has been suggested to precede BER in mammalian DNA 
demethylation (Cortellino et al., 2011; Gu et al., 2011). Based on the current knowledge, at least four 
different human DNA glycosylases may remove uracil and mismatched thymine in the genome, 
which is itself cytotoxic and potentially mutagenic. These enzymes are UNG, SMUG1, TDG and MBD4 
(Krokan et al., 2002). 
The glycosylases which are part of the BER pathway can be further classified based on their 
function:the involvment in the embryogenetic reprogramming, such as thymine-DNA glycosylase 
(TDG) and single-strand-selective monofunctional uracil-DNA glycosylase 1 (SMUG1) (Cortellino et 
al., 2011; Guo et al., 2011). Both glycosylases can convert diaminated or oxidated 5-mC to cytosine, 
and TDG knock-out mice are embryonic lethal.The direct interaction between AID and TDG has been 
demonstrated by coimmunoprecipitation experiments (Cortellino et al., 2011), suggesting that they 
might act in a partnership with TET and AID/APOBEC in the embryogenetic reprogramming. The 
other group seems to be responsible for the routine conversion of U to C or T to C in the somatic 
cells, including SMUG1 and UDG (Linhart et al., 2009; Skjeldam et al., 2010; Kemmerich et al., 2012). 
Indeed, SMUG1-knockout and SMUG1/UNG-double knockout mice could be bred normally and 
healthy beyond 12 months of age (Kemmerich et al., 2012), indicating that DNA glycosylases might 
be not only involved in the embryogenetic reprogramming, but also in other pathophysiological 
events, such as UC. In the presented study, apart from APOBEC1, which belongs to APOBEC 
deaminase family and is upregulated in UC when compared to healthy concrols, it was also shown 
that UDG, which is one glycosylase of BER, is significantly downregulated in UC (P value, 0.0002), 
suggesting a stronger tendency of mutationegenesis. Consequently, the balance between 
demethylation and remethylation might be disturbed, increasing the probability of introducing 
mutations. 
In addition, another potential DNA demethylation intermediates - 5-formylcytosine and 5-
carboxylcytosine, should be mentioned here in short. Recent reports suggested that 5-hmC can be 
further oxidized by TET proteins to form 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) (He 
et al., 2011). Interestingly, 5-caC could not only be repaired by TDG, another study also raises the 
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possibility that a putative decarboxylase could directly convert 5-caC to cytosine independent of 
DNA repair (Ito et al., 2011). However, 5-fC and 5-caC are much less abundant than 5-hmC in the 
mammalian cells, and they have been detected only in ES cells recently, therefore, I did not perform 
any experiment to detect 5-fC or 5-caC in this study.  
4.6 Concluding remarks and future studies 
To further support the clinical relevance of the presented findings, especially in the context of 
genome-wide demethylation and the cis-link between DNA methylation and gene expression, 
further studies validating these results on a functional level are required. In a first step, which is 
currently on-going, differences in demethylation in the gut mucosa between ulcerative colitis and 
other non-IBD colitis are being assessed. This is carried out by examining the DNA 
hydroxylmethylation and DNA methylation status in the gut mucosa between UC in comparison to 
non-IBD colitis. Bisulfite sequencing represents the gold standard for validating DNA methylation, 
but it cannot distinguish DNA methylation and hydroxylmethylation (Jin et al., 2010). The recent 
development of a method for the quantitative validation of DNA hydroxylmethylation, so-called 
oxidative bisulfite sequencing (Booth et al., 2012) will help to close this methodological gap. 
DNA demethylation in the gut mucosa of UC is a hallmark of these findings. The enzymes APOBEC1 
and UDG display a significantly altered expression as shown in the genome-wide data. One of the 
currently on-going therefore is to validate important enzymes that are potentially involved in the 
DNA demethylation pathways, as showed in figure 20. This will help to better understand DNA 
demethylation in the pathogenesis of UC. 
Many studies indicate that dynamics of DNA demethylation might play a significant role in the 
pathogenesis of numerous malignant diseases. This suggests to monitor the DNA methylation and 
hydroxylmethylation of colonic biopsies for classification and prediction of primary colorectal cancer. 
DNA methylation and hydroxymethylation are not the only mechanisms regulating transcription. 
There are numerous other epigenetic mechanisms participating in this network. The presented 
results emphasize the necessity to characterize the dynamics of these epigenetic modifications and 
their cis-linked transcription to unravel the nature of this regulatory principle. Since ulcerative colitis 
represents an exemplary scenario for inflammatory disorders at interfaces, the strong disease 
associated epigenetic signatures presented here might encourage future studies in related diseases. 
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5 Summary 
The etiology of ulcerative colitis (UC), a chronic inflammatory bowel disease, is still not fully 
understood. One of the current hypotheses is, that genetic and environmental factors modulate the 
epigenetic landscape and thus contribute to susceptibility, manifestation and progression of the 
disease. In the presented thesis, a three-layer epigenome-wide association study (EWAS) is reported, 
using intestinal biopsies from ten monozygotic twin pairs discordant for the manifestation of UC 
(n=20). The primary result is a map of links between disease-associated transcripts and epigenetic 
modifications. These candidates of cis-linked gene expression and DNA methylation (DNAm) were 
validated in two larger independent patient populations (n=185) by quantitative real-time PCR and 
bisulfite-pyrosequencing, resulting high DNAm/RNA correlations, indicating a potential impact of 
DNAm on transcription. Many of the identified candidate genes have been functionally implicated in 
inflammatory processes. In contrast to the observed hypomethylation of several candidate loci in 
UC, patients with acute inflammation showed no altered methylation. To validate an alternative 
epigenetic modification in these patients, hydroxymethylation was quantified at selected loci, 
indicating that this mechanism might play a role in acute inflammation when compared to chronic 
inflammation. In conclusion, this study represents the first replicated EWAS in affected tissue of UC 
patients, integrated with transcriptional signatures. The results indicate a potential role of epigenetic 
modification in disease manifestation and progression of UC. 
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6 Zusammenfassung 
Die Ätiologie von colitis Ulcerosa (UC), einer chronisch entzündlichen Darmerkrankung, ist bisher 
noch nicht vollständig aufgeklärt. Eine der gängigen Hypothesen geht davon aus, daß genetische 
Faktoren und Umwelteinflüsse das epigenetische Profil verändern und somit zu Suszeptibilität, 
Manifestation und Progression der Erkrankung beitragen. In der vorliegenden Dissertation wird eine 
epigenomweite Assoziationsstudie (EWAS) vorgestellt, die auf der Verwendung von intestinalen 
Biopsien von 10 eineiigen Zwillingspaaren basiert, die diskordant für colitis Ulcerosa (UC) sind 
(n=20). Als primäres Ergebnis wurden krankheitsassoziierte Transkripte identifiziert, die von 
epigenetische Modifikationen begleitet werden. Diese Kandidaten von Genexpression und DNA-
Methylierung (DNAm) in direkter Nachbarschaft („in cis“) wurden in zwei größeren 
Patientengruppen (n=185) mittels quantitativer Real-Time PCR und Bisulfid-Pyrosequenzierung 
validiert. Die resultierende hohe Korrelation zwischen DNAm und mRNA deutet auf den potentiellen 
Einfluss der DNAm auf das Transkriptom in UC hin. Viele der identifizierten Kandidatengene stehen 
in funktionellem Zusammenhang mit Entzündungsprozessen. Im Gegensatz zur beobachteten 
Hypomethylierung vieler Kandidatengene in UC zeigten Patienten mit akuten Darmentzündungen 
keine solchen Veränderungen. Um alternative epigenetische Modifikationen zu prüfen, wurde in 
diesen Patienten die Hydroxymethylierung quantifiziert. Die Ergebnisse hieraus sprechen für eine 
mögliche Rolle der Hydroxymethylierung bei akuter Entzündung im Vergleich zur chronischen 
Entzündung. Zusammenfassend stellt die vorgestellte Arbeit die erste replizierte EWAS in 
entzündetem Gewebe von UC Patienten dar, die mit dem Transkriptom verknüpft wurde. Die 
Ergebnisse deuten auf eine mögliche Rolle der epigenetischen Modifikationen bei Manifestation und 
Progression von UC hin. 
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Table S 1 Genome-wide significant expressional candidates (Layer I). 
Experimental ID Gene Symbol Chromosome Transcription 
Start Sites 
P value 
1554436_a_at REG4 1 120138164 0.041144451 
200662_s_at TOMM20 1 233339282 0.018875861 
200771_at LAMC1 1 181259217 0.029076187 
201969_at NASP 1 45822303 0.035722791 
202651_at LPGAT1 1 209983422 0.006164888 
202743_at PIK3R3 1 46278398 0.035722791 
202834_at AGT 1 228904891 0.007933587 
203073_at COG2 1 228844824 0.018875861 
203508_at TNFRSF1B 1 12149646 0.049944792 
203801_at MRPS14 1 173249750 0.049944792 
204607_at HMGCS2 1 120092525 0.035722791 
205309_at SMPDL3B 1 28134090 0.029076187 
205483_s_at ISG15 1 938709 0.010231873 
207826_s_at ID3 1 23756995 0.049944792 
209071_s_at RGS5 1 161378720 0.011839038 
209589_s_at EPHB2 1 22909917 0.029076187 
210651_s_at EPHB2 1 22909917 0.015061861 
212348_s_at KDM1 1 23218527 0.010231873 
214290_s_at 
HIST2H2AA3 /// 
HIST2H2AA4 1 148089280 0.049944792 
214433_s_at SELENBP1 1 149603403 0.035722791 
216336_x_at 
MT1E /// MT1H /// 
MT1M /// MT1P2 1 33189329 0.029076187 
218168_s_at CABC1 1 225194560 0.018875861 
219134_at ELTD1 1 79128036 0.041144451 
219481_at TTC13 1 229108611 0.023555392 
221486_at ENSA 1 148861222 0.015061861 
221656_s_at ARHGEF10L 1 17738916 0.010231873 
221726_at RPL22 1 6167666 0.023555392 
223223_at ARV1 1 229181445 0.049944792 
223272_s_at C1orf57 1 231152992 0.007933587 
223339_at ATPIF1 1 28435197 0.035722791 
223402_at DUSP23 1 158017382 0.015061861 
223447_at REG4 1 120138164 0.041144451 
226020_s_at DAB1 /// OMA1 1 58718725 0.041144451 
226388_at TCEA3 1 23580141 0.011839038 
227582_at KLHDC9 1 159334777 0.018875861 
229254_at MFSD4 1 203804734 0.035722791 
232219_x_at USP21 1 159395877 0.049944792 
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Experimental ID Gene Symbol Chromosome Transcription 
Start Sites 
P value 
240110_at HMGCS2 1 120092525 0.049944792 
200887_s_at STAT1 2 191542006 0.007933587 
201302_at ANXA4 2 69822630 0.007933587 
201438_at COL6A3 2 237897393 0.010231873 
202274_at ACTG2 2 73973600 0.035722791 
202351_at ITGAV 2 187163034 0.006164888 
203697_at FRZB 2 183406981 0.006164888 
203698_s_at FRZB 2 183406981 0.010231873 
205403_at IL1R2 2 101974737 0.029076187 
209969_s_at STAT1 2 191542006 0.018875861 
211161_s_at COL3A1 2 189547343 0.035722791 
211372_s_at IL1R2 2 101974737 0.018875861 
211959_at IGFBP5 2 217245072 0.041144451 
212012_at PXDN 2 1614665 0.001717581 
212013_at PXDN 2 1614665 0.011839038 
212017_at FAM168B 2 131521918 0.035722791 
212119_at RHOQ 2 46623370 0.049944792 
217860_at 
LOC732160 /// 
NDUFA10 2 240548830 0.015061861 
219093_at PID1 2 229596932 0.035722791 
219735_s_at TFCP2L1 2 121690635 0.035722791 
221729_at COL5A2 2 189604885 0.035722791 
223297_at AMMECR1L 2 128335675 0.035722791 
223312_at C2orf7 2 73308641 0.015061861 
225174_at DNAJC10 2 183289243 0.006164888 
226749_at MRPS9 2 105020914 0.049944792 
227642_at TFCP2L1 2 121690635 0.010231873 
227867_at LOC129293 2 84902306 0.023555392 
229211_at DUSP28 2 241148143 0.041144451 
AFFX-
HUMISGF3A/M97935_3_at STAT1 2 191542006 0.006164888 
1553296_at GPR128 3 101811122 0.010231873 
201904_s_at CTDSPL 3 37878672 0.00368053 
201906_s_at CTDSPL 3 37878672 0.049944792 
203140_at BCL6 3 188921858 0.023555392 
204245_s_at RPP14 3 58267011 0.006164888 
204294_at AMT 3 49429214 0.023555392 
205019_s_at VIPR1 3 42519107 0.041144451 
206286_s_at TDGF1 /// TDGF3 3 46594216 0.049944792 
207808_s_at PROS1 3 95074571 0.041144451 
208782_at FSTL1 3 121595751 0.023555392 
208911_s_at PDHB 3 58388393 0.023555392 
218440_at MCCC1 3 184215699 0.049944792 
221872_at RARRES1 3 159897590 0.023555392 
223220_s_at PARP9 3 123729451 0.041144451 
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Experimental ID Gene Symbol Chromosome Transcription 
Start Sites 
P value 
223969_s_at RETNLB 3 109957175 0.041144451 
224701_at PARP14 3 123882361 0.035722791 
226850_at SUMF1 3 4377829 0.029076187 
226987_at RBM15B 3 51403770 0.023555392 
227676_at FAM3D 3 58594709 0.002208318 
227679_at HDAC11 3 13496714 0.041144451 
228754_at SLC6A6 3 14419109 0.007933587 
229544_at --- 3 40483031 0.029076187 
1568634_a_at LRRC66 4 52554622 0.018875861 
203854_at CFI 4 110881296 0.035722791 
204351_at S100P 4 6746466 0.023555392 
204379_s_at FGFR3 4 1764836 0.023555392 
223157_at C4orf14 4 57524272 0.023555392 
225179_at UBE2K 4 39376058 0.049944792 
225391_at LOC93622 4 6726583 0.029076187 
226001_at KLHL5 4 38723053 0.011839038 
228992_at MED28 4 17225370 0.007933587 
230329_s_at NUDT6 4 124033248 0.041144451 
200665_s_at SPARC 5 151021201 0.015061861 
201278_at DAB2 5 39407536 0.010231873 
201506_at TGFBI 5 135392482 0.029076187 
203286_at RNF44 5 175886305 0.029076187 
203989_x_at F2R 5 76047623 0.029076187 
204020_at PURA 5 139473891 0.015061861 
206430_at CDX1 5 149526536 0.041144451 
214919_s_at 
ANKHD1-EIF4EBP3 /// 
EIF4EBP3 5 139888594 0.015061861 
217840_at DDX41 5 176871183 0.029076187 
218398_at MRPS30 5 44844783 0.049944792 
224782_at ZMAT2 5 140060215 0.041144451 
225275_at EDIL3 5 83273881 0.010231873 
226826_at --- 5 157117434 0.049944792 
227314_at ITGA2 5 52320912 0.018875861 
227339_at RGMB 5 98132898 0.035722791 
227628_at GPX8 5 54491740 0.049944792 
204214_s_at RAB32 6 146906520 0.041144451 
204279_at PSMB9 6 32929915 0.041144451 
204565_at ACOT13 6 24775241 0.049944792 
205771_s_at AKAP7 6 131508153 0.023555392 
208788_at ELOVL5 6 53240154 0.049944792 
209193_at PIM1 6 37245899 0.015061861 
212265_at QKI 6 163755664 0.035722791 
213540_at HSD17B8 6 33280396 0.015061861 
214106_s_at GMDS 6 1569039 0.035722791 
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219006_at NDUFAF4 6 97444860 0.018875861 
224430_s_at MTO1 6 74228174 0.011839038 
225664_at COL12A1 6 75850761 0.002208318 
225973_at TAP2 6 32897587 0.029076187 
227226_at MRAP2 6 84800138 0.023555392 
202404_s_at COL1A2 7 93861808 0.002797203 
203324_s_at CAV2 7 115926679 0.010231873 
209465_x_at PTN 7 136562634 0.002797203 
209466_x_at PTN 7 136562634 0.029076187 
211737_x_at PTN 7 136562634 0.029076187 
212345_s_at CREB3L2 7 137210264 0.011839038 
212792_at DPY19L1 7 34935017 0.018875861 
213333_at MDH2 7 75515328 0.010231873 
213546_at DKFZP586I1420 7 30376190 0.041144451 
214435_x_at RALA 7 39629686 0.015061861 
218543_s_at PARP12 7 139370017 0.049944792 
218654_s_at MRPS33 7 140352429 0.035722791 
219041_s_at REPIN1 7 149696811 0.035722791 
224848_at CDK6 7 92072172 0.049944792 
224890_s_at C7orf59 7 99584465 0.041144451 
227753_at TMEM139 7 142692184 0.041144451 
230036_at SAMD9L 7 92597303 0.041144451 
201066_at CYC1 8 145221947 0.035722791 
202625_at LYN 8 56954939 0.015061861 
202626_s_at LYN 8 56954939 0.015061861 
203000_at STMN2 8 80685934 0.011839038 
203001_s_at STMN2 8 80685934 0.049944792 
203560_at GGH 8 64090196 0.015061861 
204505_s_at EPB49 8 21967026 0.049944792 
210754_s_at LYN 8 56954939 0.035722791 
213423_x_at TUSC3 8 15442100 0.049944792 
225478_at MFHAS1 8 8679408 0.035722791 
225591_at FBXO25 8 346807 0.015061861 
225681_at CTHRC1 8 104452961 0.006164888 
231270_at CA13 8 86344967 0.029076187 
235849_at SCARA5 8 27783668 0.00473211 
201060_x_at STOM 9 123141173 0.041144451 
201061_s_at STOM 9 123141173 0.015061861 
201645_at TNC 9 116822625 0.023555392 
202151_s_at UBAC1 9 137964635 0.006164888 
202893_at UNC13B 9 35151988 0.023555392 
204083_s_at TPM2 9 35671989 0.041144451 
204772_s_at TTF1 9 134240757 0.041144451 
207214_at SPINK4 9 33230195 0.041144451 
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212068_s_at BAT2L 9 133295297 0.049944792 
212488_at COL5A1 9 136673472 0.023555392 
218189_s_at NANS 9 99858779 0.006164888 
225568_at TMEM141 9 138805597 0.041144451 
226499_at NRARP 9 139313903 0.011839038 
227186_s_at MRPL41 9 139566129 0.041144451 
228885_at MAMDC2 9 71848316 0.029076187 
229720_at BAG1 9 33242469 0.018875861 
208813_at GOT1 10 101146617 0.041144451 
212894_at SUPV3L1 10 70609998 0.035722791 
218174_s_at C10orf57 10 81828405 0.010231873 
225143_at SFXN4 10 120890414 0.041144451 
227163_at GSTO2 10 106018620 0.035722791 
227405_s_at FZD8 10 35967182 0.035722791 
227614_at HKDC1 10 70650064 0.007933587 
229450_at IFIT3 10 91077581 0.007933587 
1552703_s_at CARD16 /// CASP1 11 104417331 0.049944792 
1553828_at FAM55A 11 113897646 0.015061861 
1560587_s_at PRDX5 11 63842144 0.002797203 
200747_s_at NUMA1 11 71391558 0.035722791 
204070_at RARRES3 11 63060848 0.029076187 
204580_at MMP12 11 102238673 0.035722791 
205412_at ACAT1 11 107497467 0.035722791 
205482_x_at SNX15 11 64551485 0.015061861 
205547_s_at TAGLN 11 116575249 0.011839038 
208714_at NDUFV1 11 67130898 0.010231873 
208745_at ATP5L 11 117777313 0.035722791 
209436_at SPON1 11 13940489 0.035722791 
211368_s_at CASP1 11 104401446 0.035722791 
212573_at ENDOD1 11 94462664 0.041144451 
213869_x_at THY1 11 118793865 0.015061861 
217969_at C11orf2 11 64620258 0.011839038 
219188_s_at MACROD1 11 63522606 0.010231873 
219549_s_at RTN3 11 63205497 0.015061861 
222994_at PRDX5 11 63842144 0.00473211 
223103_at STARD10 11 72143421 0.015061861 
223305_at TMEM216 11 60916440 0.029076187 
225510_at OAF 11 119586956 0.041144451 
229369_at VSIG2 11 124122579 0.006164888 
229715_at DKFZp686O24166 11 17329892 0.010231873 
231530_s_at C11orf1 11 111255157 0.029076187 
232322_x_at STARD10 11 72143421 0.006164888 
1554599_x_at --- 12 122684337 0.049944792 
202330_s_at UNG 12 108019797 0.010231873 
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207158_at APOBEC1 12 7693262 0.049944792 
207170_s_at LETMD1 12 49728350 0.029076187 
208121_s_at PTPRO 12 15366753 0.010231873 
209195_s_at ADCY6 12 47446241 0.011839038 
210976_s_at PFKM 12 46799294 0.035722791 
212959_s_at GNPTAB 12 100663407 0.018875861 
218434_s_at AACS 12 124115877 0.049944792 
219076_s_at PXMP2 12 131774264 0.011839038 
224974_at SUDS3 12 117298740 0.029076187 
230252_at LPAR5 12 6598261 0.041144451 
233841_s_at SUDS3 12 117298740 0.011839038 
1598_g_at 
GAS6 /// 
LOC100133684 13 113546912 0.023555392 
202177_at 
GAS6 /// 
LOC100133684 13 113546912 0.015061861 
205677_s_at DLEU1 13 49554414 0.041144451 
209185_s_at IRS2 13 109204184 0.035722791 
211964_at COL4A2 13 109757631 0.041144451 
211980_at COL4A1 13 109599310 0.015061861 
211981_at COL4A1 13 109599310 0.041144451 
212768_s_at OLFM4 13 52500972 0.00473211 
218656_s_at LHFP 13 38815028 0.035722791 
221816_s_at PHF11 13 48967801 0.029076187 
227609_at EPSTI1 13 42360121 0.049944792 
200884_at CKB 14 103055748 0.000736106 
200989_at HIF1A 14 61231871 0.00473211 
201762_s_at PSME2 14 23682413 0.023555392 
202411_at IFI27 14 93646831 0.018875861 
204588_s_at SLC7A7 14 22312271 0.049944792 
206453_s_at NDRG2 14 20554761 0.007933587 
209210_s_at FERMT2 14 52393739 0.023555392 
209531_at GSTZ1 14 76856982 0.049944792 
211430_s_at 
IGH@ /// IGHG1 /// 
IGHG2 /// IGHM /// 
IGHV4-31 14 105278720 0.035722791 
215118_s_at IGHG1 14 105241338 0.007933587 
218298_s_at C14orf159 14 90650109 0.035722791 
226747_at TXNDC16 14 51967058 0.049944792 
227274_at SYNJ2BP 14 69902965 0.049944792 
228569_at PAPOLA 14 96038472 0.041144451 
237400_at --- 14 49862810 0.035722791 
202766_s_at FBN1 15 46487796 0.015061861 
204321_at NEO1 15 71131927 0.029076187 
204698_at ISG20 15 86983042 0.029076187 
218791_s_at C15orf29 15 32220166 0.049944792 
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225311_at IVD 15 38484977 0.029076187 
225330_at IGF1R 15 97010283 0.049944792 
225337_at ABHD2 15 87432384 0.010231873 
1553715_s_at C16orf14 16 631849 0.029076187 
1554078_s_at DNAJA3 16 4415858 0.049944792 
200708_at GOT2 16 57298535 0.049944792 
201468_s_at NQO1 16 68300804 0.007933587 
202183_s_at KIF22 16 89374 0.049944792 
204130_at HSD11B2 16 66022536 0.007933587 
204326_x_at MT1X 16 55273882 0.015061861 
204745_x_at MT1G 16 55258153 0.00368053 
206043_s_at ATP2C2 16 82959633 0.029076187 
206461_x_at MT1H 16 55261226 0.007933587 
207173_x_at CDH11 16 63538183 0.015061861 
208581_x_at MT1X 16 55273882 0.010231873 
208760_at UBE2I 16 1299180 0.041144451 
209230_s_at NUPR1 16 28456162 0.041144451 
209759_s_at DCI 16 2229898 0.049944792 
210519_s_at NQO1 16 68300804 0.015061861 
211456_x_at MT1P2 16 55261251 0.010231873 
212056_at KIAA0182 16 84202529 0.007933587 
212228_s_at COQ9 16 56038902 0.029076187 
212859_x_at MT1E 16 55217085 0.007933587 
213237_at C16orf88 16 19625174 0.007933587 
213629_x_at MT1F 16 55249355 0.007933587 
214035_x_at LOC399491 16 15105673 0.041144451 
214798_at ATP2C2 16 82959633 0.007933587 
217165_x_at MT1F 16 55249355 0.00368053 
217546_at MT1M 16 55224034 0.007933587 
218606_at ZDHHC7 16 83565567 0.006164888 
220335_x_at CES3 16 65552638 0.029076187 
223112_s_at NDUFB10 16 1949517 0.001717581 
224998_at CMTM4 16 65206153 0.010231873 
225129_at CPNE2 16 55684010 0.035722791 
225276_at GSPT1 16 11869485 0.041144451 
228049_x_at --- 16 2144803 0.015061861 
240303_at TMC5 16 19329557 0.049944792 
242414_at QPRT 16 29597941 0.018875861 
200659_s_at PHB 17 44836418 0.049944792 
202311_s_at COL1A1 17 45616455 0.002797203 
203858_s_at COX10 17 13913443 0.015061861 
204690_at STX8 17 9094512 0.049944792 
204719_at ABCA8 17 64375025 0.007933587 
205601_s_at HOXB5 17 44023617 0.029076187 
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210524_x_at --- 17 59248850 0.00473211 
212338_at MYO1D 17 27843740 0.011839038 
218307_at RSAD1 17 45911188 0.023555392 
219909_at MMP28 17 31116988 0.015061861 
223170_at TMEM98 17 28279040 0.018875861 
224784_at MLLT6 17 34115398 0.00368053 
225165_at PPP1R1B 17 35036704 0.007933587 
225947_at MYO19 17 31925711 0.00473211 
226905_at FAM101B 17 289998 0.015061861 
228617_at XAF1 17 6599879 0.018875861 
230784_at PRAC 17 44154080 0.011839038 
231250_at --- 17 44068914 0.041144451 
203126_at IMPA2 18 11971454 0.035722791 
212386_at TCF4 18 51040559 0.029076187 
219048_at PIGN 18 57862437 0.035722791 
227049_at ZADH2 18 71038266 0.018875861 
203576_at BCAT2 19 53990130 0.035722791 
205382_s_at CFD 19 810664 0.011839038 
205861_at SPIB 19 55614006 0.035722791 
216699_s_at KLK1 19 56014215 0.035722791 
217780_at C19orf56 19 12639880 0.018875861 
218312_s_at ZSCAN18 19 63287021 0.035722791 
218429_s_at C19orf66 19 10057805 0.041144451 
219360_s_at TRPM4 19 54352863 0.035722791 
219613_s_at SIRT6 19 4125105 0.029076187 
221692_s_at MRPL34 19 17277476 0.041144451 
226010_at SLC25A23 19 6391074 0.023555392 
227878_s_at ALKBH7 19 6323443 0.049944792 
234339_s_at GLTSCR2 19 52940604 0.023555392 
40837_at TLE2 19 2948636 0.041144451 
53720_at C19orf66 19 10057805 0.007933587 
202878_s_at CD93 20 23007992 0.018875861 
203892_at WFDC2 20 43531807 0.015061861 
217792_at SNX5 20 17870243 0.010231873 
225903_at PIGU 20 32612006 0.029076187 
226805_at --- 20 42364894 0.035722791 
227160_s_at C20orf7 20 13713681 0.023555392 
202217_at C21orf33 21 44377921 0.041144451 
205548_s_at BTG3 21 17887840 0.010231873 
213134_x_at BTG3 21 17887840 0.011839038 
217867_x_at BACE2 21 41461597 0.035722791 
222446_s_at BACE2 21 41461597 0.023555392 
227125_at --- 21 33558910 0.035722791 
1553974_at C22orf39 22 17810894 0.007933587 
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201247_at SREBF2 22 40559051 0.006164888 
212100_s_at POLDIP3 22 41309670 0.035722791 
217719_at EIF3L 22 36575315 0.011777696 
219716_at APOL6 22 34374369 0.00473211 
1555864_s_at PDHA1 X 19271931 0.015061861 
200980_s_at PDHA1 X 19271931 0.029076187 
201215_at PLS3 X 114701461 0.049944792 
202242_at TSPAN7 X 38305674 0.029076187 
203446_s_at OCRL X 128501932 0.029076187 
212741_at MAOA X 43400352 0.041144451 
213746_s_at FLNA X 153230093 0.041144451 
214752_x_at FLNA X 153230093 0.035722791 
215440_s_at BEX4 X 102356675 0.035722791 
217963_s_at NGFRAP1 X 102517923 0.015061861 
219297_at WDR44 X 117364069 0.010231873 
221196_x_at BRCC3 X 153952903 0.041144451 
221620_s_at APOO X 23761397 0.041144451 
222257_s_at ACE2 X 15489076 0.041144451 
224367_at BEX2 X 102450929 0.010231873 
227425_at REPS2 X 16874734 0.035722791 
228752_at BCORL1 X 128944349 0.041144451 
Genome-wide data set (layer I) of all individuals included in the study have been submitted to 
the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under series 
accession numbers GSE22619 (samples: GSM560961–GSM560976). 
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Experimental ID Chromosome Region Start Region End P value 
3800_0606_0724 1 89436901 89437900 0.006256901 
3800_0755_0573 1 228904908 230211618 0.006256901 
3800_0681_0089 1 85438407 85440238 0.006256901 
3800_0713_0797 1 115101847 115102877 0.008342535 
3800_0023_0719 1 195123584 195124583 0.008342535 
3800_0063_0819 1 222584197 222585257 0.008342535 
3800_0146_0154 1 203556856 203558256 0.008342535 
3800_0632_0866 1 2333246 2334620 0.015016562 
3800_0055_0193 1 228904908 230211618 0.015016562 
3800_0143_0457 1 228904908 230211618 0.015016562 
3800_0081_0915 1 228904908 230211618 0.015016562 
3800_0213_0229 1 228904908 230211618 0.015016562 
3800_0243_0005 1 228904908 230211618 0.015016562 
3800_0285_0661 1 148088526 148091815 0.01981352 
3800_0476_0484 1 36544418 36546055 0.02681529 
3800_0050_0050 1 85814818 85815523 0.031284505 
3800_0659_0845 1 224031905 224032909 0.031284505 
3800_0638_0940 1 209498729 209500757 0.031284505 
3800_0049_0567 1 226394037 226395364 0.031284505 
3800_0615_0623 1 233878465 233881427 0.031284505 
3800_0560_0390 1 47552125 47553124 0.031284505 
3800_0295_0219 1 9979593 9980799 0.031284505 
3800_0539_0495 1 78017648 78018922 0.031284505 
3800_0111_0929 1 228904908 230211618 0.031284505 
3800_0021_0625 1 159767053 159767736 0.041921237 
3800_0344_0398 1 54726482 54727875 0.041921237 
3800_0583_0461 1 226403927 226404926 0.041921237 
3800_0731_1023 1 11041618 11043394 0.041921237 
3800_0467_0019 1 1299004 1301193 0.041921237 
3800_0146_0572 1 25536194 25538146 0.041921237 
3800_0068_0956 1 26478005 26479500 0.041921237 
3800_0142_0932 1 32478112 32479728 0.041921237 
3800_0530_0460 1 32573447 32575171 0.041921237 
3800_0748_0138 1 36046087 36047165 0.041921237 
3800_0043_0731 1 228904908 230211618 0.041921237 
3800_0465_0141 2 236736534 236743501 0.006256901 
3800_0540_0720 2 24436125 24437115 0.008342535 
3800_0558_0290 2 25207788 25208506 0.010949577 
3800_0729_0331 2 89776352 89777351 0.010949577 
3800_0326_0102 2 91300424 91301423 0.010949577 
3800_0335_0975 2 136589730 136592494 0.010949577 
3800_0681_0569 2 66656395 66658335 0.015016562 
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3800_0434_0878 2 241690148 241691147 0.015016562 
3800_0041_0685 2 203901401 204925184 0.015016562 
3800_0146_0050 2 241618304 241619303 0.01981352 
3800_0441_0435 2 203901401 204925184 0.01981352 
3800_0143_0599 2 160181077 160182076 0.02681529 
3800_0577_0787 2 47030815 47031814 0.02681529 
3800_0383_0259 2 12774077 12776470 0.02681529 
3800_0653_0815 2 173000314 173001429 0.02681529 
3800_0720_0674 2 187764982 188209235 0.02681529 
3800_0052_1016 2 45093877 45095083 0.031284505 
3800_0516_0902 2 160626711 160628117 0.031284505 
3800_0754_0494 2 177965416 177966499 0.031284505 
3800_0203_0451 2 203901401 204925184 0.031284505 
3800_0484_0618 2 219505705 220755705 0.031284505 
3800_0623_0873 2 219505705 220755705 0.031284505 
3800_0623_0353 2 156884498 156885592 0.041921237 
3800_0143_0049 2 232959458 232961658 0.041921237 
3800_0067_0899 2 53848207 53849206 0.041921237 
3800_0760_0782 2 230286307 230288268 0.041921237 
3800_0362_0276 2 241156031 241157721 0.041921237 
3800_0639_0875 2 70847956 70849587 0.041921237 
3800_0208_1010 2 187764982 188209235 0.041921237 
3800_0608_0248 2 203901401 204925184 0.041921237 
3800_0697_0449 2 203901401 204925184 0.041921237 
3800_0047_0353 3 174595965 174596624 0.006256901 
3800_0414_0038 3 106854807 107075518 0.006256901 
3800_0667_0713 3 42517825 42519871 0.006256901 
3800_0556_0512 3 198153093 198154692 0.008342535 
3800_0056_0146 3 143824785 143825784 0.015016562 
3800_0331_0061 3 79721502 79722501 0.015016562 
3800_0001_0233 3 139530646 139531645 0.015016562 
3800_0632_0446 3 48673340 48676671 0.01981352 
3800_0125_0565 3 106854807 107075518 0.02681529 
3800_0153_1005 3 186752801 186753813 0.02681529 
3800_0439_0793 3 39123382 39125608 0.02681529 
3800_0044_0878 3 106854807 107075518 0.031284505 
3800_0053_0693 3 158193315 158194314 0.031284505 
3800_0514_0324 3 40403440 40404439 0.031284505 
3800_0487_0879 3 72578215 72579542 0.031284505 
3800_0143_0549 3 106854807 107075518 0.041921237 
3800_0704_0726 3 9152626 9153189 0.041921237 
3800_0597_0677 3 115149050 115150188 0.041921237 
3800_0600_0274 3 49178290 49179522 0.041921237 
3800_0071_0785 3 5203959 5205732 0.041921237 
3800_0114_0722 4 110968335 110969334 0.010949577 
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3800_0434_0672 4 1386292 1391730 0.010949577 
3800_0174_0134 4 69464892 69465891 0.01981352 
3800_0033_0053 4 114901519 114902927 0.01981352 
3800_0067_0559 4 95591825 95592884 0.01981352 
3800_0080_0806 4 143571613 143572612 0.031284505 
3800_0027_0023 4 114901519 114902927 0.031284505 
3800_0434_0050 4 41057010 41058396 0.031284505 
3800_0556_0510 4 75122818 75124020 0.031284505 
3800_0764_0066 4 42093910 42095559 0.041921237 
3800_0336_0154 4 104216658 104218129 0.041921237 
3800_0540_0122 4 140695832 140698078 0.041921237 
3800_0526_1014 5 139818777 139819776 0.006256901 
3800_0161_0689 5 148864177 148865176 0.010949577 
3800_0145_0669 5 153805517 153806719 0.015016562 
3800_0208_0420 5 158584694 158713204 0.02681529 
3800_0757_0499 5 158584694 158713204 0.02681529 
3800_0422_0930 5 159671360 159672491 0.031284505 
3800_0735_0905 5 72778365 72780693 0.031284505 
3800_0057_0307 5 158584694 158713204 0.031284505 
3800_0198_0708 5 39238570 39239569 0.041921237 
3800_0623_0049 5 146812754 146814203 0.041921237 
3800_0722_0278 5 1576026 1577826 0.041921237 
3800_0146_0774 5 176169343 176170916 0.041921237 
3800_0022_0824 5 39109639 39111012 0.041921237 
3800_0674_0012 6 1549606 1560865 0.006256901 
3800_0110_0028 6 110974237 112440374 0.008342535 
3800_0386_0350 6 110974237 112440374 0.010949577 
3800_0375_0011 6 116971007 116972006 0.015016562 
3800_0600_0116 6 16868158 16870964 0.015016562 
3800_0542_0694 6 29797000 33606563 0.015016562 
3800_0130_0714 6 29797000 33606563 0.015016562 
3800_0723_0969 6 29797000 33606563 0.015016562 
3800_0050_0458 6 29797000 33606563 0.015016562 
3800_0026_0774 6 29797000 33606563 0.01981352 
3800_0207_0831 6 158572694 158574058 0.02681529 
3800_0072_0648 6 116681615 116682614 0.02681529 
3800_0303_0069 6 139391286 139392433 0.02681529 
3800_0623_0707 6 29797000 33606563 0.02681529 
3800_0527_0671 6 152160379 152502429 0.02681529 
3800_0254_0374 6 110974237 112440374 0.02681529 
3800_0649_0125 6 110974237 112440374 0.02681529 
3800_0130_0902 6 27968657 27969932 0.031284505 
3800_0673_0897 6 29797000 33606563 0.031284505 
3800_0027_0065 6 110974237 112440374 0.031284505 
3800_0242_0384 6 29797000 33606563 0.04152307 
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3800_0239_0047 6 29797000 33606563 0.041921237 
3800_0051_0183 6 29797000 33606563 0.041921237 
3800_0101_0177 6 152160379 152502429 0.041921237 
3800_0527_0977 6 152160379 152502429 0.041921237 
3800_0678_0634 6 110974237 112440374 0.041921237 
3800_0008_0484 6 110974237 112440374 0.041921237 
3800_0237_0193 6 110974237 112440374 0.041921237 
3800_0043_0007 7 86965883 87185500 0.015016562 
3800_0443_0775 7 102576500 102577499 0.015016562 
3800_0576_0808 7 92056997 92058390 0.015016562 
3800_0539_0941 7 98083742 98085695 0.025809717 
3800_0114_0594 7 86965883 87185500 0.02681529 
3800_0613_0745 7 71987711 71988701 0.02681529 
3800_0455_0711 7 136678837 136679836 0.031284505 
3800_0616_0718 7 107318598 107319597 0.031284505 
3800_0653_0759 7 138370585 138372065 0.041921237 
3800_0689_0467 7 149706723 149708133 0.041921237 
3800_0434_0152 8 145390882 145392024 0.006256901 
3800_0596_0152 8 65655119 65657006 0.010949577 
3800_0335_0151 8 96350021 96351344 0.015016562 
3800_0609_0887 8 124849468 124850634 0.01981352 
3800_0500_0654 8 20098735 20099734 0.02681529 
3800_0503_0997 8 143691433 143693585 0.02681529 
3800_0097_0807 8 116749800 116751179 0.041921237 
3800_0075_0967 8 33543132 33544935 0.041921237 
3800_0239_0049 8 61591729 61592863 0.041921237 
3800_0626_0776 9 139265302 139266301 0.006256901 
3800_0685_0577 9 139083977 139085599 0.010949577 
3800_0369_0517 9 2611309 2613685 0.010949577 
3800_0153_0391 9 8877887 8878886 0.010949577 
3800_0735_0181 9 101621613 101627382 0.015016562 
3800_0723_0709 9 93225473 93227117 0.015016562 
3800_0748_0384 9 99784804 99787589 0.015016562 
3800_0496_0218 9 71476625 71477901 0.01981352 
3800_0669_0225 9 130077413 130079072 0.02681529 
3800_0653_0127 9 139006077 139010164 0.02681529 
3800_0483_0803 9 97307956 97313729 0.031284505 
3800_0530_0052 9 136949289 136950380 0.041921237 
3800_0023_0171 9 101621613 101627382 0.041921237 
3800_0523_0201 9 204587 206146 0.041921237 
3800_0166_0348 9 37312007 37313006 0.041921237 
3800_0626_0152 10 26540600 26638493 0.006256901 
3800_0614_0804 10 99521016 99522477 0.006256901 
3800_0434_0154 10 124729671 124730670 0.008342535 
3800_0753_0517 10 122698501 122699322 0.010949577 
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3800_0527_0049 10 44180619 44205548 0.015016562 
3800_0089_0561 10 4995204 4996203 0.01981352 
3800_0693_0657 10 43421612 43422611 0.01981352 
3800_0606_0716 10 75303443 75305099 0.01981352 
3800_0321_0723 10 31642430 31863133 0.01981352 
3800_0684_0182 10 5126319 5127318 0.02681529 
3800_0527_0877 10 50639665 50641125 0.02681529 
3800_0273_0289 10 79215557 79303959 0.031284505 
3800_0582_0638 10 38685045 38686115 0.031284505 
3800_0533_0245 10 126595111 126596202 0.041921237 
3800_0010_0752 10 101180087 101181086 0.041921237 
3800_0575_0107 10 13429212 13431036 0.041921237 
3800_0208_0896 10 63092476 63093475 0.041921237 
3800_0555_0773 10 72826171 72827960 0.041921237 
3800_0719_0353 11 117252313 117253327 0.008342535 
3800_0764_0068 11 13440850 13442314 0.015016562 
3800_0581_0053 11 66790252 66791257 0.01981352 
3800_0680_0310 11 62449950 62451348 0.02681529 
3800_0053_0491 11 30909778 30910777 0.02681529 
3800_0494_0568 11 45899523 45902108 0.02681529 
3800_0361_0657 11 47163765 47165752 0.02681529 
3800_0639_0701 11 60885610 60887182 0.02681529 
3800_0582_0106 11 65535789 65536788 0.02681529 
3800_0143_0047 11 109468451 109469887 0.031284505 
3800_0645_0677 11 45895873 45897055 0.031284505 
3800_0679_0245 11 808653 810271 0.031284505 
3800_0050_0154 11 87710150 87711336 0.031284505 
3800_0458_0656 11 61032402 61033905 0.041921237 
3800_0239_0337 11 55776057 55777056 0.041921237 
3800_0738_0968 11 109671775 109673297 0.041921237 
3800_0107_0715 11 119103593 119105710 0.041921237 
3800_0690_0330 11 120668455 120669458 0.041921237 
3800_0600_0270 11 47192840 47193839 0.041921237 
3800_0160_0742 11 63815385 63816694 0.041921237 
3800_0653_0613 11 67831677 67978301 0.041921237 
3800_0726_0768 12 55767065 55770072 0.008342535 
3800_0050_0356 12 108755332 108756345 0.010949577 
3800_0722_0978 12 124236071 124238065 0.015016562 
3800_0143_0671 12 122964710 122965709 0.01981352 
3800_0239_0671 12 52696691 52697690 0.01981352 
3800_0528_0460 12 73889529 73890528 0.01981352 
3800_0269_0247 12 61225477 61226476 0.01981352 
3800_0599_0021 12 122016653 122017746 0.02681529 
3800_0434_0776 12 51394128 51394738 0.031284505 
3800_0678_1014 12 31634028 31635969 0.031284505 
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3800_0014_0932 12 54610964 54612829 0.031284505 
3800_0542_0680 12 67012098 67013129 0.031284505 
3800_0473_0727 12 59165655 59179739 0.031284505 
3800_0528_0154 13 33014558 33015140 0.010949577 
3800_0242_0254 13 92677247 92678878 0.015016562 
3800_0012_0446 13 109232468 109238181 0.041921237 
3800_0541_0071 13 114018227 114019408 0.041921237 
3800_0434_0354 13 78073612 78076446 0.041921237 
3800_0146_0254 14 77034325 77035696 0.010949577 
3800_0713_0805 14 35347530 35348371 0.015016562 
3800_0757_0343 14 64001633 64002295 0.015016562 
3800_0719_0773 14 105138861 105139860 0.015016562 
3800_0040_0298 14 19800342 19999532 0.015016562 
3800_0681_0925 14 56116015 56117046 0.02681529 
3800_0242_0980 14 36056114 36060327 0.02681529 
3800_0343_0375 14 23674923 23675968 0.031284505 
3800_0140_0458 14 92720499 92721832 0.031284505 
3800_0044_0060 14 100510647 100511646 0.041921237 
3800_0001_0395 14 100514843 100516832 0.041921237 
3800_0239_0669 15 68174857 68180286 0.006256901 
3800_0765_0391 15 92561236 94081236 0.006256901 
3800_0432_0010 15 92561236 94081236 0.010949577 
3800_0061_0931 15 32446268 32447521 0.01981352 
3800_0599_0369 15 92561236 94081236 0.01981352 
3800_0370_0526 15 78331070 78331717 0.02681529 
3800_0457_0525 15 88446003 88447462 0.02681529 
3800_0004_0784 15 92561236 94081236 0.02681529 
3800_0335_0773 15 92561236 94081236 0.02681529 
3800_0087_0071 15 87541220 87542219 0.031284505 
3800_0296_0348 15 92561236 94081236 0.031284505 
3800_0012_0688 15 92561236 94081236 0.031284505 
3800_0115_0801 15 63870894 63872390 0.041921237 
3800_0562_0316 15 81471012 81472032 0.041921237 
3800_0088_0756 15 92561236 94081236 0.041921237 
3800_0146_0458 15 92561236 94081236 0.041921237 
3800_0272_0806 15 92561236 94081236 0.041921237 
3800_0152_0758 15 43052799 43053798 0.041921237 
3800_0431_0047 16 3096251 3096890 0.008342535 
3800_0718_0656 16 74024352 74025638 0.010949577 
3800_0673_0187 16 18719889 18721712 0.015016562 
3800_0573_0999 16 66119972 66121833 0.015016562 
3800_0662_0998 16 87280022 87281040 0.015016562 
3800_0046_0884 16 85156857 85160150 0.01981352 
3800_0617_0235 16 78190121 78193038 0.02681529 
3800_0606_0650 16 1410504 1411283 0.031284505 
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3800_0613_0959 16 2226220 2228074 0.041921237 
3800_0338_0570 16 30528502 30529933 0.041921237 
3800_0510_1018 17 43455797 43457903 0.006256901 
3800_0623_0355 17 1873749 1876158 0.008342535 
3800_0623_0975 17 30593255 30594953 0.008342535 
3800_0419_0861 17 33971254 33972119 0.010949577 
3800_0527_0771 17 7965484 7967587 0.010949577 
3800_0478_0482 17 35549861 35550860 0.010949577 
3800_0651_0679 17 73694477 73695788 0.015016562 
3800_0527_0669 17 37422315 37423947 0.015016562 
3800_0259_0699 17 16282823 16284825 0.015016562 
3800_0074_0362 17 18624891 18625890 0.01981352 
3800_0367_0523 17 7995276 7997177 0.01981352 
3800_0722_0280 17 77279977 77281673 0.031284505 
3800_0626_0358 17 59349681 59350680 0.041921237 
3800_0335_0251 17 77128351 77130594 0.041921237 
3800_0242_0878 18 45973865 45975926 0.006256901 
3800_0661_0691 18 12647045 12649479 0.006256901 
3800_0767_0969 18 32020390 32022230 0.008342535 
3800_0434_0052 18 46339837 46341587 0.015016562 
3800_0128_0326 18 17662798 17663797 0.031284505 
3800_0570_0548 18 12981062 12981696 0.041921237 
3800_0573_0187 18 44755333 44756974 0.041921237 
3800_0011_0049 18 42936233 42937232 0.041921237 
3800_0477_0983 18 64654707 64656295 0.041921237 
3800_0199_0211 19 38978025 38981323 0.006256901 
3800_0618_0436 19 218086 218762 0.015016562 
3800_0335_0049 19 8814083 8815082 0.01981352 
3800_0235_0323 19 4074522 4075876 0.01981352 
3800_0143_0149 19 55012577 55013574 0.031284505 
3800_0329_0681 19 63720165 63720751 0.031284505 
3800_0688_0250 19 12941183 12942182 0.031284505 
3800_0490_0500 19 59384842 59387309 0.031284505 
3800_0634_0214 19 2439288 2440641 0.041921237 
3800_0650_0580 19 44689431 44690131 0.041921237 
3800_0529_0841 20 60557856 60559928 0.006256901 
3800_0667_0063 20 48844689 48845765 0.006256901 
3800_0157_0483 20 29656504 29657686 0.015016562 
3800_0369_0611 20 34005017 34006592 0.02681529 
3800_0698_0798 20 47986072 47987071 0.02681529 
3800_0662_0992 20 47965011 47966225 0.041921237 
3800_0719_0357 20 57947467 57949701 0.041921237 
3800_0549_0761 21 46911629 46912534 0.010949577 
3800_0755_0651 21 42512018 42513827 0.010949577 
3800_0516_0214 21 43400233 43401453 0.015016562 
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3800_0588_0370 21 37366576 37368367 0.031284505 
3800_0506_1002 21 16833031 16834764 0.041921237 
3800_0550_0472 22 30016637 30017371 0.008342535 
3800_0241_0975 22 21742225 21743597 0.015016562 
3800_0646_0848 22 48980775 48982516 0.015016562 
3800_0146_0456 22 19386259 19388793 0.02681529 
3800_0494_0448 22 37231500 37233012 0.02681529 
3800_0735_0509 22 27467770 27468769 0.031284505 
3800_0456_0290 22 45307982 45313525 0.031284505 
3800_0316_0228 X 266967 268377 0.01981352 
3800_0527_0875 X 153241104 153242142 0.02681529 
3800_0611_0231 X 48803211 48804210 0.031284505 
3800_0013_1017 X 13957665 13958682 0.031284505 
3800_0431_0787 X 152699463 152700462 0.041921237 
3800_0632_0766 X 133757705 133759651 0.041921237 
3800_0177_0839 Y 19477494 19478493 0.015016562 
3800_0211_0071 Y 19264407 19265406 0.02681529 
3800_0083_0777 Y 16414655 16415654 0.02681529 
3800_0291_0669 Y 15698041 15699040 0.031284505 
3800_0063_0693 * * * 0.006256901 
3800_0017_0957 * * * 0.010949577 
3800_0532_0440 * * * 0.02681529 
3800_0060_0448 * * * 0.02681529 
3800_0070_0936 * * * 0.031284505 
3800_0057_0603 * * * 0.031284505 
3800_0656_0846 * * * 0.041921237 
3800_0737_0587 * * * 0.041921237 
3800_0029_0879 * * * 0.041921237 
3800_0066_0450 * * * 0.041921237 
3800_0530_0570 * * * 0.041921237 
3800_0695_0985 * * * 0.041921237 
3800_0039_0401 * * * 0.041921237 
3800_0750_0244 * * * 0.041921237 
* indicates that for the artificial control does not map to the human genome, and genome-
wide data sets (layer II) of all individuals included in the study have been submitted to the NCBI 
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under series accession 
numbers GSE 27899 (samples GSM688907–GSM688926). 
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cg02813121 1 151615535 0.001584793 
cg01053621 1 159460615 0.001584793 
cg25856811 1 151240581 0.002091046 
cg15756091 1 180686278 0.003714358 
cg00625425 1 62558100 0.004915793 
cg10904672 1 148019991 0.004915793 
cg04567009 1 159867393 0.008344175 
cg25020850 1 180908809 0.008344175 
cg22077553 1 169888355 0.008344175 
cg01377755 1 145609882 0.010620314 
cg01426743 1 177260866 0.016932758 
cg14467840 1 151867596 0.016932758 
cg19685066 1 17954590 0.016932758 
cg15361231 1 191341814 0.016932758 
cg12234947 1 109958343 0.016932758 
cg01459162 1 17446917 0.016932758 
cg05190718 1 116112235 0.016932758 
cg16776350 1 158815782 0.016932758 
cg01214209 1 38031582 0.021130572 
cg06589885 1 144124550 0.021130572 
cg00974864 1 159867677 0.021130572 
cg08763351 1 151209834 0.021130572 
cg08477744 1 17180619 0.021130572 
cg21919219 1 103999422 0.021130572 
cg26073060 1 32459323 0.021130572 
cg11750883 1 150753574 0.021130572 
cg24987706 1 165327412 0.024548753 
cg03329572 1 155789877 0.024548753 
cg04743063 1 100504122 0.024548753 
cg01459453 1 167865836 0.024548753 
cg02327719 1 26057973 0.024548753 
cg27341860 1 246166503 0.024548753 
cg09118625 1 68285559 0.024548753 
cg12467090 1 202725762 0.024548753 
cg14615807 1 55236761 0.024548753 
cg18354594 1 245343270 0.024548753 
cg16456919 1 202922001 0.024548753 
cg00095526 1 199348309 0.030265142 
cg06101324 1 151222167 0.030265142 
cg17241310 1 90955444 0.030265142 
cg05606799 1 202431930 0.030265142 
cg10331038 1 173642651 0.030265142 
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cg18354264 1 224477631 0.030265142 
cg19370451 1 150653185 0.030265142 
cg07689731 1 31166502 0.030265142 
cg12869058 1 94360460 0.030265142 
cg03941108 1 22858524 0.030265142 
cg01770400 1 172153108 0.036908993 
cg13626881 1 201325801 0.036908993 
cg09448880 1 151550465 0.036908993 
cg16501235 1 148512612 0.036908993 
cg27210447 1 16221436 0.036908993 
cg08555657 1 151334855 0.036908993 
cg12114524 1 199657417 0.036908993 
cg24051818 1 54880506 0.036908993 
cg05248781 1 150749823 0.036908993 
cg20839149 1 155053225 0.036908993 
cg23909633 1 205137162 0.036908993 
cg23282674 1 205105925 0.044803416 
cg04629204 1 26220912 0.044803416 
cg14448116 1 159436734 0.044803416 
cg00532890 1 162795306 0.044803416 
cg19728577 1 42391750 0.044803416 
cg22165507 1 163867631 0.044803416 
cg13447818 1 150565508 0.044803416 
cg11832543 1 176748441 0.044803416 
cg27336379 1 75850818 0.044803416 
cg04138756 1 151240473 0.044803416 
cg24641737 1 111544794 0.044803416 
cg03641225 1 68285127 0.044803416 
cg26112639 1 245646729 0.044803416 
cg18854666 2 218955299 0.001584793 
cg22415472 2 107968793 0.001584793 
cg27485921 2 46600883 0.003714358 
cg24697329 2 131390846 0.004915793 
cg17518825 2 46376965 0.006405205 
cg11346450 2 234302782 0.006405205 
cg11827101 2 8385873 0.008344175 
cg18638581 2 74913110 0.010620314 
cg10062065 2 220016991 0.013511376 
cg13877895 2 69054513 0.013511376 
cg18374517 2 232979819 0.013511376 
cg19132372 2 206787397 0.016932758 
cg23667432 2 232952683 0.016932758 
cg25066857 2 85774949 0.016932758 
cg10807560 2 40510169 0.021130572 
cg11078738 2 69093957 0.021130572 
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cg21004129 2 218740269 0.021130572 
cg21364150 2 183651796 0.021130572 
cg00573606 2 237987419 0.021130572 
cg03380645 2 85748559 0.021130572 
cg17327492 2 49235663 0.024548753 
cg11024597 2 106047843 0.024548753 
cg06627364 2 87536203 0.024548753 
cg09425228 2 228386249 0.030265142 
cg06971096 2 219881835 0.030265142 
cg11811840 2 234333905 0.030265142 
cg00918005 2 79106718 0.030265142 
cg13531460 2 231499057 0.030265142 
cg24560809 2 95303066 0.030265142 
cg27342801 2 79240781 0.030265142 
cg02799466 2 229844655 0.030265142 
cg26385743 2 130817933 0.036908993 
cg07412254 2 120940004 0.036908993 
cg11206634 2 128174869 0.036908993 
cg26154999 2 224974590 0.036908993 
cg25651505 2 85665534 0.036908993 
cg19394737 2 219600605 0.036908993 
cg27003571 2 144768299 0.044803416 
cg15746445 2 234489672 0.044803416 
cg25928444 2 220145681 0.044803416 
cg24579667 2 156988657 0.044803416 
cg00795812 2 242450682 0.044803416 
cg05020203 2 242617502 0.044803416 
cg08861115 2 113451848 0.044803416 
cg09947274 2 27293419 0.044803416 
cg23759710 2 42844461 0.044803416 
cg10159529 3 3127530 0.001584793 
cg04569233 3 39296453 0.002091046 
cg15051063 3 144376637 0.003714358 
cg24287460 3 130230716 0.003714358 
cg14483391 3 185231921 0.004915793 
cg04387658 3 123257770 0.004915793 
cg17142134 3 172227335 0.008344175 
cg14717170 3 166397165 0.008344175 
cg00400028 3 142432606 0.008344175 
cg24315815 3 147452269 0.010620314 
cg22083047 3 64186504 0.010620314 
cg13742532 3 42825852 0.010620314 
cg00037940 3 139961975 0.010620314 
cg13550608 3 50289658 0.010620314 
cg26838900 3 195571421 0.010620314 
Appendix 
 
107 
Experimental ID Chromosome MVP P value 
cg21706946 3 12775469 0.010620314 
cg14375111 3 14140187 0.013511376 
cg15113803 3 130729809 0.013511376 
cg04347447 3 50516471 0.013511376 
cg24389347 3 127760383 0.013511376 
cg05564657 3 153014065 0.016932758 
cg13144783 3 46224799 0.016932758 
cg04739149 3 101315983 0.021130572 
cg12894629 3 197427114 0.021130572 
cg03109316 3 115440593 0.021130572 
cg05445326 3 197549966 0.021130572 
cg15439078 3 46879647 0.024548753 
cg03391568 3 46893270 0.024548753 
cg07361385 3 187813720 0.024548753 
cg15946807 3 30868233 0.024548753 
cg04848046 3 173312843 0.024548753 
cg10883352 3 144378065 0.024548753 
cg21044104 3 42426880 0.024548753 
cg14458615 3 120347642 0.030265142 
cg12242338 3 141879779 0.030265142 
cg16396948 3 113086084 0.030265142 
cg22356117 3 184364121 0.036908993 
cg07084746 3 129777337 0.036908993 
cg17386185 3 52296306 0.036908993 
cg15423862 3 157320803 0.036908993 
cg21572897 3 120760511 0.036908993 
cg03019000 3 51679391 0.036908993 
cg25982743 3 12175236 0.036908993 
cg25298754 3 112796792 0.036908993 
cg11761535 3 150533721 0.036908993 
cg25781123 3 9379598 0.044803416 
cg12069042 3 48441704 0.044803416 
cg21951612 3 139574779 0.044803416 
cg13099330 3 140740489 0.044803416 
cg18669588 3 52249091 0.044803416 
cg02912041 3 191650257 0.044803416 
cg09841009 4 145281410 0.001584793 
cg08649013 4 9651296 0.003714358 
cg26701826 4 109034053 0.006405205 
cg07364841 4 3413945 0.008344175 
cg16998872 4 145046282 0.010620314 
cg16418329 4 71235340 0.013511376 
cg19000186 4 47650768 0.013511376 
cg17725968 4 96980049 0.016932758 
cg07625840 4 119493789 0.016932758 
Appendix 
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Experimental ID Chromosome MVP P value 
cg02255004 4 80967684 0.016932758 
cg22252999 4 77215438 0.016932758 
cg26125600 4 74937842 0.016932758 
cg27108154 4 96980400 0.016932758 
cg13255629 4 88971684 0.016932758 
cg10375110 4 40032200 0.021130572 
cg10307548 4 24404928 0.021130572 
cg20357806 4 75072643 0.021130572 
cg12243271 4 110942151 0.024548753 
cg07360692 4 106286401 0.024548753 
cg22670329 4 74920939 0.024548753 
cg09816180 4 72868952 0.030265142 
cg08493463 4 185376072 0.030265142 
cg24829483 4 14950739 0.030265142 
cg14078518 4 80548308 0.030265142 
cg02992596 4 155921670 0.036908993 
cg22461018 4 174774586 0.036908993 
cg22960952 4 76700193 0.036908993 
cg02936740 4 68678590 0.036908993 
cg02029926 4 74953738 0.036908993 
cg17738194 4 80548412 0.044803416 
cg25421002 4 146778997 0.044803416 
cg10409560 4 76700323 0.044803416 
cg20950277 4 122304691 0.044803416 
cg02955988 4 129104744 0.044803416 
cg17854440 4 111617030 0.044803416 
cg12845808 5 141318788 0.001155578 
cg20131596 5 102229027 0.001155578 
cg24585690 5 135259413 0.004915793 
cg03503295 5 13997491 0.008344175 
cg02196805 5 131437536 0.008344175 
cg19421752 5 1278224 0.013511376 
cg19530885 5 147238325 0.016932758 
cg10345936 5 150708005 0.016932758 
cg16434306 5 32823885 0.021130572 
cg08818984 5 142795020 0.021130572 
cg24363955 5 32824224 0.024548753 
cg16360372 5 147192921 0.030265142 
cg21652012 5 170143587 0.030265142 
cg27606341 5 39255389 0.030265142 
cg06501790 5 176743863 0.030265142 
cg07233761 5 54317194 0.036908993 
cg03504701 5 20016614 0.036908993 
cg13590277 5 149999689 0.044803416 
cg15512851 6 37081496 0.002091046 
Appendix 
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Experimental ID Chromosome MVP P value 
cg24063382 6 29565040 0.003714358 
cg14023451 6 24597866 0.006405205 
cg06196379 6 41362863 0.008344175 
cg17407908 6 32261093 0.008344175 
cg01669948 6 39398855 0.008344175 
cg01980222 6 41238895 0.008344175 
cg25488021 6 131319140 0.008344175 
cg09299388 6 49863149 0.008344175 
cg00333528 6 89984204 0.010620314 
cg20790540 6 42992328 0.010620314 
cg09508556 6 31214961 0.010620314 
cg26424956 6 34209504 0.013511376 
cg07434278 6 32114223 0.013511376 
cg18201198 6 6568577 0.016932758 
cg17741572 6 32022284 0.021130572 
cg21789545 6 71069112 0.021130572 
cg20095587 6 41238696 0.030265142 
cg03835296 6 25938901 0.030265142 
cg02611419 6 39390510 0.030265142 
cg00024396 6 53321967 0.036908993 
cg11847949 6 32114000 0.044803416 
cg20856834 6 29450501 0.044803416 
cg16268563 6 31621659 0.044803416 
cg04645843 6 31026632 0.044803416 
cg12629515 6 27967790 0.044803416 
cg21440587 6 31691437 0.044803416 
cg10681065 7 100077108 0.002091046 
cg11693019 7 133862160 0.003714358 
cg15001372 7 44196417 0.004915793 
cg14898779 7 23716132 0.006405205 
cg06506864 7 34664713 0.013511376 
cg25650811 7 31523600 0.013511376 
cg12150401 7 122422758 0.016932758 
cg26756862 7 142723082 0.016932758 
cg20748065 7 75421357 0.021130572 
cg11808544 7 55724354 0.021130572 
cg03843951 7 50597128 0.024548753 
cg17754680 7 44548356 0.024548753 
cg09966445 7 38638184 0.024548753 
cg18463686 7 141293159 0.024548753 
cg06943865 7 94131716 0.030265142 
cg19465374 7 99411214 0.030265142 
cg06762858 7 99809192 0.030265142 
cg00644033 7 100382640 0.030265142 
cg17628717 7 43317733 0.030265142 
Appendix 
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Experimental ID Chromosome MVP P value 
cg11091262 7 151284387 0.030265142 
cg11828089 7 71516057 0.036908993 
cg05279864 7 86947255 0.036908993 
cg12643449 7 111849574 0.036908993 
cg06942110 7 1511911 0.036908993 
cg18117847 7 50411395 0.036908993 
cg25612145 7 23716164 0.044803416 
cg00245878 7 64088310 0.044803416 
cg20080624 7 96489047 0.044803416 
cg06981910 7 129634282 0.044803416 
cg22066521 7 20653748 0.044803416 
cg03716937 8 39815019 0.010620314 
cg23704362 8 67568296 0.010620314 
cg22218909 8 6863796 0.013511376 
cg02658251 8 7788776 0.013511376 
cg16303562 8 16094704 0.013511376 
cg06276653 8 139233817 0.013511376 
cg17191715 8 86478130 0.016932758 
cg23566335 8 39561504 0.016932758 
cg00319692 8 87180235 0.021130572 
cg19391527 8 28229651 0.021130572 
cg09314766 8 39814854 0.021130572 
cg11695358 8 144869951 0.024548753 
cg18939260 8 125810527 0.024548753 
cg07005767 8 107851714 0.030265142 
cg04017769 8 38764096 0.036908993 
cg24243265 8 130869033 0.036908993 
cg23067535 8 124264314 0.036908993 
cg14120879 8 7332048 0.036908993 
cg27212977 8 6770817 0.036908993 
cg07459489 8 118216344 0.036908993 
cg19982860 9 21156581 0.00066033 
cg01074640 9 21218142 0.002091046 
cg22161874 9 76692862 0.003714358 
cg17357062 9 136950169 0.006405205 
cg04103317 9 33230960 0.008344175 
cg17683775 9 131555630 0.010620314 
cg02602411 9 103396998 0.010620314 
cg14611112 9 138763172 0.013511376 
cg26164184 9 136911327 0.016932758 
cg21122774 9 135594817 0.021130572 
cg23815000 9 137552833 0.021130572 
cg10726357 9 114693364 0.021130572 
cg17301902 9 79453039 0.030265142 
cg26776077 9 65233711 0.030265142 
Appendix 
 
111 
Experimental ID Chromosome MVP P value 
cg21023114 9 21231233 0.036908993 
cg09547190 9 94897398 0.036908993 
cg11873854 9 138762696 0.036908993 
cg18506679 9 126603681 0.036908993 
cg09427311 9 128925551 0.036908993 
cg15248035 9 36159949 0.036908993 
cg16112945 9 135275627 0.036908993 
cg15582789 9 98185346 0.036908993 
cg00563932 9 138990870 0.044803416 
cg04995717 9 27099293 0.044803416 
cg15526708 9 100906254 0.044803416 
cg23693510 9 23815759 0.044803416 
cg00691625 9 126309628 0.044803416 
cg11959435 9 21430836 0.044803416 
cg24392274 9 129961663 0.044803416 
cg05050341 9 129657355 0.044803416 
cg08458487 10 81699171 0.001155578 
cg05441133 10 48036897 0.003714358 
cg11762346 10 70650118 0.004915793 
cg18833140 10 115302543 0.006405205 
cg00532335 10 95506851 0.008344175 
cg10548978 10 72215059 0.010620314 
cg00623593 10 128657600 0.013511376 
cg13882988 10 54201351 0.013511376 
cg02876062 10 14856660 0.016932758 
cg11639651 10 70649817 0.016932758 
cg20340596 10 100196915 0.016932758 
cg00899659 10 44815977 0.021130572 
cg06692050 10 99522388 0.021130572 
cg02803836 10 131302497 0.024548753 
cg00025991 10 726625 0.024548753 
cg24949488 10 98054352 0.024548753 
cg04189838 10 96513337 0.030265142 
cg15777781 10 11087277 0.030265142 
cg13434852 10 128658171 0.030265142 
cg21194776 10 74984134 0.030265142 
cg05322019 10 102722313 0.030265142 
cg13181019 10 28611588 0.030265142 
cg05064181 10 116435388 0.036908993 
cg06825166 10 98109069 0.036908993 
cg05046097 10 88707906 0.036908993 
cg05835416 10 96432664 0.036908993 
cg25833031 10 30679302 0.036908993 
cg04444771 10 44793718 0.044803416 
cg22545356 10 88706639 0.044803416 
Appendix 
 
112 
Experimental ID Chromosome MVP P value 
cg21033494 10 51220120 0.044803416 
cg06206628 10 49152832 0.044803416 
cg07882535 11 2401968 0.000880441 
cg25943276 11 131038494 0.000880441 
cg13916742 11 61714364 0.001155578 
cg18484189 11 7941549 0.001155578 
cg09632136 11 113670871 0.002091046 
cg20910746 11 27018992 0.002829987 
cg25406518 11 60858741 0.002829987 
cg17092637 11 104345246 0.003714358 
cg21111471 11 63627576 0.003714358 
cg24252809 11 18914027 0.004915793 
cg24776407 11 68818210 0.004915793 
cg19906550 11 2877375 0.006405205 
cg05921324 11 116199324 0.008344175 
cg19560971 11 118723448 0.008344175 
cg13412615 11 63814383 0.008344175 
cg20029201 11 118287023 0.010620314 
cg25072962 11 60281151 0.010620314 
cg13765961 11 59979814 0.010620314 
cg18589858 11 74538633 0.013511376 
cg16873863 11 2877752 0.013511376 
cg04048249 11 116205766 0.016932758 
cg15227610 11 111287226 0.016932758 
cg16466334 11 102219568 0.016932758 
cg02347487 11 7015679 0.016932758 
cg21407055 11 3623059 0.021130572 
cg21633698 11 118799744 0.021130572 
cg10148841 11 124272665 0.021130572 
cg21019522 11 2877365 0.021130572 
cg22658979 11 102331679 0.021130572 
cg24411312 11 129534054 0.021130572 
cg03087937 11 26550132 0.024548753 
cg03856801 11 116214348 0.024548753 
cg11802013 11 69178356 0.024548753 
cg22994720 11 74119636 0.024548753 
cg22862656 11 61794235 0.024548753 
cg20311730 11 7941759 0.024548753 
cg06917325 11 62539699 0.024548753 
cg25101936 11 113434374 0.030265142 
cg11173246 11 831376 0.030265142 
cg11494699 11 36544793 0.036908993 
cg01697865 11 117361217 0.036908993 
cg04962134 11 55409886 0.036908993 
cg26202340 11 125657567 0.036908993 
Appendix 
 
113 
Experimental ID Chromosome MVP P value 
cg26149678 11 71387565 0.036908993 
cg01987509 11 100507255 0.036908993 
cg13179915 11 65119525 0.036908993 
cg12493906 11 4965887 0.044803416 
cg00041575 11 2279317 0.044803416 
cg02477931 11 131037931 0.044803416 
cg12949760 11 2499438 0.044803416 
cg24506604 12 50865769 0.002091046 
cg09447105 12 15017287 0.008344175 
cg25463779 12 123339189 0.008344175 
cg23256150 12 99391889 0.008344175 
cg08640498 12 56114782 0.008344175 
cg25697314 12 66905823 0.008344175 
cg11465372 12 51457458 0.010620314 
cg21922731 12 55443397 0.010620314 
cg14162076 12 8556359 0.010620314 
cg03986640 12 55134622 0.010620314 
cg11051139 12 50866695 0.013511376 
cg03014680 12 10013789 0.013511376 
cg02554564 12 5473392 0.013511376 
cg23696712 12 51514408 0.016932758 
cg13446622 12 55614673 0.016932758 
cg25372195 12 53328560 0.021130572 
cg00495491 12 26714080 0.021130572 
cg07017706 12 51299598 0.021130572 
cg20200335 12 51253821 0.021130572 
cg12572827 12 15016776 0.024548753 
cg09418321 12 4569879 0.024548753 
cg12650635 12 48630730 0.024548753 
cg15711744 12 47152405 0.030265142 
cg13053396 12 7038806 0.030265142 
cg03490200 12 8866463 0.030265142 
cg23767977 12 51233732 0.030265142 
cg01007201 12 8166472 0.030265142 
cg24664957 12 121946956 0.036908993 
cg13928961 12 51298276 0.036908993 
cg19824441 12 55674579 0.036908993 
cg15569340 12 7173757 0.036908993 
cg03064067 12 83831047 0.036908993 
cg06270401 12 4569346 0.036908993 
cg03538436 12 116283753 0.044803416 
cg04303901 12 96410443 0.044803416 
cg04375036 12 109666202 0.044803416 
cg14338062 12 56169546 0.044803416 
cg20870559 12 111900901 0.044803416 
Appendix 
 
114 
Experimental ID Chromosome MVP P value 
cg12682367 13 23421698 0.006405205 
cg27065979 13 51632135 0.008344175 
cg11635563 13 43139849 0.008344175 
cg12071073 13 51334282 0.013511376 
cg05823029 13 113360759 0.021130572 
cg15648315 13 112349637 0.021130572 
cg24821554 13 50537954 0.021130572 
cg16194715 13 36351926 0.021130572 
cg07744166 13 26029484 0.030265142 
cg09878269 13 112860525 0.030265142 
cg10246520 13 52499945 0.036908993 
cg24222324 13 42043414 0.036908993 
cg03721967 13 113057721 0.036908993 
cg22539738 13 44460280 0.044803416 
cg18960218 14 22355205 0.000880441 
cg08495878 14 94097612 0.001584793 
cg26191951 14 20493306 0.004915793 
cg03770548 14 22594880 0.004915793 
cg24812523 14 31868513 0.006405205 
cg24526899 14 53493899 0.010620314 
cg02507952 14 105461686 0.013511376 
cg19042947 14 94097194 0.016932758 
cg14541311 14 22946970 0.021130572 
cg05788638 14 93828773 0.024548753 
cg26514492 14 104602938 0.030265142 
cg02681442 14 28305759 0.030265142 
cg05485062 14 94053616 0.036908993 
cg27504299 14 95221862 0.036908993 
cg16937611 14 94117855 0.036908993 
cg09721659 14 80491864 0.044803416 
cg22090592 14 104245687 0.044803416 
cg00174500 14 22916319 0.044803416 
cg24355048 14 24114868 0.044803416 
cg01429391 14 22974770 0.044803416 
cg06319346 15 28474184 0.001155578 
cg12703269 15 75073287 0.004915793 
cg22563815 15 76644004 0.006405205 
cg27257408 15 76313891 0.010620314 
cg14694011 15 49418316 0.013511376 
cg10173075 15 87565840 0.013511376 
cg08433095 15 53588361 0.016932758 
cg25003924 15 50649046 0.021130572 
cg20225681 15 63290500 0.024548753 
cg02982734 15 21442141 0.030265142 
cg11540997 15 43195110 0.030265142 
Appendix 
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cg26704579 15 72805743 0.044803416 
cg09207718 15 72828439 0.044803416 
cg07888040 15 49456818 0.044803416 
cg21917349 15 27001152 0.044803416 
cg04731384 16 88604267 0.003714358 
cg07842062 16 3246525 0.003714358 
cg27298262 16 88603817 0.003714358 
cg13897627 16 47935998 0.004915793 
cg06810461 16 66075645 0.006405205 
cg12564453 16 55553341 0.006405205 
cg12125117 16 56258962 0.008344175 
cg21686987 16 73810474 0.008344175 
cg25101056 16 82831498 0.010620314 
cg03297731 16 30031794 0.010620314 
cg15206445 16 88100813 0.010620314 
cg01351032 16 10878692 0.010620314 
cg23444894 16 19205244 0.013511376 
cg21085768 16 2807089 0.013511376 
cg06793062 16 74901369 0.013511376 
cg14221831 16 65510215 0.016932758 
cg02164442 16 31312602 0.016932758 
cg06172871 16 70645745 0.016932758 
cg26916607 16 55552271 0.021130572 
cg24110063 16 31347253 0.024548753 
cg14296374 16 82398640 0.030265142 
cg16480209 16 56561961 0.030265142 
cg11667117 16 86527463 0.036908993 
cg07595943 16 82782402 0.036908993 
cg23514672 16 10696145 0.036908993 
cg07434382 16 68541873 0.036908993 
cg24217877 16 47936080 0.036908993 
cg14792480 16 65511758 0.036908993 
cg24652919 16 3013192 0.044803416 
cg12343082 16 86527646 0.044803416 
cg23487586 16 83873424 0.044803416 
cg16799087 16 88655862 0.044803416 
cg02552572 16 55155247 0.044803416 
cg11258532 16 65435374 0.044803416 
cg06100324 16 751348 0.044803416 
cg14893129 17 75766646 0.002091046 
cg22264436 17 39191949 0.003714358 
cg16826286 17 31290403 0.004915793 
cg02580606 17 36780252 0.004915793 
cg00597076 17 1342630 0.004915793 
cg22392708 17 36347296 0.010620314 
Appendix 
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Experimental ID Chromosome MVP P value 
cg15005385 17 31650167 0.013511376 
cg10315334 17 31231445 0.013511376 
cg10057218 17 35327675 0.013511376 
cg16806597 17 18891060 0.013511376 
cg27622610 17 2976935 0.016932758 
cg02784874 17 36982488 0.016932758 
cg12954718 17 4972090 0.021130572 
cg22377428 17 69875477 0.021130572 
cg10213812 17 23874449 0.021130572 
cg06144905 17 24393906 0.021130572 
cg23674788 17 36876839 0.021130572 
cg23276115 17 18891062 0.021130572 
cg13337865 17 6675715 0.024548753 
cg03330678 17 72827828 0.024548753 
cg17839611 17 44641801 0.024548753 
cg21230133 17 36807046 0.024548753 
cg23355492 17 43288592 0.024548753 
cg12380854 17 43262759 0.030265142 
cg02593766 17 45963676 0.030265142 
cg03742272 17 7931430 0.030265142 
cg13098960 17 7434875 0.030265142 
cg22467071 17 59817613 0.030265142 
cg02756698 17 36276534 0.030265142 
cg21636577 17 7062605 0.030265142 
cg00689014 17 37122664 0.030265142 
cg05766474 17 31332781 0.036908993 
cg12894984 17 35077157 0.036908993 
cg13053608 17 37599199 0.036908993 
cg05187322 17 75766923 0.036908993 
cg08696192 17 35910836 0.036908993 
cg19056418 17 73638812 0.036908993 
cg24747122 17 60484391 0.044803416 
cg06799664 17 74078716 0.044803416 
cg16678925 17 3047722 0.044803416 
cg22182666 17 53760154 0.044803416 
cg04882759 17 12510626 0.044803416 
cg10539808 18 22474735 0.003714358 
cg11435943 18 59373667 0.013511376 
cg18121684 18 59405541 0.016932758 
cg24691255 18 59704946 0.030265142 
cg18382305 18 29275063 0.030265142 
cg13445249 18 27211109 0.044803416 
cg10533434 18 59480206 0.044803416 
cg26026726 19 40554254 0.00066033 
cg13407883 19 56319655 0.00066033 
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cg10126923 19 56567263 0.002829987 
cg02903525 19 52505329 0.002829987 
cg10305797 19 40673517 0.004915793 
cg09018862 19 47574484 0.006405205 
cg26136776 19 12859426 0.008344175 
cg05348870 19 6622045 0.008344175 
cg14366490 19 17432825 0.008344175 
cg13434203 19 47936342 0.013511376 
cg24654350 19 60020679 0.013511376 
cg23264413 19 48402117 0.013511376 
cg24734575 19 38052466 0.016932758 
cg12387247 19 7672974 0.016932758 
cg08475088 19 60941103 0.016932758 
cg08539991 19 40895672 0.016932758 
cg16069910 19 17432528 0.016932758 
cg10280342 19 6327576 0.021130572 
cg07425555 19 13910018 0.021130572 
cg18967533 19 56164537 0.021130572 
cg10857774 19 50978523 0.024548753 
cg15586352 19 48382983 0.024548753 
cg14757492 19 18890194 0.024548753 
cg04000821 19 59705878 0.024548753 
cg02981853 19 7351850 0.030265142 
cg18493147 19 425445 0.030265142 
cg25221254 19 6284547 0.030265142 
cg27519373 19 62042104 0.030265142 
cg02686662 19 243245 0.036908993 
cg25187533 19 48278627 0.036908993 
cg21930712 19 56452928 0.036908993 
cg11170796 19 1601224 0.036908993 
cg04349727 19 56149201 0.036908993 
cg19776453 19 47725641 0.036908993 
cg25033144 19 59740102 0.036908993 
cg22039846 19 59973065 0.044803416 
cg09395833 19 15097755 0.044803416 
cg05241571 19 40673064 0.044803416 
cg14333565 19 5775065 0.044803416 
cg18971671 19 54093533 0.044803416 
cg11159299 19 494432 0.044803416 
cg06123346 19 40746359 0.044803416 
cg26149550 19 56026308 0.044803416 
cg25843439 19 15713574 0.044803416 
cg16101800 20 55569975 0.001584793 
cg09868035 20 61962518 0.002829987 
cg26206598 20 46878839 0.002829987 
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cg09076077 20 58063710 0.002829987 
cg23713742 20 33666135 0.003714358 
cg02882813 20 23808078 0.004915793 
cg11061975 20 1587325 0.006405205 
cg24513045 20 62181963 0.010620314 
cg20485165 20 43186463 0.013511376 
cg21835643 20 43368775 0.016932758 
cg20732137 20 61721671 0.016932758 
cg26540515 20 844349 0.021130572 
cg03658707 20 32312087 0.024548753 
cg24122922 20 24397392 0.024548753 
cg00138126 20 55720103 0.030265142 
cg05932408 20 47618046 0.030265142 
cg14271690 20 36643413 0.030265142 
cg19241311 20 29492554 0.030265142 
cg09458237 20 3660191 0.030265142 
cg25718438 20 43177335 0.030265142 
cg18462653 20 29441837 0.036908993 
cg10938286 20 23754999 0.036908993 
cg18223379 20 31083308 0.036908993 
cg09276978 20 34428931 0.036908993 
cg26873164 20 48032382 0.036908993 
cg10099900 20 1041733 0.044803416 
cg18034859 20 29870349 0.044803416 
cg13265003 21 42792092 0.004915793 
cg00895324 21 40160387 0.008344175 
cg03801286 21 34806378 0.008344175 
cg27456885 21 30894784 0.010620314 
cg07658590 21 45788015 0.013511376 
cg24423088 21 31107236 0.021130572 
cg25608949 21 42689424 0.021130572 
cg10569414 21 42315323 0.024548753 
cg10719920 21 45549271 0.025629073 
cg02066681 21 45648228 0.030265142 
cg09964921 21 34807637 0.036908993 
cg24523456 21 37285030 0.036908993 
cg00516481 21 42946271 0.036908993 
cg15536230 21 43809520 0.036908993 
cg07374637 21 30797319 0.044803416 
cg17398613 21 42792922 0.044803416 
cg05615487 22 49523273 0.002091046 
cg10073042 22 21303200 0.002829987 
cg00556408 22 35830534 0.008344175 
cg17505463 22 17160198 0.008344175 
cg07986773 22 43937273 0.016932758 
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cg15303841 22 28163804 0.016932758 
cg08088989 22 21204447 0.021130572 
cg18365380 22 22971011 0.021130572 
cg18294257 22 29197673 0.024548753 
cg04541607 22 25343978 0.030265142 
cg02763671 22 18483541 0.030265142 
cg21271753 22 35829397 0.030265142 
cg10490064 22 23947422 0.036908993 
cg23173455 22 21318684 0.044803416 
cg17568996 22 41158069 0.044803416 
cg01474260 22 15453884 0.044803416 
cg10127415 X 26120444 0.002091046 
cg18787449 X 151670926 0.004915793 
cg15408454 X 151617883 0.008344175 
cg12391921 X 70438375 0.010620314 
cg05772663 X 113724668 0.016932758 
cg21489722 X 8961881 0.021130572 
cg14942312 X 129346742 0.021130572 
cg00596686 X 7147332 0.024548753 
cg22762309 X 69198828 0.024548753 
cg22495120 X 146870786 0.030265142 
cg03791917 X 100527943 0.030265142 
cg16022279 X 151837379 0.036908993 
cg03291145 X 2994515 0.036908993 
cg06220755 X 17730979 0.036908993 
cg12728629 X 151673029 0.036908993 
cg15741706 X 134134072 0.044803416 
cg19481953 X 99785577 0.044803416 
cg11110686 X 140819380 0.044803416 
cg24489034 X 148485237 0.044803416 
cg21825364 Y 14677489 0.00066033 
Genome-wide data set (layer III) of all individuals included in the study have been submitted to 
the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under series 
accession numbers GSE 27899 (samples GSM688887–GSM688906). 
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